WO2022203930A9 - Fluorogenic cyanine carbamates - Google Patents
Fluorogenic cyanine carbamates Download PDFInfo
- Publication number
- WO2022203930A9 WO2022203930A9 PCT/US2022/020708 US2022020708W WO2022203930A9 WO 2022203930 A9 WO2022203930 A9 WO 2022203930A9 US 2022020708 W US2022020708 W US 2022020708W WO 2022203930 A9 WO2022203930 A9 WO 2022203930A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- targeting agent
- independently
- aliphatic
- Prior art date
Links
- -1 cyanine carbamates Chemical class 0.000 title claims abstract description 56
- 150000001875 compounds Chemical class 0.000 claims abstract description 257
- 239000000126 substance Substances 0.000 claims abstract description 54
- 102000004190 Enzymes Human genes 0.000 claims abstract description 49
- 108090000790 Enzymes Proteins 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 101
- 230000008685 targeting Effects 0.000 claims description 100
- 125000003118 aryl group Chemical group 0.000 claims description 83
- 206010028980 Neoplasm Diseases 0.000 claims description 82
- 125000001931 aliphatic group Chemical group 0.000 claims description 74
- 229940079593 drug Drugs 0.000 claims description 74
- 239000003814 drug Substances 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 68
- 239000012472 biological sample Substances 0.000 claims description 54
- 229940088598 enzyme Drugs 0.000 claims description 48
- 125000004429 atom Chemical group 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 27
- 238000011503 in vivo imaging Methods 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 238000001727 in vivo Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 10
- 229910052805 deuterium Inorganic materials 0.000 claims description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 229960003180 glutathione Drugs 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 4
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims description 4
- 108090000712 Cathepsin B Proteins 0.000 claims description 4
- 102000004225 Cathepsin B Human genes 0.000 claims description 4
- 102100032404 Cholinesterase Human genes 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 150000008300 phosphoramidites Chemical class 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 108010049990 CD13 Antigens Proteins 0.000 claims description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 2
- 108010051152 Carboxylesterase Proteins 0.000 claims description 2
- 102000013392 Carboxylesterase Human genes 0.000 claims description 2
- 108090000613 Cathepsin S Proteins 0.000 claims description 2
- 102100035654 Cathepsin S Human genes 0.000 claims description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 2
- 102000004459 Nitroreductase Human genes 0.000 claims description 2
- 101100172720 Rattus norvegicus Ces1e gene Proteins 0.000 claims description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 2
- 108020001162 nitroreductase Proteins 0.000 claims description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 claims description 2
- 150000003958 selenols Chemical class 0.000 claims description 2
- 101150053185 P450 gene Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 abstract description 23
- 230000007017 scission Effects 0.000 abstract description 23
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract description 22
- 230000002378 acidificating effect Effects 0.000 abstract description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 150
- 210000004027 cell Anatomy 0.000 description 125
- 239000000523 sample Substances 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 51
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 39
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 37
- 239000007787 solid Substances 0.000 description 36
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 239000000203 mixture Substances 0.000 description 33
- 239000000562 conjugate Substances 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 29
- 125000005647 linker group Chemical group 0.000 description 29
- 125000001424 substituent group Chemical group 0.000 description 29
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 28
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 27
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- 238000011534 incubation Methods 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000004007 reversed phase HPLC Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000005284 excitation Effects 0.000 description 15
- 230000002132 lysosomal effect Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 229940049595 antibody-drug conjugate Drugs 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 13
- 238000011002 quantification Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 206010061289 metastatic neoplasm Diseases 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000010253 intravenous injection Methods 0.000 description 11
- 210000003712 lysosome Anatomy 0.000 description 11
- 230000001868 lysosomic effect Effects 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000008351 acetate buffer Substances 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000001994 activation Methods 0.000 description 9
- 239000000611 antibody drug conjugate Substances 0.000 description 9
- 238000000386 microscopy Methods 0.000 description 9
- 230000005588 protonation Effects 0.000 description 9
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 8
- NTFPDEDRMYYPAC-UHFFFAOYSA-N 2-amino-4-[[3-(carboxymethyl)phenoxy]-methoxyphosphoryl]butanoic acid Chemical compound OC(=O)C(N)CCP(=O)(OC)OC1=CC=CC(CC(O)=O)=C1 NTFPDEDRMYYPAC-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 238000010226 confocal imaging Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 7
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 7
- 238000011717 athymic nude mouse Methods 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine group Chemical group N1=CCC2=CC=CC=C12 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
- 229960001972 panitumumab Drugs 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108090000279 Peptidyltransferases Proteins 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000004700 cellular uptake Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 150000003512 tertiary amines Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 5
- 108010084457 Cathepsins Proteins 0.000 description 5
- 102000005600 Cathepsins Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 4
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000000942 confocal micrograph Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 150000002019 disulfides Chemical class 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000005309 thioalkoxy group Chemical group 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HWUYCMXSBJWZOS-UHFFFAOYSA-N [C-]#[N+][S+]=C=NS(N=O)(=O)=O Chemical compound [C-]#[N+][S+]=C=NS(N=O)(=O)=O HWUYCMXSBJWZOS-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000012632 fluorescent imaging Methods 0.000 description 3
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 150000002484 inorganic compounds Chemical class 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 231100000324 minimal toxicity Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000009438 off-target cleavage Effects 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000006862 quantum yield reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- FLHJIAFUWHPJRT-UHFFFAOYSA-N 2,3,3-trimethylindole Chemical compound C1=CC=C2C(C)(C)C(C)=NC2=C1 FLHJIAFUWHPJRT-UHFFFAOYSA-N 0.000 description 2
- SYIFSIGCMOMQRB-UHFFFAOYSA-N 4-methyl-4-sulfanylpentanoic acid Chemical compound CC(C)(S)CCC(O)=O SYIFSIGCMOMQRB-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 244000056139 Brassica cretica Species 0.000 description 2
- 235000003351 Brassica cretica Nutrition 0.000 description 2
- 235000003343 Brassica rupestris Nutrition 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000725630 Ectromelia virus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 2
- 241000702623 Minute virus of mice Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 241000701168 Murine adenovirus 1 Species 0.000 description 2
- 241000711466 Murine hepatitis virus Species 0.000 description 2
- 241000711941 Murine orthopneumovirus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 102100020749 Pantetheinase Human genes 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000710209 Theiler's encephalomyelitis virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012094 cell viability reagent Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000010460 mustard Nutrition 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000030589 organelle localization Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 108010029648 pantetheinase Proteins 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BZNDDHWTEVCBAD-BQBZGAKWSA-N (2s)-2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)OC(C)(C)C BZNDDHWTEVCBAD-BQBZGAKWSA-N 0.000 description 1
- ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical compound CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- VZHNAVSRNGLHRD-UHFFFAOYSA-N 5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)CCCC(O)=O VZHNAVSRNGLHRD-UHFFFAOYSA-N 0.000 description 1
- UOGHZHPESMATDD-UHFFFAOYSA-N 5-methoxy-2,3,3-trimethylindole Chemical compound COC1=CC=C2N=C(C)C(C)(C)C2=C1 UOGHZHPESMATDD-UHFFFAOYSA-N 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910008293 Li—C Inorganic materials 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000003800 Staudinger reaction Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018404 cysteine homeostasis Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004521 toxicity profiling Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/558—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a chemiluminescent acceptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0075—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of an heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
- C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
- C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/10—The polymethine chain containing an even number of >CH- groups
- C09B23/107—The polymethine chain containing an even number of >CH- groups four >CH- groups
Definitions
- Fluorogenic cyanine carbamates are disclosed, as well as methods of making and using the Anorogenic cyanine carbamates.
- Fluorogenic probes are powerful tools with significant potential to non-invasively monitor enzymatic processes and other stimuli in real time in living organisms.
- a common tactic uses multi-chromophore systems that rely on quenching through Fluorescence Resonance Energy Transfer (FRET) and related mechanisms.
- FRET Fluorescence Resonance Energy Transfer
- Another approach uses Auorogenic probes, where the change in signal results from chemical transformations to the chromophore itself. The latter often provides improved tum-ON ratios and benefits from requiring only a single chromophore.
- the most broadly used Auorogenic chemistry is based on derivatization of the coumarin, rhodamine, and hybrid cyanine scaffolds, which absorb and emit light in the visible to far-red range.
- NIR near- infrared
- ADCs Antibody-drug conjugates
- ADC activity generally requires lysosomal processing of a linker domain to release the active payload. Consequently, the linker component should be stable in circulation, but selectively cleaved following target binding and internalization - a significant chemical challenge.
- ADCs are conventionally assessed by examining tumoricidal activity and toxicity profiling. While these methods are important benchmarks, they provide only indirect insights into the site and mechanism of drug release.
- Enzyme-linked immunosorbent assays are also broadly employed, but only determine the blood-pool concentration and biodistribution of the antibody component. Radiolabeling methods can provide important insights regarding mAb localization, but are costly and do not directly report on the linker cleavage step. Optical imaging has the potential to provide critical insights to the ADC design and optimization process.
- Anorogenic probes comprising a single chromophore that has a high turn- ON ratio and emits NIR light.
- the cyanine carbamate is a compound according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof: where L is substituted or unsubstituted C n conjugated alkenyl, each carbon having sp 2 hybridization, where n is 7, 3, 5, or 9; R 1 is substituted aryl or substituted heteroaliphatic, and the bond between the nitrogen atom and -C(O)-O-CH2-R 1 is cleavable by an enzyme or chemical trigger; Y 1 and Y 2 independently are C(R b )2, N(R C ), S, O, or Se, wherein each R b independently is aliphatic, H, deuterium, aryl, -(OCH2CH2) X OH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent,
- R 2 and R 2 independently are aryl, heteroaryl, heterocycloaliphatic
- R 11 independently is H, halo, alkyl, or aryl; and (i) R 11 together with R 12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and, if present, R 11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R 11 together with R 12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R 11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug or (iii) each of R 11 , R 11 , and R 12
- L is and A' independently are absent, -CHR d -, -CH2CHR 1 -, -CHR d CH2-, or -NR d -, where R d is H, alkyl, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- the compound may have a structure according to Formula Ila:
- Y 1 and Y 2 independently may be C(R b )2, where each R b independently is aliphatic or aryl; R 2 and R 2 independently may be phenyl, H, halo, -OR a , -NR a 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug; R 5 and R 8 independently may be -SO3", , , H, or -OCH3; A and A' independently may be -N(CH3)- or -CH2-; and R 3 , R 4 , R 6 , R 7 , R 9 , and R 10 may be H.
- a or A' is -N(CH3)-.
- Y 1 and Y 2 are -C(CH3)2-.
- R 3 and Y 1 together with the atoms to which they are bound form a 6-membered aryl ring; and R 4 and Y 2 together with the atoms to which they are bound form a 6-membered aryl ring.
- a pharmaceutical composition comprise a cyanine carbamate as disclosed herein, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
- a method of using a cyanine carbamate includes contacting a biological sample with a compound as disclosed herein; exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R 1 from the compound to provide a cleaved compound; exposing the cleaved compound to a pH less than 8; subsequently exposing the cleaved compound to light having a wavelength greater than 700 nm; and detecting fluorescence from the cleaved compound.
- the biological sample comprises the enzyme, and exposing the compound to the enzyme comprises contacting the biological sample comprising the enzyme with the compound; or the biological sample comprises the chemical trigger, and exposing the compound to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the compound; or exposing the compound to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the compound.
- the biological sample may comprise an environment having a pH less than 7, thereby exposing the cleaved compound to the pH less than 7.
- the biological sample may comprise, or be suspected of comprising, a target; the compound comprises a group comprising a targeting agent that binds to the target; and detecting fluorescence from the cleaved compound indicates presence of the target in the biological sample.
- the targeting agent is an antibody.
- contacting the biological sample with the compound may be performed in vivo.
- contacting the biological sample in vivo comprises administering the compound or a pharmaceutical composition comprising the compound to a subject; and detecting fluorescence from the cleaved compound is performed via in vivo imaging.
- FIG. 1 is a reaction scheme showing cleavage of a cyanine carbamate (CyBam-N ) to produce a norcyanine (Sulfo-NorCy7) and subsequent indolenine protonation of the norcyanine (NorCy7-[H + ]).
- FIG. 2 shows absorbance spectra of CyBam-Na, Sulfo-NorCy7, and Sulfo-NorCy7-[H + ].
- FIGS. 3A and 3B show the effects of pH on absorbance (3A) and fluorescence (3B) spectra of CyBam-Na and Sulfo-NorCy7.
- FIGS. 4A and 4B are graphs showing conversion of CyBam-Na to Sulfo-NorCy7 by reaction with triphenyl phosphine at pH 5.2 over time (4 A) and the increased fluorescence after the conversion occurred (4B).
- FIGS. 5A-5F are graphs comparing properties of two xanthene cyanines.
- FIGS. 5A and 5B show the absorbance spectra at pH 7.2 (5 A) and 4.5 (5B).
- FIGS. 5C and 5D show the emission spectra at pH 7.2 (5C) and 4.5 (5D) with an excitation wavelength of 640 nm.
- FIGS. 5E and 5F show the emission spectra at pH 7.2 (5E) and 4.5 (5F) with an excitation wavelength of 690 nm.
- FIGS. 6A-6C are graph showing fluorescence intensity of CyBam-y-Glu (20 pM) after incubation with increasing concentrations of y-glutamyl transpeptidase (GGT, 0-400 U/L) (6A), rate of activation in the presence of GGT (0-400 U/L in PBS (pH 7.4) for 30 minutes (6B), and kinetics of Anorogenic probe activations at different concentrations of CyBam-y-Glu (2.5-50 pM) in PBS (pH 7.4, 37 °C) with 100 U/L GGT (6C). Mean ⁇ SD of Auorescent signal from three independent experiments.
- FIG. 7 is a graph showing activation of CyBam-y-Glu (20 pM) after incubation with GGT (100 U/L), leucine aminopeptidase (LAP; 800 U/L), pig-liver esterase (PLE; 800 U/L) at 37 °C for 30 mins in PBS pH 7.4 followed by pH adjustment to pH 5.2.
- Cathepsin B CatB; 2.5 mg was used in acetate buffer pH 5.2 for 30 mins at 37 °C.
- FIG. 8 is a graph showing the inhibition of CyBam-y-Glu in the presence of inhibitors DON and GGsTop (1 mM). Mean ⁇ SD of absorbance signal from at least three independent experiments.
- FIG. 9 is a series of images showing cellular uptake of Sulfo-NorCy7 (20 pM, red channel) in SHIN-3 cells after 4 h incubation followed by organelle staining (green channel).
- the upper panels show uptake in mitochondria (Mitotracker Green) and the lower panels show uptake in lysosomes (Lysotracker Green).
- FIG. 10 shows confocal images of fluorescence activation of CyBam-y-Glu (20 pM) and CyBam-N.C. (20 pM) showing in vitro uptake of CyBam-y-Glu in SHIN-3 cells.
- FIG. 12 shows in vivo imaging of a SHIN-3-ZsGreen metastatic tumor model at 3h after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels, respectively. Fluorescent line graphs show correlation between fluorescent signal from GFP and Cy7 channel across the metastatic tumor in two different regions (A and B). Data points are displayed as mean ⁇ SD, and the p-values were evaluated by student t-test (*** p-value ⁇ 0.001).
- FIG. 13 shows brightfield, GFP channel, Cy7 channel, and merged images of the SHIN- 3 -Zs Green metastatic tumor model at Ih after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels respectively.
- FIG. 14 shows brightfield, GFP channel, Cy7 channel, and merged images of the SHIN- 3 -Zs Green metastatic tumor model at 6h after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels respectively.
- FIG. 15 shows brightfield and Cy7 channel images of mice 4 h after injection with CyBam-y-Glu and CyBam-N.C (25 nM). Signal from tumors, liver and background in mice are shown in red, blue and magenta dotted circles. Green pseudo colors are used to represent fluorescent signal from and Cy7 channel.
- FIGS. 16A and 16B are graphs quantifying the fluorescence signal emitting from the tumors of FIG. 15 (16A) and tumor to background ratio in the mice (16B).
- FIGS. 17A and 17B are graphs showing absorbance and fluorescence spectra of A-Me-NorCy7 (5 pM) in PBS pH 7.20 and acetate buffer pH 4.25 (ex. 690 nm) (17A), and determination of pKa in buffers ranging from pH 3.5 - pH 7.4 (17B).
- FIG. 18 is graph showing flow cytometry quantification of in vitro uptake of norcyanine heptamethine cyanines (5 mM) in MDA-MB-468 after 1 h incubation.
- FIGS. 19A-19F show confocal microscopy images of NorCy7 compounds (5 pM) in MDA-MB-468 cells after 6 h of incubation: A-Me-Pip-NorCy7 (19A), A-Me-NorCy7 (19B), H-NorCy7 (19C), Pip-NorCy7 (19D), OMe-NorCy7 (19E) and Sulfo-NorCy7 (19F). Nucleus and fluorescent signal from probes are shown in the left and center images, respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji.
- FIGS. 20A and 20B show organelle localization of N-Me-NorCy7 (5 pM; red channel) in MDA-MB-468 cells after 6 h incubation followed by organelle staining (green channel) with lysosome (Lysotracker Green; 20A) and mitochondria (Mitotracker Green; 20B). Nucleus stained using NucBlue (blue channel). Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/ contrast using Fiji. Scale bar 10 pm.
- FIG. 21 is a table calculating degree of labeling (DOL) for Pan-Sulfo-CyBam and Pan-N-Me CyBams cathepsin (VC) and non-cleavable (NC) linkers.
- DOL degree of labeling
- FIG. 22 shows chemical structures of two CyLBam antibody conjugates and two CyBam antibody conjugates.
- FIG. 23 shows confocal images (63X) of Pan-VC-CyLBam, Pan-NC-CyLBam, Pan-VC-CyBam, and Pan-NC-CyBam in MDA-MB-468 (EGFR+) after 24 h incubation (23A). Fluorescent signal from the probe and nucleus (Hoechst) is shown in red and blue, respectively. Scale bar 10 pm.
- FIG. 25 is confocal microscopy images of Pan-VC-CyLBam (A) Pan-NC-CyLBam (B), Pan-VC-CyBam (C) and Pan-NC-CyBam (D) probes in MDA-MB-468 cells. The probes were incubated for 24 h (50 pg; DOL 4). Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji. Scale bar 10 pm.
- FIG. 26 is confocal microscopy images of Pan-VC-CyBam probe (50 pg; DOL 4) in MDA-MB-468 (A) and MCF-7 (B) cells after 24 h of incubation. Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The signal in red channel is enhanced to visualize the fluorescent signal from the probe. The images were processed with identical brightness/contrast using Fiji. Scale bar 8 pm.
- FIG. 27 is confocal microscopy images of Pan-VC-CyLBam probe (50 pg; DOL 4) in MDA-MB-468 (A) and MCF-7 cells (B); and Pan-NC-CyLBam probe (50 pg; DOL 4) in MDA-MB-468 (C) and MCF-7 cells (D) after 24 h of incubation. Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji. Scale bar 10 pm.
- FIG. 29 shows side view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
- FIG. 30 shows ventral view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
- FIG. 31 shows dorsal view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
- FIG. 32 shows side view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
- FIG. 33 shows ventral view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
- FIG. 34 shows dorsal view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
- FIG. 35 shows chemical structures of four Pan-CyLBam conjugates - Pan-AA-CyLBam, Pan-S,S-CyLBam and Pan-S,SMe2-CyLBam.
- FIG. 36 is a table showing calculation of DOL of Pan-CyLBam conjugates (Pan-CyLBam: VC, AA, S,S, S,SMe2 and NC) with cathepsin and glutathione (GSH) cleavable linkers.
- FIG. 40 is a graph showing quantification of tumor-to-background ratio 48 hours post injection in the mice of FIG. 39.
- FIG. 41 is a graph showing quantification of fluorescent signal of Pan-AA-CyLBam from liver and tumor in the mice of FIG. 39. Tumor-to-liver ratio (TLR) is depicted in insert. Data points are displayed as mean ⁇ SD, and the p- values were evaluated by the Student’s t-test (** p- value ⁇ 0.01, *** p-value ⁇ 0.001).
- FIG. 42 shows ventral view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2).
- Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
- FIG. 43 shows side view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2).
- Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
- FIG. 44 shows dorsal view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2).
- Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
- FIG. 45 shows ex vivo imaging of mice at 48 h after intravenous injection of Pan-CyLBam conjugates (100 pg in 100 pL PBS pH 7.2).
- Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S-CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
- FIGS. 46A and 46B are graphs showing ex vivo quantification of Pan-VC-CyLBam, Pan-AA-CyLBam, Pan-S,S- CyLBam, Pan-S,SMe2-CyLBam, and Pan-NC-CyLBam.
- tumor to liver ratio 46 A
- tumor to muscle ratio 46B
- the p-values were evaluated by Student’s t-test (ns p- value > 0.05, * p-value ⁇ 0.05, *** p-value ⁇ 0.001).
- FIG. 47 is a table showing calculation of DOL of m276-SL and IgG-CyLBams with cathepsin and GSH cleavable linkers.
- FIG. 51 is fluorescence images of the mice of FIG. 50 72 h post injection. Tumors are highlighted in dotted circles.
- FIG. 52 shows in vivo imaging of mice intravenously injected with m276-SL-VC-CyLBam (100 pg in 100 pL PBS pH 7.2) at different orientations, side view (panel A), dorsal view (panel B), and ventral view (panel C).
- the mice were imaged at 4, 24, 48, 72 and 168 h. Images were captured at (ex/em filter 710/760 nm).
- FIG. 53 shows in vivo imaging of mice intravenously injected with m276-SL-S,SMe2-CyLBam (100 pg in 100 pL PBS pH 7.2) at different orientations, side view (panel A), dorsal view (panel B), and ventral view (panel C).
- the mice were imaged at 4, 24, 48, 72 and 168 h. Images were captured at (ex/em filter 710/760 nm).
- FIGS. 54A-54C are graphs quantifying fluorescent signal from Pan-VC-CyLBam and Pan-NC-CyLBam (ex/em 710/760 nm): total fluorescent signal (54A), tumor to liver ratio (54B), and liver to background ratio (54C).
- Fluorogenic cyanine carbamates are disclosed. Methods of making and using the compounds also are disclosed.
- the compounds include a carbamate group that may be cleaved by an enzyme or chemical trigger to produce a corresponding pH-responsive norcyanine. Following cleavage of the carbamate group, fluorescence intensity of the compound increases in a near-neutral or acidic environment (e.g., when the cleaved compound is protonated) when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce fluorescence, preferably in the near-infrared range.
- Fluorogenic tum-ON probes that use near-infrared (NIR) wavelengths (-700-900 nm) have significant potential to provide insight into dynamics and localization of biological phenomena in complex tissue settings.
- NIR near-infrared
- fluorogenic cyanine carbamates that exhibit exceptional turn-ON ratios.
- untargeted compounds enable in vivo imaging in a metastatic tumor model.
- mAb-conjugated variants provide a real-time, quantitative approach to determine the site and extent of antibody-drug-conjugate linker cleavage in complex model organisms.
- inclusion of a basic amine in the cyanine carbamate molecule dramatically improves cellular photon output, likely due to enhanced lysosomal uptake and retention.
- Aliphatic A substantially hydrocarbon-based compound, or a radical thereof (e.g., Cetin, for a hexane radical), including alkanes, alkenes, alkynes, including cyclic versions thereof (cycloaliphatic), and further including straight- and branched-chain arrangements, and all stereo and position isomers as well.
- an aliphatic group contains from one to twenty-five carbon atoms; for example, from one to fifteen, from one to ten, from one to six, or from one to four carbon atoms.
- An aliphatic chain may be substituted or unsubstituted. Unless otherwise specified, an aliphatic group can either be unsubstituted or substituted.
- substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amide, amino, aminoalkyl, aryl, arylalkyl, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, oxo, sulfonamide, sulfhydryl, thioalkoxy, or other functionality.
- Alkyl A hydrocarbon group having a saturated carbon chain. The chain may be branched, unbranched, or cyclic (cycloalkyl). Unless otherwise specified, the term alkyl encompasses substituted and unsubstituted alkyl.
- Alkylaryl An alkyl radical substituted with a terminal aryl group. One nonlimiting example of an alkylaryl group is -(CH2) n -aryl, such as benzyl. Unless otherwise specified, the aryl group may be substituted or unsubstituted. The alkyl radical may include substituents in addition to the aryl group.
- Amino A chemical functional group -N(R)R' where R and R' are independently hydrogen, alkyl, heteroalkyl, haloalkyl, aliphatic, heteroaliphatic, aryl (such as optionally substituted phenyl or benzyl), heteroaryl, alkylsulfano, or other functionality.
- a “primary amino” group is -NH2.
- “Mono-substituted amino” means a radical -N(H)R substituted as above and includes, e.g., methylamino, (l-methylethyl)amino, phenylamino, and the like.
- Di-substituted amino means a radical -N(R)R' substituted as above and includes, e.g., dimethylamino, methylethylamino, di(l-methylethyl)amino, and the like.
- Antibody A protein (or protein complex) that includes one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes.
- the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad of immunoglobulin variable region genes.
- Light chains are classified as either kappa or lambda.
- Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
- IgY antibodies are equivalent to mammalian IgG.
- the basic immunoglobulin (antibody) structural unit is generally a tetramer.
- Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” (about 50-70 kDa) chain.
- the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
- the terms “variable light chain” (VL) and “variable heavy chain” (Vn) refer, respectively, to these light and heavy chains.
- IgY antibodies The structure of IgY antibodies is similar to the structure of mammalian IgG, with two heavy ("nu" chains; approximately 67-70 kDa) and two light chains (22-30 kDa).
- the molecular weight of an IgY molecule is about 180 kDa, but it often runs as a smear on gels due to the presence of about 3% carbohydrate.
- Heavy chains (H) of IgY antibodies are composed of four constant domains and one variable domain, which contains the antigen-binding site.
- antibodies includes intact immunoglobulins as well as a number of well-characterized fragments. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to target protein (or epitope within a protein or fusion protein) would also be specific binding agents for that protein (or epitope).
- SCFvs single-chain Fvs
- antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab’, the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab’ fragments are obtained per antibody molecule; (3) (Fab’)2, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab’)2, a dimer of two Fab’ fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody, a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single
- antibodies includes antibodies comprising one or more unnatural (i.e., non-naturally occurring) amino acids (e.g., p-acetyl-phenylalanine) to facilitate site-specific conjugation.
- unnatural amino acids e.g., p-acetyl-phenylalanine
- Antibodies for use in the methods of this disclosure can be monoclonal or polyclonal, and for example specifically bind a target such as the target antigen.
- monoclonal antibodies can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (Nature 256:495-97, 1975) or derivative methods thereof. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999.
- Antigen A compound, composition, or substance that can stimulate the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal.
- An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens.
- a “target antigen” is an antigen (including an epitope of the antigen) that is recognized and bound by a targeting agent. “Specific binding” does not require exclusive binding.
- the antigen is obtained from a cell or tissue extract.
- the target antigen is an antigen on a tumor cell.
- An antigen need not be a full-length protein.
- Antigens contemplated for use include any immunogenic fragments of a protein, such as any antigens having at least one epitope that can be specifically bound by an antibody.
- Aryl A monovalent aromatic carbocyclic group of, unless specified otherwise, from 6 to 15 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings in which at least one ring is aromatic (e.g., quinoline, indole, benzodioxole, and the like), provided that the point of attachment is through an atom of an aromatic portion of the aryl group and the aromatic portion at the point of attachment contains only carbons in the aromatic ring. If any aromatic ring portion contains a heteroatom, the group is a heteroaryl and not an aryl.
- Aryl groups are monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise specified, the term aryl encompasses substituted and unsubstituted aryl.
- a “biological sample” refers to a sample obtained from a subject (such as a human or veterinary subject) or other type of organism, such as a plant, bacteria or insect.
- Biological samples from a subject include, but are not limited to, cells, tissue, serum, blood, plasma, urine, saliva, cerebral spinal fluid (CSF) or other bodily fluid.
- the biological sample is a tissue sample.
- Chemical trigger refers to a non-enzyme compound capable of cleaving a carbamate group from a Anorogenic cyanine carbamate compound as disclosed herein.
- triphenylphosphine is capable of cleaving a -C(O)-O-CH2-C6HSN3 group from a cyanine carbamate compound as disclosed herein.
- Conjugatable moiety A portion of a molecule that allows the molecule to be conjugated (i.e., coupled or bound) to another molecule, e.g., to a drug or targeting agent such as an antibody.
- drug refers to a substance which has a physiological effect when administered to a subject, and is intended for use in the treatment, mitigation, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being.
- small molecule drug refers to a drug having a molecular weight ⁇ 1,000 Daltons.
- Effective amount refers to an amount sufficient for detection in a biological sample, e.g., by Auorescence.
- Enzyme A protein molecule that is capable of catalyzing a chemical reaction.
- galactosidase is an enzyme capable of hydrolyzing P-galactosides into monosaccharides through the breaking of a glycosidic bond.
- Halogen refers to Auorine, chlorine, bromine, iodine, and radicals thereof.
- Heteroaliphatic An aliphatic compound or group having at least one heteroatom, i.e., one or more carbon atoms has been replaced with an atom having at least one lone pair of electrons, typically nitrogen, oxygen, phosphorus, silicon, or sulfur.
- heteroaliphatic compounds or groups may be substituted or unsubstituted, branched or unbranched, cyclic (heterocycloaliphatic) or acyclic, and include "heterocycle", “heterocyclyl”, “heterocycloaliphatic", or “heterocyclic” groups.
- heteroalkylaryl refers to a heteroalkyl radical substituted with a terminal aryl group. Unless otherwise specified, the aryl group may be substituted or unsubstituted.
- the heteroalkyl radical may include substituents in addition to the aryl group.
- Heteroaryl An aromatic compound or group having at least one heteroatom, i.e., one or more carbon atoms in the ring has been replaced with an atom having at least one lone pair of electrons, typically nitrogen, oxygen, phosphorus, silicon, or sulfur. Unless otherwise specified, the term heteroaryl encompasses substituted and unsubstituted heteroaryl.
- Ligand A molecule that binds to a receptor, having a biological effect.
- NIR Near-infrared
- NIR wavelengths for optical imaging of tissue may be divided into three windows - NIR-I, 650-950 nm; NIR-II, 1000-1350 nm (sometimes defined as 1000-1700 nm); and NIR-III, 1600-1870 nm.
- the terms “near-infrared” and “NIR” as used herein refer to wavelengths within the range of 650-1350 nm.
- Norcyanine refers to the product following cleavage of the carbamate group from a cyanine carbamate compound.
- parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- the pharmaceutically acceptable carrier may be sterile to be suitable for administration to a subject (for example, by parenteral, intramuscular, or subcutaneous injection).
- pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- compositions A biologically compatible salt of a disclosed conjugate, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like.
- Pharmaceutically acceptable acid addition salts are those salts that retain the biological effectiveness of the free bases while formed by acid partners that are not biologically or otherwise undesirable, e.g., inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, -lol uenesul Ionic acid, salicylic acid and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like
- organic acids such as acetic acid, tri
- Pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
- salts of primary, secondary, and tertiary amines substituted amines including naturally occurring substituted amines, cyclic amines
- organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for example, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharrn. Sci., 1977; 66:1-19, which is incorporated herein by reference.)
- Specific binding partner A member of a pair of molecules that interact by means of specific, non-covalent interactions that depend on the three-dimensional structures of the molecules involved.
- Exemplary pairs of specific binding partners include antigen/antibody, hapten/antibody, receptor/ligand, nucleic acid strand/complementary nucleic acid strand, substrate/enzyme, inhibitor/enzyme, carbohydrate/lectin, biotin/avidin (such as biotin/streptavidin), and virus/cellular receptor.
- Substituent An atom or group of atoms that replaces another atom in a molecule as the result of a reaction.
- substituted typically refers to an atom or group of atoms that replaces a hydrogen atom, or two hydrogen atoms if the substituent is attached via a double bond, on a parent hydrocarbon chain or ring.
- substituted may also cover groups of atoms having multiple points of attachment to the molecule, e.g., the substituent replaces two or more hydrogen atoms on a parent hydrocarbon chain or ring. In such instances, the substituent, unless otherwise specified, may be attached in any spatial orientation to the parent hydrocarbon chain or ring.
- substituents include, for instance, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thioalkoxy groups.
- alkyl alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, aryl
- a fundamental compound such as an aryl or aliphatic compound, or a radical thereof, having coupled thereto one or more substituents, each substituent typically replacing a hydrogen atom on the fundamental compound.
- a substituted aryl compound may have an aliphatic group coupled to the closed ring of the aryl base, such as with toluene.
- a long-chain hydrocarbon may have a hydroxyl group bonded thereto.
- Sulfonate-containing group A group including SO3".
- the term sulfonate-containing group includes -SO3" and -RSO3" groups, where R is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- Target An intended molecule to which a disclosed conjugate comprising a targeting agent is capable of specifically binding.
- targets include proteins and nucleic acid sequences present in tissue samples.
- a target area is an area in which a target molecule is located or potentially located.
- Targeting agent An agent that promotes preferential or targeted delivery to a target site, for example, a targeted location in a subject’s body, such as a specific organ, organelle, physiologic system, tissue, or site of pathology such as a tumor, area of infection, or area of tissue injury.
- Targeting agents function by a variety of mechanisms, such as selective concentration in a target site or by binding to a specific binding partner.
- Suitable targeting agents include, but are not limited to, proteins, polypeptides, peptides, glycoproteins and other glycoslyated molecules, oligonucleotides, phospholipids, lipoproteins, alkaloids, steroids, and nanoparticles.
- Exemplary targeting agents include antibodies, antibody fragments, affibodies, aptamers, albumin, cytokines, lymphokines, growth factors, hormones, enzymes, immune modulators, receptor proteins, antisense oligonucleotides, peptides, avidin, nanobodies (small (15kDa) antigen-binding VHH fragments derived from heavy chain only antibodies present in camelids and cartilaginous fishes), nanoparticles, and the like.
- Particularly useful targeting agents are antibodies, peptides, nanobodies, nucleic acid sequences, and receptor ligands, although any pair of specific binding partners can be readily employed for this purpose.
- Fluorogenic cyanine carbamate compounds are disclosed.
- the compounds include a carbamate group that may be cleaved by an enzyme or chemical trigger. Following cleavage of the carbamate group, the compound is fluorescent in an acidic environment (i.e., when the cleaved compound is protonated) when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce fluorescence.
- the fluorogenic cyanine carbamate has a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof:
- the bond indicated by ” is an optional bond, which is present when R x is present and absent when R x is absent.
- L is substituted or unsubstituted conjugated alkenyl, each carbon having sp 2 hybridization.
- R 1 is substituted aryl or substituted heteroaliphatic, and the bond between the nitrogen atom and -C(O)-O-CH2-R 1 is cleavable by an enzyme or chemical trigger.
- Y 1 and Y 2 independently are C(R b )2, N(R C ), S, O, or Se, wherein each R b independently is aliphatic, H, deuterium, aryl, -(OCfFCfFjxOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each R c independently is H, deuterium, aliphatic, or heteroaliphatic.
- R 3 and R 4 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R 3 and Y 1 together with the atoms to which they are bound form a 6-membered aryl ring, and R 4 and Y 2 together with the atoms to which they are bound form a 6-membered aryl ring.
- R 5 -R 10 independently are H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- R x is absent, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H, wherein if R x is present, the nitrogen to which R x is attached has a +1 charge and a counterion X’ is also present.
- Suitable counterions include, but are not limited to, halide (fluoride, chloride, iodide, or bromide), hydroxy, carboxylate (e.g., formate, acetate), nitrate, hydrogen sulfate, hydrogen carbonate, dihydrogen phosphate, and hexafluorophosphate, among others.
- the recited groups may be substituted or unsubstituted, unless otherwise specified.
- the term “aryl” encompasses both substituted and unsubstituted aryl groups.
- the substituent is further substituted.
- the substituent may be substituted with any substituent that does not interfere with cleavage of the carbamate group and/or near-infrared fluorescence of the cleaved compound.
- Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thioalkoxy groups, and combinations thereof.
- R 1 is a substituted aryl group wherein the substituent is a substituted heteroaliphatic chain, e.g.,
- L is substituted or unsubstituted conjugated alkenyl, each carbon having sp 2 hybridization.
- L is substituted or unsubstituted C n conjugated alkenyl where n is 3, 5, 7, or
- n 7. In certain embodiments, L is
- R 2 and R 2 independently are aryl, heteroaryl, heterocycloaliphatic, H, halo, -OR a , -NR a 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- Each R a independently is H, halo, alkyl, or aryl.
- R 11 and R 12 independently are H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R 11 and R 12 together with the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring.
- R 11 when L contains R 11 , R 11 , and R 12 , then (i) R 11 together with R 12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R 11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R 11 together with R 12 and the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R 11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug or (iii) each of R 11 , R 11 , and R 12 independently is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (iv)
- L may be any of the foregoing or following embodiments.
- a and A' independently are -CHR d - or -NR d -.
- a and A' independently are -CH2- or -N(CH3)-.
- a CyLBam compound When A and/or A' is -N(CH3)-, the compound may hereinafter be referred to as a CyLBam compound.
- a CyLBam exhibits improved cellular permeability and lysosomal accumulation in vivo.
- presence of -N(CH3)- at A and/or A' dramatically improves cellular photon output, likely due to enhanced lysosomal uptake and retention.
- a and/or A' may comprise a targeting agent or a conjugatable moiety.
- R d is -(CH2) m -R e , -(CH2) m CH(NH2)-R e , -(CH2) m C(O)R e , -(CH 2 ) m N(H)R e , -(CH 2 ) m N(H)C(O)R e , -(CH 2 ) m C(O)N(H)R e , -(CH 2 ) m C(O)SR e , -C(O)R e , -C(O)N(H)R e , -C(O)N(H)(CH2CH 2 O)n(CH2)mC(O)R e , -N(H)C(O)R e , -N(H)R e , or -SR e , where
- the Anorogenic cyanine carbamate has a structure according to any one of Formulas II-IV, or a stereoisomer or pharmaceutically acceptable salt thereof:
- R'-R 12 , R 2 , R 11 , R X , Y 1 , and Y 2 are as previously defined.
- R x is absent.
- R 11 and/or R 11 together with R 12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring, and the Anorogenic cyanine carbamate has a structure according to formula Ila, Va, Vb, or Vc, or a stereoisomer or pharmaceutically acceptable salt thereof.
- R ⁇ -R 11 , R 2 , R 11 , R x , A, A', Y 1 , and Y 2 are as previously defined.
- a and A' independently are -CHR d - or -NR d -, where R d is H or alkyl.
- a and A' independently are -CH2- or -N(CH3)-.
- R x is absent. If R x is present, then the nitrogen to which R x is attached has a +1 charge and a counterion X’ is also present.
- Y 1 and Y 2 independently may be C(R b )2, N(R C ), S, O, or Se, wherein each R b independently is H, deuterium, aliphatic, aryl, -(OCH2CH2) X OH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each R c independently is H, deuterium, aliphatic, or heteroaliphatic.
- Y 1 and Y 2 independently are C(R b )2, where each R b independently is aliphatic or aryl.
- each R b independently is aliphatic, such as C1-C5 alkyl.
- Y 1 and Y 2 are -C(CH3)2-.
- R 3 and R 4 independently may be H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R 3 and Y 1 together with the atoms to which they are bound may form a 6-membered aryl ring, and R 4 and Y 2 together with the atoms to which they are bound may form a 6-membered aryl ring.
- R 3 and R 4 are H.
- R 3 and Y 1 together with the atoms to which they are bound form a 6-membered aryl ring
- R 4 and Y 2 together with the atoms to which they are bound form a 6-membered aryl ring.
- the Anorogenic cyanine carbamate may have a structure according to any one of Formulas lib, Illa, IVa, or Vd, or a stereoisomer or pharmaceutically acceptable salt thereof:
- R 1 , R 2 , R 2 , R 5 -R 12 , R 11 , and R x are as previously defined.
- R 13 -R 18 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- R 11 and/or R 11 together with R 12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring, and the Anorogenic cyanine carbamate has a structure according to formula lie, Ve, Vf, or Vg , or a stereoisomer or pharmaceutically acceptable salt thereof.
- R 1 , R 2 , R 2 , R 5 -R n , R 11 , R 13 -R 18 , R X , A, and A' are as previously defined.
- R 2 and R 2 independently are aryl, heteroaryl, heterocycloaliphatic, H, halo, -OR a , -NR a 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each R a independently is H, halo, alkyl, or aryl.
- R 2 and/or R 2 is aryl.
- R 2 and/or R 2 is unsubstituted phenyl.
- R 2 and/or R 2 is phenyl substituted with -(CH 2 ) P CO 2 H where p is an integer from 0 to 10 (e.g., -CO 2 H or -C 2 H4CO 2 H), an aryl group, or a group comprising a conjugatable moiety, a targeting agent (e.g., an antibody, a peptide, or a nanobody), or a drug.
- the substituent is para to the attachment of R 2 and/or R 2 to the remainder of the molecule.
- R 2 and/or R 2 is H, halo (e.g., chloro), -OR a , or -NR a 2 , where each R a independently is H, halo, alkyl, or aryl.
- R 2 and R 2 when R 2 and R 2 are both present, one of R 2 and R 2 is H and the other of R 2 and R 2 is aryl, heteroaryl, heterocycloaliphatic, H, halo, -OR a , -NR a 2 , or a group comprising a conjugatable moiety, a targeting agent, or a drug. or a targeting agent, where y is an integer > 1.
- R 2 and/or R 2 may be unsubstituted or substituted phenyl as previously described above, H, halo, -OR a , -NR a 2 , or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- R 5 and R 8 independently may be H or a sulfonate-containing group, such as -SO3" or
- Anorogenic cyanine carbonate comprises a ring comprising A, a ring comprising A', or rings comprising A and A'
- a and A' independently may be -CH 2 - or -N(CH3)-.
- R 3 , R 4 , R 6 , R 7 , R 9 , R 10 , and R 13 -R 18 are H. If present, R 11 or R 11 may also be H.
- R 5 -R 10 independently may be H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- R 5 and R 8 independently may be H, a sulfonate-containing group, or heteroahphatic.
- R 3 and R 8 independently are -SO3", 0 , 0 , H, or -OCH3.
- R 3 , R 4 , R 6 , R 7 , R 9 , and R 10 are H.
- R 3 , R 4 , R 6 , R 7 , R 9 , R 10 , and R 13 -R 18 are H.
- R x may be absent, aliphatic, heteroaliphatic, aryl, heteroaryl, or H, wherein if R x is present, the nitrogen to which R x is attached has a +1 charge and a counterion X’ is also present. In some embodiments, R x is absent. In some implementations, R x is aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H; in such implementations, the nitrogen to which R x is attached has a +1 charge and the counterion X" is present.
- R x is alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, or H.
- R x may be H, C1-C10 straight, branched, or cyclo alkyl or alkenyl, C2-C10 straight, branched, or cyclo heteroalkyl or heteroalkenyl, phenyl, pyridinyl, pyrrolyl, pyrimidinyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, furyl, or thiophenyl.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl (2-methylpropyl), sec-butyl (butan-2-yl), tert-butyl, and the like.
- Exemplary heteroalkyl groups include, but are not limited to, alkoxy groups (methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, and the like), as well as groups including nitrogen or sulfur heteroatoms.
- Exemplary cycloalkyl and cycloalkenyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl.
- Exemplary cycloheteroalkyl groups include, but are not limited to, piperidinyl, pyrrolidinyl, piperazinyl, furyl, tetrahydrofuryl, and morpholinyl groups.
- the Anorogenic cyanine carbamate has a structure according to Formula IIA where R 1 and R x are as previously defined, R 2 is substituted or unsubstituted phenyl; A is -CH2- or -N(CH 3 )-; Y 1 and Y 2 are C(CH 3 ) 2 ; R 3 , R 4 , R 6 , R 7 , R 9 , and R 10 are H; and R 5 and R 8 are -SO3", , , H, or -OCH3.
- the compound has a structure according to any one of Formulas Ild-IIi, or a stereoisomer or pharmaceutically acceptable salt thereof, where R 1 and R 13 are as previously defined.
- R x is absent.
- R x may be absent, and the Anorogenic cyanine carbamate may have a formula as shown in Table 1, wherein R ⁇ -R 18 , R 2 , R 11 , Y 1 , Y 2 , A, and A' are as previously defined.
- the carbamate group, -C(O)OCH 2 R 1 is cleavable by one or more enzymes or chemical triggers.
- R 1 may be chosen to provide selectivity for a particular enzyme or chemical trigger.
- R 1 may be substituted aryl or substituted heteroaliphatic.
- R 1 is substituted phenyl or substituted heteroaliphatic.
- R 1 is
- R s is aliphatic, heteroaliphatic, heterocycloaliphatic, alkylaryl, or heteroalkylaryl.
- R h is aliphatic.
- heterocycle, heterocycloaliphatic, heteroaliphatic, alkyl, aryl, aliphatic, or heteroaliphatic portions may be substituted or unsubstituted.
- Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thio
- Aliphatic, heteroaliphatic, and alkyl moieties may be straight or branched chains.
- -C(O)OCH 2 R 1 may not be cleavable, and the compound may be utilized as a nonfluorescent control compound.
- one of R 1 -R 1 s , R 2 ’ A, A', Y 1 , or Y 2 may comprise a group comprising a targeting agent.
- R 2 , R 2 , A, or A' comprises the group comprising the targeting agent.
- R 1 comprises the targeting agent, and the targeting agent thus is cleaved from the compound upon exposure to the enzyme or chemical trigger.
- the targeting agent may be an antibody, a peptide, or a nanobody.
- the targeting agent is an antibody.
- the antibody is panitumumab.
- one of R 2 -R 18 , R 2 , R 11 , A, A', Y 1 , or Y 2 may comprise a group comprising a drug.
- exemplary groups comprising a drug include, but are not limited to, groups having a formula -Li-C(O)-X 1 -drug, where Li is a linker moiety or is absent and X 1 is O, N(H), or N(CH3). In one embodiment, Li is absent. In another embodiment, Li is O.
- Li is aryl or heteroaryl substituted with at least one substituent comprising a substituted or unsubstituted aliphatic or heteroaliphatic moiety, wherein the aryl or heteroaryl ring is the site of attachment to the remainder of the conformationally restricted cyanine fluorophore and the substituent is bonded to the -C(O)-X 1 -drug moiety.
- the group comprising a drug is: independently are H, alkyl, -NO2, -NR*2, -NR 1 , alkoxy, or sulfonate, wherein each R 1 independently is H, halo, or alkyl.
- R 19 -R 26 are H.
- the group comprising a drug is -C(O)-X 1 -Drug.
- the drug can be any drug capable of conjugation to the remainder of the group.
- the drug is a small-molecule drug, e.g., a drug having a molecular weight ⁇ 1,000 Daltons.
- the drug moiety is an anti-cancer drug.
- Exemplary compounds include, but are not limited to:
- compositions comprising at least one Anorogenic cyanine carbamate compound as disclosed herein.
- Some embodiments of the pharmaceutical compositions include a pharmaceutically acceptable carrier and at least one fluorogenic cyanine carbamate.
- Useful pharmaceutically acceptable carriers and excipients are known in the art.
- compositions comprising one or more fluorogenic cyanine carbamates may be formulated in a variety of ways depending, for example, on the mode of administration and/or on the location to be imaged.
- Parenteral formulations may comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like.
- Excipients may include, for example, nonionic solubilizers, such as Cremophor®, or proteins, such as human serum albumin or plasma preparations.
- the pharmaceutical composition to be administered may also contain non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
- the form of the pharmaceutical composition will be determined by the mode of administration chosen.
- Embodiments of the disclosed pharmaceutical compositions may take a form suitable for virtually any mode of administration, including, for example, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, etc., or a form suitable for administration by inhalation or insufflation.
- embodiments of the disclosed pharmaceutical compositions will be administered by injection, systemically, or orally.
- Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles.
- the compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent.
- the formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, and may contain added preservatives.
- the composition may take such forms as suspension, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- parenteral administration may be done by bolus injection or continuous infusion.
- the fluorogenic cyanine carbamate may be in powder form for reconstitution with a suitable vehicle, e.g. sterile water, before use.
- Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
- Oral formulations may be liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powder, tablets, or capsules). Oral formulations may be coupled with targeting ligands for crossing the endothelial barrier. Some fluorogenic cyanine carbamate formulations may be dried, e.g., by spray-drying with a disaccharide, to form Anorogenic cyanine carbamate powders.
- Solid compositions prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, mannitol, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
- binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, mannitol, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g., potato starch or
- Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, Cremophor® or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, preservatives, Aavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the Auorophore, as is well known.
- the Anorogenic cyanine carbamate(s) may be formulated as solutions (for retention enemas) suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
- the Anorogenic cyanine carbamate(s) can be conveniently delivered in the form of an aerosol spray or mist from pressurized packs or a nebulizer with the use of a suitable propellant, e.g., dichlorodiAuoromethane, trichloro Auoromethane, dichlorotetraAuoroethane, Auorocarbons, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodiAuoromethane, trichloro Auoromethane, dichlorotetraAuoroethane, Auorocarbons, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- compositions comprising Anorogenic cyanine carbamates as described herein may be formulated in unit dosage form suitable for individual administration of precise dosages.
- the pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the Anorogenic cyanine carbamate.
- the pack may, for example, comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the amount of Anorogenic cyanine carbamate administered will depend at least in part on the subject being treated, the target (e.g., the size, location, and characteristics of a tumor), and the manner of administration, and may be determined as is known to those skilled in the art of pharmaceutical composition and/or contrast agent administration.
- the formulation to be administered will contain a quantity of the Anorogenic cyanine carbamate disclosed herein in an amount effective to enable visualization of the Anorogenic cyanine carbamate by suitable means after administration to the subject.
- the Anorogenic cyanine carbamate comprises a drug bound to the molecule, and the formulation to be administered will contain a quantity of the drug bound to the Anorogenic cyanine carbamate effective to provide a therapeutically effective dose of the drug to the subject being treated.
- the pharmaceutical composition includes a second agent other than the Anorogenic cyanine carbamate.
- the second agent may be, for example, an anti-tumor agent or an angiogenesis inhibitor.
- Embodiments of the disclosed Anorogenic cyanine carbamates are suitable for in vivo, ex vivo, or in vitro use.
- the compound is Auorescent in an acidic or neutral pH environment when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce Auorescence.
- a method of using a Anorogenic cyanine carbamate as disclosed herein includes contacting a biological sample with the compound, exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R 1 from the compound to provide a cleaved compound (hereinafter referred to as a “norcyanine”), exposing the norcyanine to a pH less than 8, subsequently exposing the norcyanine to light having a wavelength greater than 700 nm, and detecting Auorescence from the norcyanine.
- the cyanine carbamate does not include an R x substituent, and the norcyanine is exposed to a pH less than 7 to provide a protonated norcyanine.
- both the initial compound and the norcyanine exhibit minimal absorbance and emission in the near-infrared range.
- exposing the norcyanine to a pH less than 8, or a pH less than 7, provides a shift in absorbance and dramatically increased Auorescence signal in the NIR range.
- the norcyanine has a Auorescence intensity at least 100X greater than the cyanine carbamate or norcyanine, such as a Auorescence intensity that is at least 125X greater, at least 150X greater, or even at least 170X greater than the cyanine carbamate or the norcyamne at a pH greater than 8 or a pH greater than 7.
- fluorescence may be detected at pH ranges near neutral, e.g., pH 7-8, or 7-7.5.
- protonation provides a dramatic increase in fluorescence when the compound does not include an R x substituent.
- the cyanine carbamate is a CyBam (a cyanine carbamate wherein the linker includes a 6-membered aliphatic ring where A or A' is -CH2-) or a CyLBam (a cyanine carbamate wherein the linker includes a 6-membered heteroaliphatic ring where A or A' is -N(CH3)-) as disclosed herein.
- a CyLBam exhibits improved cellular permeability and lysosomal accumulation in vivo.
- the cyanine carbamate has an absorbance maximum of 400-450 nm, whereas the resulting norcyanine has an absorbance maximum of 700-800 nm.
- the cyanine carbamate is:
- the carbamate group is cleaved in situ by an enzyme or a chemical trigger.
- the biological sample comprises the enzyme, and exposing the cyanine carbamate to the enzyme comprises contacting the biological sample comprising the enzyme with the cyanine carbamate.
- the biological sample comprises the chemical trigger, and exposing the cyanine carbamate to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the cyanine carbamate.
- exposing the cyanine carbamate to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the cyanine carbamate.
- the cleaved compound, or norcyanine is exposed to a pH less than 8, such as pH less than 7.
- the norcyanine does not include an R x substituent and the norcyanine is protonated by exposure to a pH less than 7.
- the biological sample comprises an environment having a pH less than 7, thereby exposing the norcyanine to the pH less than 7.
- the pH of the biological sample may be reduced, e.g., with a mild acid, to provide expose the compound to a pH less than 8 or a pH less than 7.
- sufficient fluorescence may be detectable at a neutral pH, e.g., a pH of 7-8 or 7-7.5.
- subsequently exposing the cleaved compound, or norcyanine, to light having a wavelength greater than 700 nm and detecting fluorescence from the norcyanine may comprise irradiating the biological sample, or a targeted portion of a subject comprising the biological sample, with targeted application of a quantity of light having a wavelength in the visible, far-red, or near-infrared range and a selected intensity, wherein the quantity of light is sufficient to produce fluorescence of the norcyanine, and detecting any fluorescence emitted by the norcyanine.
- the light has a wavelength at or near a maximum absorption wavelength of the norcyanine in an environment having a pH less than 8 or a pH less than 7.
- the light has a wavelength at or near a maximum absorption wavelength of the protonated norcyanine.
- the biological sample may be irradiated with light having a wavelength within a range of 600 nm to 2500 nm, such as from 600-900 nm, or 600-700 nm.
- the light source is a laser. Suitable light intensities may range from 1 mW/cm 2 to 1000 mW/cm 2 , such as 1-750 mW/cm 2 or 300-700 mW/cm 2 , depending on the target site and method of application.
- Near-infrared light sources can be obtained from commercial sources, including Thorlabs (Newton, NJ), Laser Components, USA (Hudson, NH), ProPho tonix (Salem, NH) and others.
- the effective quantity of far-red or NIR light is 10-250 J, such as 10-200 J, 10-150 J, or 10-100 J.
- visualization may include techniques such as fluoroscopy, single-molecule localization microscopy (SMLM), photo-activated localization microscopy (PALM), stochastic optical reconstruction microscopy (STORM), direct stochastic optical reconstruction microscopy (dSTORM), biplane imaging (BP), temporal radial-aperture based intensity estimation (TRABI), fluorescence resonance energy transfer (FRET), and combinations thereof.
- SMLM single-molecule localization microscopy
- PAM photo-activated localization microscopy
- STORM stochastic optical reconstruction microscopy
- dSTORM direct stochastic optical reconstruction microscopy
- BP biplane imaging
- TRABI temporal radial-aperture based intensity estimation
- FRET fluorescence resonance energy transfer
- the carbamate group may be selected to provide desired stimuli-dependent information.
- R 1 is selected to provide cleavage of the carbamate group by a particular enzyme or chemical trigger.
- a glutamate-substituted compound can be activated by y-glutamyl transpeptidase (GGT) with high selectivity in vitro and in a metastatic model of ovarian cancer.
- GTT y-glutamyl transpeptidase
- Table 3 provides several exemplary combinations of enzyme and/or chemical triggers and suitable R 1 groups for those triggers. Table 3
- the biological sample may comprise, or be suspected of comprising a target.
- the cyanine carbamate may comprise a group comprising a targeting agent that binds to the target, and detecting fluorescence from the norcyanine indicates presence of the target in the biological sample.
- the targeting agent is an antibody, a nanobody, or a peptide.
- the targeting agent is an antibody.
- the antibody is panitumumab.
- contacting the biological sample with the cyanine carbamate may be performed in vivo.
- contacting the biological sample in vivo comprises administering the cyanine carbamate or a pharmaceutical composition comprising the cyanine carbamate to a subject, and detecting fluorescence from the norcyanine is performed via in vivo imaging.
- the amount of the cyanine carbamate administered may be an amount effective to provide detectable fluorescence from the norcyanine.
- Administration is performed by any suitable method, e.g., intravenous, intra-arterial, intramuscular, intratumoral, or subcutaneous injection, or oral, intranasal, or sublingual administration.
- a suitable period of time for cleavage of the carbamate group from the cyanine carbamate is allowed to elapse.
- the suitable period of time may further include time for and subsequent protonation of the norcyanine.
- the period of time ranges from a few minutes to several days.
- the period of time may be from 15 minutes to 7 days, such as from 30 minutes to 48 hours, 30 minutes to 24 hours, 30 minutes to 12 hours, 1 hour to 12 hours, or 3 hours to 12 hours.
- the norcyanine is subsequently irradiated by targeted application of a quantity of light having a wavelength in the visible, far-red, or near-infrared range and a selected intensity to a target area of the subject, wherein the quantity of light is sufficient to excite the protonated cleaved compound.
- the effective quantity of far-red or NIR light may be 1-250 J/cm 2 , such as 1-250 J/cm 2 , such as 5-250 J/cm 2 , 10-250 J/cm 2 , 10-200 J/cm 2 , 10-150 J/cm 2 , 10-100 J/cm 2 , or 30-100 J/cm 2 . Any fluorescence from the protonated cleaved compound in the targeted portion of the subject is detected, thereby diagnosing the subject as having the condition.
- certain cells within the biological sample may express enzymes or chemical triggers capable of cleaving the carbamate group from the compound.
- the norcyanine then may be taken up by the cell and protonated intracellularly.
- the cleaved compound Sulfo-NorCy7 (below) may be taken up by ovarian cancer cells with strong lysosomal localization, and subsequently protonated in the lysosome.
- the protonated Sulfo-NorCy7 is detectable by excitation at 710 nm and subsequent fluorescence detection at 760-800 nm. Detection of the protonated compound may diagnose the subject as having ovarian cancer.
- the subject has, or is suspected of having, a cancer characterized in part by overexpression of y-glutamyl transpeptidase, and R 1 of the compound is .
- Cancers characterized in part by overexpression of y-glutamyl transpeptidase include, for example, ovarian cancer, cervical cancer, liver cancer, colon cancer, gastric cancer, astrocytic glioma, soft tissue sarcoma, melanoma, and leukemia.
- embodiments of the disclosed compounds may be used in theranostic procedures and/or for research uses.
- embodiments of the disclosed compounds may be used as activatable probes for in vivo imaging, including for optically guided surgical procedures.
- the compounds may be used to non-invasively monitor enzymatic processes and other stimuli in real time in living organisms.
- the compounds When conjugated to a targeting agent, the compounds may also be useful as probes for detecting enzymatic activity at a particular cell type or location of interest.
- an amount of an effective enzyme or chemical trigger may be administered to the location of interest after the compound comprising the targeting agent has bound to the target cell or location of interest, thereby inducing cleavage of the carbamate group so that the cleaved compound may be protonated and visualized.
- R 1 is substituted aryl or substituted heteroaliphatic
- R 2 is aryl, heteroaryl, heterocycloaliphatic, H, halo, -OR a , -NR a 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each R a independently is H, halo, alkyl, or aryl
- Y 1 and Y 2 independently are C(R b )2, N(R C ), S, O, or Se, wherein each R b independently is H, deuterium, aliphatic, aryl, -(OCFFCFbjxOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug
- each R c independently is H, deuterium, aliphatic, or heteroaliphatic
- R 3 and R 4 independently are H
- R 5 -R 10 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug; and R 11 and R 12 independently are H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R 11 and R 12 together with the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring.
- Y 1 and Y 2 independently are C(R b )2, where each R b independently is aliphatic or aryl; R 2 is, H, halo, -OR a , -NR a 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug; R 5 and R 8 independently are -SO3", are H.
- R d is H, aliphatic, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
- R 2 is phenyl, H, halo, -OR a , -NR a 2 , or a group comprising a conjugatable moiety, a targeting agent, or a drug
- R 5 and R 8 are -SO3", s an integer > 1
- m is an integer > 1.
- R 1 is , or , -O-alkylaryl, or -O-aryl, where R' is aliphatic and each R" independently is H or aliphatic; R s is aliphatic, heteroaliphatic, heterocycloaliphatic, alkylaryl, or heteroalkylaryl; and R h is aliphatic.
- R 2 is unsubstituted phenyl, , R h , H, Cl, -OR a , or -NR a 2 ;
- R h is -(CH 2 ) m -R e , -(CH 2 ) m CH(NH 2 )-R e , -(CH 2 ) m C(O)R e , -(CH 2 ) m N(H)R e , -(CH 2 ) m N(H)C(O)R e , -(CH 2 ) m C(O)N(H)R e , -(CH 2 ) m C(O)SR e , -C(O)R e , -N(H)C(O)R e , -N(H)R e , or -SR e ;
- R e is -OH, phosphoramidite, or
- a pharmaceutical composition comprising a compound, or stereoisomer thereof, according to any one of paragraphs 1-18, and a pharmaceutically acceptable carrier.
- a method comprising: contacting a biological sample with a compound according to any one of paragraphs 1-18; exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH 2 R 1 from the compound to provide a cleaved compound; exposing the cleaved compound to a pH less than 7 to provide a protonated cleaved compound; subsequently exposing the protonated cleaved compound to light having a wavelength greater than 700 nm; and detecting fluorescence from the protonated cleaved compound.
- the biological sample comprises the enzyme
- exposing the compound to the enzyme comprises contacting the biological sample comprising the enzyme with the compound
- the biological sample comprises the chemical trigger
- exposing the compound to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the compound
- exposing the compound to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the compound.
- the enzyme or chemical trigger and R 1 are selected from the following combinations: carboxy esterase (CES 1, 2) and acetylcholinesterase (ACHe) and butyrylcholinesterase (BCHe) and aminopeptidase N and cathepsin B and cathepsin S and cathepsin L and cathepsin K and pantetheinase (Vanin- 1) and caspase 3/7 and caspase 8 and trysin and chymotrypsin and alkaline phosphatase and fibroblast activating protein and dipeptidyl peptidase 4 and furin and galactosidase and granzymes and nuraminidase and leucine aminopeptidase and legumain and neutrophil elastase and gamma glutamyltranspeptidase (GGT) and tyrosinase and lysyl oxidase and
- NAD(P)H quinone oxidoreductase isozyme 1 and monoamine oxidase A or B and cytochormide P450 and nitro reductase and hydrogen peroxide and super oxide and hydrogen sulfide or triphenyl phosphine and hypochlorous acid and peroxynitrite and carbon monoxide and selenol and thiophenol and glutathione, cysteine, or homocysteine and
- the biological sample comprises, or is suspected of comprising, a target
- the compound comprises a group comprising a targeting agent that binds to the target
- detecting fluorescence from the protonated cleaved compound indicates presence of the target in the biological sample.
- the targeting agent is an antibody.
- contacting the biological sample in vivo comprises administering the compound or a pharmaceutical composition comprising the compound to a subject; and detecting fluorescence from the protonated cleaved compound is performed via in vivo imaging.
- Electrospray ionization mass spectrometry (ESI-MS) data were collected on triple-stage quadrupoleinstrument in a positive mode. Flash column chromatography was performed using reversed phase (100 A, 20- 40-micron particle size, RediSep® Rf Gold® Reversed-phase Cl 8 or C18Aq) and silica on a CombiFlash® Rf 200i (Teledyne Isco, Inc.).
- LC/MS was performed using a Shimadzu LCMS-2020 SingleQuadrupole utilizing a Kinetex 2.6 pm C18 100 A (2.1 x 50 mm) column obtained from Phenomenex, Inc(Torrance, CA). Runs employed a gradient of 0-90% MeCN/H2O with 0.1% formic acid over 4.5 min at a flow rate of 0.2 mL/min.
- Preparatory HPLC was performed on Waters HPLC equipped with Waters 515 HPLC Pump, Waters 2998 Photodiode Array Detector, Waters 2545 Binary Gradient Module and Waters 2767 Sample Manager.
- the HPLC was installed with Luna 10 pm C18 column (100 x 30 mm) and each run employed 10-95% or 60-95% CH 3 CN/H 2 O gradient with 0.1% TFA over 10 mins.
- Absorbance curves were obtained on a Shimadzu UV-2550 spectrophotometer operated by UVProbe 2.32 software. Fluorescence traces were recorded on a PTI QuantaMaster steady state spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, and a 0.1 s integration rate.
- Analytical LC analyses were collected from Agilent 1260 Infinity Quaternary LC module using Poroshell 120 EC-C18 2.7 pM (4.6 x 50 mm) column in 5-95% CH 3 CN/water gradient with 0.1% formic acid over 25 minutes. Microplates were read on Synergy Mx microplate reader. All statistical analyses were carried out by Graphpad Prism version 9.0 (Graphpad Software).
- Absorbance and Fluorescence Measurements Absorbance curves were obtained on a Shimadzu UV- 2550 spectrophotometer operated by UVProbe 2.32 software. Fluorescence traces were recorded on a PTIQuantaMaster steady-state spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, and a 0.1 s integration rate.
- Molar absorption coefficients were determined in PBS (pH 7.2) or acetate buffer (pH 4.5) using Beer’s law, from plots of absorbance vs. concentration (1 - 10 pM). Spectra were recorded with disposable micro-UV-Cuvette holder with 10 mm path length, with absorbance at the highest concentration ⁇ 0.20. Three independent readings were taken at each concentration.
- Absolute Fluorescence Quantum Yields Absolute Fluorescence Quantum Yields. Absolute fluorescence quantum yields (OF) were measured in PBS (pH 7.2), acetate buffer (pH 4.5), or methanol + 0.1% formic acid using a Horiba fluorimeter QM-8075-11-C equipped with R928 PMT point detector and an integrating sphere to determine photons absorbed and emitted by a sample. Probe was excited at 710 nm and emission was collected from 730-850 nm or 730-900 nm. Measurements were carried out a concentration with optical density of less than 0.1 in buffer or solvent and self-absorption corrections were performed using the instrument software.
- CyBam-y-Glu (20 pM) was incubated with GGT (100 U/L), LAP (leucine amino peptidase; 800 U/L) and PLE (pig liver esterase; 800 U/L).
- 2V-Me-NorCy7 (10 pM) in DMEM/10%FBS media was incubated for 6 h followed by addition of Lysosome (Lysotracker Green DND 26; Invitrogen), Mitochondria (Mitotracker Green FM; Invitrogen) for 1 h. Afterwards, the cells were washed with DPBS (pH 7.2) and nucleus was stained with NucBlueTM Live Ready Probes (Invitrogen) for 15 mins. Following concentrations of probes were used in the study: Mitotracker Green (500 nM), Lysotracker Green (75 nM) and NucBlue (1 drop/500 pL).
- Live cell microscopy was carried out in DMEM phenol red free media.
- the images were captured using three different lasers: nucleus (405, blue channel), mitochondria and lysosome (488 nm, green channel) and 2V-Me-NorCy7 (640 nm, red channel).
- Group 1 contained untreated cells
- Group 2 contained blocked probes
- Group 3 contained nonselective and non-cleavable probe.
- Group 2 was treated with DON (1 mM) and GGsTop (1 mM), 1 h prior to study.
- CyBam-y-Glu (20 pM) was incubated in Group 1 and 2
- CyBam-N.C was incubated in Group 3.
- y- Glutamyltranspeptidase from equine kidney (Type VI, 5-12 units/mg solid), leucine aminopeptidase, microsomal from porcine kidney (Type IV-S, 10-40 units/mg protein), Cathepsin B from human liver and Esterase from porcine liver (>15 units/mg solid) were purchased from Millipore Sigma.
- 5000 cells/well (MDA-MB-468 and MCF-7) were seeded on 96 well plate and allowed to adhere overnight.
- Stock solutions (10 mM in DMSO) of all six compounds in NorCy7 library were diluted in media for each respective cell lime to make desired final concentrations varying of 1 , 5 and 10 pM.
- the cells were incubated with the desired concentration for 24h.
- PC-3 cells (250,000) were seeded in 12 well plate (Coming Costar) and allowed to adhere overnight. The cells were divided in five groups: Group 1 - doxorubicin (20 pM), Group 2 CyBam- B(OHji (20 pM), Group 3 CyBam-P(OPh)2 (20 pM), Group 4 coincubation of CyBam-B(OH)2 (20 pM) + doxorubicin (20 pM) and Group 5 coincubation of CyBam-P(OPh)2 (20 pM) + doxorubicin (20 pM). The groups were incubated with compounds for 12 hours.
- SHIN-3 cells were generously provided by Dr. Hisataka Kobayashi. MDA-MB-468 and PC-3 were bought from ATCC. SHIN-3 cells were cultured in Roswell Park Memorial Institute media (RPMI) containing 10% FBS and 1% PS. MDA-MB-468 cells were grown in Dulbecco's Modified Eagle'smedium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-dtreptomycin (PS). PC-3 cells were grown in F-12K media containing 10% FBS and 1%PS. Cells were grown in a cell culture incubator at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were grown in T-75 or T-175 culture flask till 70% confluency before splitting into next passage.
- RPMI Roswell Park Memorial Institute media
- FBS fetal bovine serum
- PS penicillin-dtreptomycin
- PC-3 cells were grown in F-12K media containing 10% FBS and 1%PS. Cells were grown in a cell culture
- MDA-MB-468, MDA-MB-231 and JIMT-1 cells were grown in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (PS).
- MCF-7 cells were grown in Eagle's Minimal Essential Medium (EMEM) containing 10% fetal bovine serum (FBS), 1% penicillin- streptomycin (PS) and 1% L-glutamine. Cells were grown in a cell culture incubator at 37 °C in a humidified atmosphere containing 5% CO 2 . Cells were grown in T-75 or T-175 culture flask till 70% confluency before splitting into next passage following trypsinization with 5% trypsin-EDTA.
- DMEM Dulbecco's Modified Eagle's medium
- FBS fetal bovine serum
- PS Penicillin-Streptomycin
- L-glutamine penicillin-Streptomycin
- the cells were evaluated for molecular testing of biological materials by animal health diagnostic laboratory at Frederick National Laboratory for Cancer Research. The results confirmed the absence of the following agents within the cells: Ectromelia virus (ECT), Mouse rotavirus (EDIM), Lymphocytic coriomeningitis virus (LCMV), Lactic dehydrogenase elevating virus (LDHV), Mouse adenovirus (MAD), Mouse cytomegalovirus (MCMV), Mouse hepatitis virus (MHV), Mouse norovirus (MNV), Mouse parvovirus (MPV), Minute virus of mice (MVM), Mycoplasma spp. (MYCO), Polyoma virus (POLY), Pneumonia virus of mice (PVM), Reovirus 3 (REO3), Sendai virus (SEN), Theiler's murine encephalomyelitis virus (TMEV).
- ECT Ectromelia virus
- EDIM Mouse rotavirus
- LCMV Lymphocytic coriomeningitis virus
- LDHV
- Flow Cytometry was performed at Flow Cytometry Core (CCR) using BD LSRII.
- the fluorescence signal in the near infrared region was excited using 633 nm laser (18 mW) and emission detected on APC-Cy7 detectors (780/60).
- the flow cytometry data was processed using FlowJo software. Geometric mean fluorescent intensity was calculated in APC-Cy7 channel.
- DAPI was imaged at Blue channel (excitation 405 nm, emission 450/50 nm) and Cy7 fluorophores were images at red channel (excitation 640 or 710 nm, emission 810/90).
- the images were taken at 63x/1.4 oil immersed objective.
- the images were processed using Fiji software.
- the images were taken at 63x/1.4 oil immersed objective.
- the images were processed using Fiji software.
- SHIN-3 metastatic tumor model Animal experiments were approved by the Institutional Animal Care and Use Committee of the NIH and conducted in compliance with the Guide for the Care and Use of Laboratory Animal Resources and the National Research Council.
- the tumors were implanted by intraperitoneal injection of 2 x 10 6 SHIN- 3 -Zs Green cells suspended in 300pl of PBS into female athymicnude mice (Athymic NCr-nu/nu, strain #553). Experiments with tumor-bearing mice were performed afterl5 days of implantation of SHIN-3-ZsGreen models, when disseminated peritoneal implants grew to about 1 mm in size.
- Static 2D images were acquired with the following parameters: excitation filter 745 ⁇ 15 nm, emission filter 800 ⁇ 10 nm, f/stop2, medium binning (8x8) and auto exposure (typically 1-60 seconds or 1-120 seconds). 4-7- week-old female athymic nude mice were purchased from Charles River Laboratories International, Inc. (Frederick, MD).
- MDA-MB-468 tumor model 5xl0 6 human breast cancer cells (MDA-MB-468) in 100 pL of Hanks Balanced Salt Solution (HBSS) were subcutaneously injected in the right flank of the mice. Tumors were monitored daily until they reach 4-6 mm in the longest diameter or 25-35 mm 3 . In vivo studies were initiated 10 days post cell injection of the mice.
- HBSS Hanks Balanced Salt Solution
- JIMT-1 tumor model 5xl0 6 human breast cancer cells (JIMT-1) in 100 pL of MatrigekPBS (1:1) were injected subcutaneously in the inguinal memory fat pad of mice. Tumors were monitored daily until they reached 200-250 mm 3 . In vivo studies were initiated 21 days post cell injection.
- Panitumumab, m276-SL and IgG conjugation 1 mg of 25 mg/mL of antibody and 10X of CyBam and CyLBams (10 mM stock in DMSO) was added to 300 pL of PBS (pH 7.2) in 1.5 mL Eppendorf tube. The mixture was covered in aluminum foil and stirred for 2 h on orbital shaker. The reaction mixture was eluted through a pH 7.4 PBS equilibrated Zeba spin DS column (7K MWCO, Thermo Fisher Scientific) to remove unreacted free dye.
- protein cone (mg/mL) [(A280 - 0.03 x A430)/ ⁇ protein] x MW pr otein x dilution factor Fluorescent Imaging in Live Cells with Pan Conjugates: 15,000 cells/well (MDA-MB-468 or MCF-7) were seeded on Greiner Bio-One CELLviewTM Cell Culture Slides (10 compartments and allowed to adhere overnight. Compounds in Panitumumab conjugates (50 pg; DOL 4) were incubated with for 24 h in respective media (with FBS), followed by wash with DPBS (twice). Nucleus was stained with NucBlueTM Live Ready Probes (Invitrogen; 1 drop/ 500 pL) for 15 min. Live cell microscopy was carried out in DMEM phenol red free media. The images were captured using two different lasers: nucleus (405, blue channel) and Cy7 (640 nm, red channel).
- NorCy7 compounds 300,000 cells/well were seeded on 12 well plate (Coming Costar). The cells were treated with NorCy7 library (5 pM) for 1, 3 and 6 h, followed by wash with cold DPBS (twice). The cells were cleaved using GibcoTM Cell Dissociation Buffer, enzyme-free, PBS. and were centrifuged at 200 ref using Eppendorf centrifuge 5425. The cells were resuspended in cold DPBS and cells were counted on flow cytometer. Geometric mean fluorescence intensity was measured at least in three independent trials ( ⁇ 10,000 cells counted).
- Sulfo-NorCy7 was prepared as shown below.
- CyBam-Ns was prepared from Sulfo-NorCy7 and 1 in reasonable yield following purification by reversed-phase chromatography (Scheme 1).
- Compound S3 was prepared according to a known procedure (Huang et al., J Med Chem 2017, 60(21):8847-8857). To a 20 mL microwave vial, S3 (100 mg, 0.20 mmol) and 4-nitrophenyl chloroformate (45 mg, 0.22 mmol) were added sequentially to dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (57 pL, 0.40 mmol) was added dropwise, and the solution was stirred for 12 h. The resulting white precipitate were filtered, and the solvent was evaporated.
- CyBam-v-Glu To a 5 mL microwave vial, Sulfo-NorCy7 (30 mg, 0.046 mmol) and CS2CO3 (30 mg, 0.092) were added sequentially to dry DMF (2 mL) and stirred for 3 h. Compound S4 (60 mg, 0.092 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 10 mins. The reaction mixture was monitored at different intervals using LC/MS. After 3 h, the reaction was quenched using H2O (1 mL). The crude product concentrated and then dissolved in 20% piperidine in DMF (1 mL).
- Compound S6 Compound S6 was synthesized according to known procedure (Blaser et al., Helvetica Chimica Acta 2001, 84(7):2119-2131). To 20 mL microwave vial, S5 (500 mg, 1.99 mmol) and 4-nitrophenyl chloroformate (400 mg, 2.38 mmol) were added sequentially in dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (550 pL, 4.00 mmol) was added dropwise and the solution was stirred for 12 h. White precipitate were filtered, and the solvent was evaporated.
- Compound S13 Compound S12 was synthesized according to known procedure (Chem Commun (Camb) 2017, 53(10): 1653- 1656). To 20 mL microwave vial, S5 (250 mg, 0.77 mmol) and 4-nitrophenyl chloroformate (171 mg, 0.85 mmol) were added sequentially in dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (600 pL, 1.54 mmol) was added dropwise and the solution was stirred for 12 h.
- Compound S2 Compound S2.
- Compound SI was synthesized according to literature procedure (Reynolds, et al., J Org Chem 1977, 42(5): 885-888).
- SI 400 mg, 2.32 mmol
- phenylboronic acid 562.7 mg, 4.65 mmol
- K3PO4 493.6 mg, 2.32 mmol
- Pd(PPh3)4 95 mg, 0.081 mmol
- Boc-Val-Cit-PABA- PNB (140 mg, 0.183 mmol, obtained from BroadPharm, Cat:BP-24175) was dissolved in dry DMF (3 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored at different intervals using LC/MS. After 6 h, the reaction was quenched using H2O (1 mL). The crude product concentrated and then dissolved in TFA:CH2Ch (1 mL) on ice. After 1 h, the solvent was evaporated, followed by addition of glutaric anhydride (4.30 mg, 0.037 mmol) and DIPEA (7.45 pL, 0.056 mmol) in dry DMF. The reaction mixture was stirred at room temperature.
- reaction was monitored by LC/MS. After 3 h the reaction was complete.
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyBam as amorphous purple solid (28 mg, 30% yield).
- VC-CyBam-NHS VC-CyBam-NHS.
- VC-CyBam 10 mg, 0.0085 mmol
- TSTU 7.7 mg, 0.025 mmol
- DIPEA 4.4 pL, 0.025 mmol
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyBam-NHS as amorphous purple solid (8.6 mg, 80% yield).
- HRMS (ESI) calculated for C64H73N8O16S2 [M+H] + 1273.4580; observed: 1273.4579.
- NC-CyBam-NHS Compound NC-CyBam was synthesized according to our reported procedure. 2 To a 10 mL microwave vial, NC-CyBam (5.0 mg, 0.0065 mmol), TSTU (5.9 mg, 0.019 mmol) and DIPEA (2.5 pL, 0.019 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give N.C-CyBam-NHS as amorphous purple solid (4.1 mg, 72% yield).
- CS2CO3 38 mg, 0.11 mmol were added sequentially to dry DMF (2 mL) and stirred for 1 h. Subsequently, Boc-Val-Cit-PABA- PNB (140 mg, 0.18 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored using LC/MS and quenched using H2O (1 mL). The crude product concentrated and then dissolved in TFA:CH2C12 (1 mL) on ice.
- VC-CyLBam-NHS VC-CyLBam-NHS.
- VC-CyLBam 8.0 mg, 0.0077 mmol
- TSTU 4.7 mg, 0.015 mmol
- DIPEA 4.05 pL, 0.023 mmol
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyLBam-NHS as amorphous dark blue solid (6.5 mg, 75% yield).
- LRMS (ESI) calculated for C64H74N9O10 [M+H] + 1128.5; observed: 1128.4.
- NC-CyLBam To a 10 mL microwave vial compound S12 was dissolved in TFA:CH2C12 (1 mL) on ice and stirred for 1 h. Afterwards the solvent was evaporated and crude product was purified over reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to give NC-CyLBam as amorphous dark blue solid (11.5 mg, 62% yield). !
- NC-CyLBam-NHS N-CyLBam-NHS.
- NC-CyLBam 6 mg, 0.0077 mmol
- TSTU 4.7 mg, 0.015 mmol
- DIPEA 4.05 pL, 0.023 mmol
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give NC-CyLBam-NHS as amorphous dark blue solid (6.5 mg, 86% yield).
- LRMS (ESI) calculated for C53H54N5O7 [M+H] + 871.39; observed: 871.4.
- reaction mixture was stirred at room temperature and was monitored by LC/MS. After 3 h the reaction was complete.
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give AA-CyLBam as amorphous dark blue solid (10.2 mg, 58% yield).
- AA-CyLBam-NHS AA-CyLBam-NHS.
- AA-CyLBam 10 mg, 0.014 mmol
- TSTU 8.7 mg, 0.028 mmol
- DIPEA 4.50 pL, 0.028 mmol
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give AA-CyLBam-NHS as amorphous dark blue solid (6.8 mg, 70% yield).
- LRMS (ESI) calculated for C59H64N7O9 [M+H] + 1014.3; observed: 1014.4.
- reaction mixture was monitored using LC/MS and quenched using H2O (1 mL).
- the reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S17 as amorphous dark blue solid (26 mg, 60% yield).
- CyBam -Ns allowed examination of the tum-ON chemistry using a chemical trigger. Azide reduction, involving aza-ylide formation and hydrolysis, was hypothesized to initiate 1,6 elimination and carbamic acid hydrolysis to result in unmasking of the pH-sensitive norcyanine (FIG. 1). CyBam-Ns exhibited minimal absorbance and emission in the NIR range at either neutral (pH 7.2) or acidic pH (pH 4.5) (FIG. 2). Examining the absorbance profiles of CyBam-Ns and Sulfo-NorCy7 at both neutral and acidic pH revealed three readily distinguishable species as shown in FIG. 2. FIGS.
- 3A and 3B show the absorbance (300-800 nm) and fluorescence (720-850 nm) spectra, respectively, with 710 nm excitation of CyBam-Ns (10 pm) and Sulfo-NorCy7 (10 pm) at pH 7.2 (PBS) and pH 4.5 (acetate buffer)
- the pKa of Sulfo-NorCy7 was determined as 5.4 by absorbance and 5.2 by fluorescence.
- the photophysical properties of the three species are summarized in Table 4. The stability of CyBam-Ns at physiological pH values ranging from 4.5-7.5 and in serum was evaluated and little degradation ( ⁇ 5%) was observed over 24 h. Table 4
- y-Glutamyl transpeptidase is a cell-surface-bound enzyme involved in maintaining cellular glutathione (GSH) and cysteine homeostasis (Wickham et al., Anal Biochem 2011, 414(2):208-214).
- Sulfo-NorCy7 exhibited significant cellular uptake in SHIN-3 cells with strong lysosomal localization, consistent with prior results and the requirement for chromophore protonation (FIG. 9).
- the upper panels show uptake in mitochondria (Mitotracker Green) and the lower panels show uptake in lysosomes (Lysotracker Green).
- Overlap in the green and red channel was analyzed using fluorescent line graph in the green and the red channel. Nucleus stained using NucBlue (blue channel). Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/ contrast using Fiji.
- FIG. 10 shows confocal images of fluorescence activation of CyBam-y-Glu (20 mM) and CyBam-N.C (20 mM). Fluorescent signal from the probe and nucleus (Hoechst) is shown in red and blue, respectively.
- FIG. 11 shows quantification of fluorescent signal after incubation of CyBam-y-Glu (20 mM) in presence of GGT inhibitors (DON, GGsTop) and CyBam-N.C. in SHIN-3 cells using flow cytometry.
- CyBam-y-Glu was evaluated in a metastatic tumor model of ovarian cancer. This model entails intraperitoneal injection of SHIN-3-ZsGreen cells, resulting in formation of a significant primary tumor in the greater omentum and locally disseminated metastases (Urano et al., Sci Transl Med 2011, 3(110: 1 lOral 19). CyBam-y-Glu (30 nmol) was injected intraperitoneally in mice which were euthanized after 1, 3, and 6 h and both the primary tumor and local metastases were imaged. Excellent colocalization between CyBam-y-Glu and the ZsGreen signal suggests that the probe was activated and taken up selectively by tumor cells, with significant signal at all three time points (FIGS.
- FIG. 12 shows imaging of the SHIN-3-ZsGreen metastatic tumor model at 3h after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels, respectively.
- the fluorescent line graphs show correlation between fluorescent signal from GFP and Cy7 channel across the metastatic tumor in two different regions (A and B).
- FIGS. 13 and 14 show brightfield, GFP channel, Cy7 channel, and merged images of a SHIN-3-ZsGreen metastatic tumor model at Ih and 6 h, respectively, after injection with CyBam-y-Glu (30 nmol). After 1 h, the mouse was euthanized, and tumors (omental cake and metastatic) were imaged.
- CyBam-y-Glu and CyBam-N.C were injected (in sterile IX PBS pH 7.4) intravenously in mice containing MDA-MB-468 xenograft tumors. Mice were imaged after 4 h in bright field and Cy7 channel (ex/em filter 745/800 nm) (FIG. 15). Signal from tumors, liver and background in mice are shown in red, blue and magenta dotted circles. Green pseudo colors are used to represent fluorescent signal from and Cy7 channel.
- FIGS. 16A and 16B show quantification of fluorescent signal emitting from tumors (16A) and tumor to background ratio in mice by drawing ROIs (16B); p-values were evaluated by student t-test (*** p-value ⁇ 0.001).
- CyBam-y-Glu has a turn-ON ratio that dramatically exceeds those found with existing far-red Anorogenic probes, particularly in acidic conditions. Unlike existing far-red Anorogenic probes, the cationic chromophore is only formed through cleavage of the carbamate group and subsequent protonation of the resulting norcyanine, leading to an exceptional turn-ON ratio (>150X).
- the CyBam is selectively activated upon protonation in the lysosome.
- Sulfo-NorCy7 can provide high contrast imaging, relatively high concentrations (20 - 40 mM) were required for sufficient in vitro signal. This requirement might be problematic for mAb targeted imaging because probe concentrations are intrinsically limited by antigen levels. Microscopy studies indicated that the cellular signal of Sulfo-NorCy7 was predominately from the lysosome - an observation consistent with probe protonation and a pX a between 4 and 5. Poor lysosomal accumulation might be responsible for the modest cellular fluorescence of this probe. It was hypothesized that improving cellular permeability and, perhaps, introducing a lysosomal targeting element could improve the fluorescent output.
- lysotracker probes contain tertiary amines, suggesting this functional group can promote lysosomal targeting (Xu et al., Angew Chem Int Ed Engl 2016, 55(44):13658-13699; Zhu et al., Acc Chem Res 2016, 49(10):2115-2126; Choi et al., Molecules 2021, 26(1)).
- the NorCy7 series was determined to have minimal toxicity in MDA-MB-468 and MCF-7 cells.
- Signal in MDA-MB-468 cells was quantified at 1, 3 and 6 h time points with flow cytometry using the APC-Cy7 channel.
- the uptake of the six norcyanines follows the rank order: 2V-Me-NorCy7 > -Me-Pip-NorCy7 » Pip-NorCy7, OMe-NorCy7, H-Nor-Cy7 » Sulfo-NorCy7.
- FIG. 18 shows flow cytometry quantification of in vitro uptake of the compounds (5 mM) in MDA-MB-468 after 1 h incubation.
- the 2V-Me-NorCy7 and -Me-Pip-NorCy7 exhibited 187-fold and 72-fold higher uptake, respectively, in MDA-MB-468 cells after only 1 h incubation compared to previously used Sulfo-NorCy7.
- the fluorescent signal remained constant at the 1 , 3 and 6 h time points suggesting efficient uptake and high retention of tertiary amine substituted norcyanines (2V-Me-NorCy7 and 2V-Me-Pip-NorCy7).
- FIGS. 20A and 20B show organelle localization of 2V-Me-NorCy7 (5 pM; red channel) in MDA-MB-468 cells after 6 h incubation followed by organelle staining (green channel) with lysosome (Lysotracker Green; 20A) and mitochondria (Mitotracker Green; 20B).
- 2V-Me-NorCy7 was converted to the cyanine lysosome-targeting carbamate (CyLBam) variant by attaching a cathepsin cleavable dipeptide (valine-citrulline, VC) and a non-cleavable (NC) glutaric anhydride linker substituted with a lysine reactive NHS ester (see Example 1 for synthesis details).
- CyLBam cyanine lysosome-targeting carbamate
- the four probes were conjugated to the FDA-approved anti-Epidermal Growth Factor Receptor (EGFR) antibody Panitumumab (Pan) at pH 7.4 (degree of labeling (DOL) ⁇ 4; FIG. 21).
- EGFR epigallocate growth Factor Receptor
- Panitumumab Panitumab
- DOL degree of labeling
- the resulting conjugates were purified by both spin column and dialysis to ensure that no free small molecule remained.
- the inventors’ prior work had shown that similar conjugates maintain the in vitro and in vivo targeting properties of the parent mAb (Gorka et al., Acc Chem Res 2018, 51 (12) :3226-3235 ; Usama et al., Curr Opin Chem Biol 2021, 63:38-45).
- Pan-VC-CyLBam Pan-NC-CyLBam
- Pan-VC-CyBam Pan-NC-CyBam
- FIG. 22 The series of Pan probes was compared in cellular assays.
- the fluorescent signal emitting from Pan-VC-CyLBam was 50-fold higher than Pan-VC-CyBam after incubation with MDA-MB-468 cells for 24 h (FIGS. 23, 24).
- the conjugates (200 mg) were injected intravenously into female athymic nude mice with MDA-MB-468 xenograft tumors (25-35 mm 3 ).
- the mice were imaged at 4, 24, 48, 72, and 168 h post-injection using an In Vivo Imaging System (IVIS) (FIG. 28A and FIGS. 29-34).
- IVIS In Vivo Imaging System
- TBRs tumor-to-background ratios
- Pan-VC-CyBam group had lower TBRs (1-2) at all time points - similar to the two non-cleavable probes, Pan-NC-CyLBam and Pan-NC-CyBam.
- Significant liver signal was observed with the two probes containing the protease cleavable linker (Pan-VC-CyLBam and Pan-VC-CyBam) at early time points (4 h and 24 h), and the fluorescent signal decreased afterwards.
- a small panel of probes was designed to compare two commonly used cathepsin-cleavable peptide linkers, valine-citrulline, Pan-VC-CyLBam (Example 5, FIG. 22) and alanine-alanine, Pan-AA-CyLBam, and two disulfides, one hindered gem-dimethyl-substituted variant, Pan-S,SMe2-CyLBam and one primary disulfide, Pan-S,S-CyLBam (FIGS. 35, 36).
- the non-cleavable probe, Pan-NC-CyLBam Example 5, FIG. 22
- the signals of the panel of conjugates were examined in cells expressing variable levels of EGFR.
- the fluorescent signal from linker cleavage was quantified using flow cytometry at 6 and 24 h post-incubation (FIG. 37).
- Pan-S,S-CyLBam exhibited the highest fluorescent signal in EGFR+ MDA-MB-468 cells.
- the other three cleavable probes had only modest fluorescent signal after 6 h, but the signal increased substantially after 24 h.
- Pan-VC-CyLBam had the highest fluorescent signal among the cleavable probes after 24 h, indicating the most extensive linker cleavage.
- CyLBams were tested against an alternative cancer target.
- VC and S,SMe2 linkers were selected for comparison.
- CD276 targeting antibody m276-SL
- non-cleavable NC control m276-SL conjugates were prepared, as well as a non-binding mAb IgG control (DOL 4, FIG. 47).
- DOL 4 FIG. 47
- both cleavable m276-SL conjugates showed high levels of cleavage, with little activation using the control non-binding IgG antibody (FIGS. 48, 49).
- Protease-cleavable m276-SL-VC-CyLBam and the disulfide-cleavable m276-SL-S,SMe2-CyLBam conjugates were compared in JIMT-1 tumors (200-250 mm 3 ) grown orthotopically in the mammary fat pad. As observed in the studies above, only the protease-cleavable m276-SL-VC-CyLBam conjugate exhibited a TBR greater than 5 (5.2 after 48 h), while the disulfide m276-SL-S,SMe2-CyLBam probe exhibited much lower tumor signal (FIGS. 50-53, 54A-54C).
- ADCs The mode of action of ADCs is complex. Optimal efficacy depends on target binding, internalization, and, finally, lysosomal catabolism to initiate payload release. While the linker domain plays a central role in determining the efficacy and selectivity of ADCs, it is challenging to directly assess the site and extent of linker cleavage using conventional methods. This is an important issue because off-target cleavage of ADCs contributes significantly to ADC toxicity (Masters et al., Invest New Drugs 2018, 36:121-135).
- the optical imaging approach detailed here provides a general means to analyze linker chemistry across cellular, tissue, and body-wide scales. This work identified probes suitable for mAb-targeted activatable imaging.
- linker chemistries can be obtained by varying the linker component.
- the properties of the payload molecule e.g. charge, hydrophobicity
- the norcyanine probe is a hydrophobic, sp 2 -rich small molecule, so too are many ADC payloads.
- Further variations of the cyanine component could provide additional insights into the role of pay load properties on tumor and normal tissue distributions. CyLBam imaging could provide insights that directly inform the development of ADCs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Fluorogenic cyanine carbamate compounds have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. The carbamate group may be cleaved by an enzyme or chemical trigger. Following cleavage of the carbamate group, the compound is fluorescent in an acidic environment when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce fluorescence.
Description
FLUOROGENIC CYANINE CARBAMATES
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of the earlier filing date of U.S. Provisional Application No. 63/165,511, filed March 24, 2021, which is incorporated by reference herein in its entirety.
ACKNOWLEDGMENT OF GOVERNMENT SUPPORT
This invention was made with government support under project number Z01 ZIA BC011506 by the National Institutes of Health, National Cancer Institute. The government has certain rights in the invention.
FIELD
Fluorogenic cyanine carbamates are disclosed, as well as methods of making and using the Anorogenic cyanine carbamates.
BACKGROUND
Selectively activating a Auorescent signal is a powerful approach to interrogate biological processes. Fluorogenic probes are powerful tools with significant potential to non-invasively monitor enzymatic processes and other stimuli in real time in living organisms. A common tactic uses multi-chromophore systems that rely on quenching through Fluorescence Resonance Energy Transfer (FRET) and related mechanisms. Another approach uses Auorogenic probes, where the change in signal results from chemical transformations to the chromophore itself. The latter often provides improved tum-ON ratios and benefits from requiring only a single chromophore. The most broadly used Auorogenic chemistry is based on derivatization of the coumarin, rhodamine, and hybrid cyanine scaffolds, which absorb and emit light in the visible to far-red range. To carry out such experiments in living organisms, it would be desirable to have tum-ON probes that absorb and emit long wavelength near- infrared (NIR) light (>700 nm), which is less attenuated by tissue. However, only systems based on FRET pairs or self-quenching have routinely been applied in this range.
Antibody-drug conjugates (ADCs) are a rapidly emerging therapeutic platform. The chemical linker between the antibody and the drug payload plays an essential role in the efficacy and tolerability of these agents. New methods that quantitively assess cleavage efficiency in complex tissue settings could provide valuable insights into the ADC design process. ADC activity
generally requires lysosomal processing of a linker domain to release the active payload. Consequently, the linker component should be stable in circulation, but selectively cleaved following target binding and internalization - a significant chemical challenge. ADCs are conventionally assessed by examining tumoricidal activity and toxicity profiling. While these methods are important benchmarks, they provide only indirect insights into the site and mechanism of drug release. Enzyme-linked immunosorbent assays (ELISAs) are also broadly employed, but only determine the blood-pool concentration and biodistribution of the antibody component. Radiolabeling methods can provide important insights regarding mAb localization, but are costly and do not directly report on the linker cleavage step. Optical imaging has the potential to provide critical insights to the ADC design and optimization process. Prior efforts using stimuli-responsive fluorophores with conventional visible wavelengths have quantified payload processing and internalization kinetics in cellular imaging experiments (Sorkin et al., cell Chem Biol 2019, 26(12):1643-1651e4; Lee et al., Bioconjug Chem 2018, 29(7):2468-2477); Knewtson et al., ACS Omega 2019, 4(7): 12955-19268). However, these probes are not suitable for applications in deep tissue due to the poor penetration depth of wavelengths in the visible region.
Thus, a need exists for Anorogenic probes comprising a single chromophore that has a high turn- ON ratio and emits NIR light.
SUMMARY
Embodiments of cyanine carbamates are disclosed as well as methods of making and using the cyanine carbamates. In some embodiments, the cyanine carbamate is a compound according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof:
where L is substituted or unsubstituted Cn conjugated alkenyl, each carbon having sp2 hybridization, where n is 7, 3, 5, or 9; R1 is substituted aryl or substituted heteroaliphatic, and the bond between the nitrogen atom and -C(O)-O-CH2-R1 is cleavable by an enzyme or chemical trigger; Y1 and Y2 independently are C(Rb)2, N(RC), S, O, or Se, wherein each Rb independently is aliphatic, H, deuterium, aryl, -(OCH2CH2)XOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each Rc independently is H,
deuterium, aliphatic, or heteroaliphatic; R3 and R4 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring; R5-R10 independently are H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a group comprising a conjugatable moiety, a targeting agent, or a drug; and Rx is absent, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H, wherein if Rx is present, the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present.
H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each Ra independently is H, halo, alkyl, or aryl; and (i) R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and, if present, R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug or (iii) each of R11, R11 , and R12 independently is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (iv) R11, R11 , and R12 together with the atoms to which they are bound form a fused cycloaliphatic or heterocycloaliphatic ring system, each ring comprising 5-7 members. In certain embodiments, L is
and A' independently are absent, -CHRd-, -CH2CHR1 -, -CHRdCH2-, or -NRd-, where Rd is H, alkyl, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
In any of the foregoing or following embodiments, the compound may have a structure according to Formula Ila:
In any of the foregoing or following embodiments, Y1 and Y2 independently may be C(Rb)2, where each Rb independently is aliphatic or aryl; R2 and R2 independently may be phenyl, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug; R5 and R8 independently may be -SO3",
, , H, or -OCH3; A and A' independently may be -N(CH3)- or -CH2-; and R3, R4, R6, R7, R9, and R10 may be H. In some embodiments, A or A' is -N(CH3)-. In some embodiments, Y1 and Y2 are -C(CH3)2-. In an independent embodiment, R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring; and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring.
In some embodiments, a pharmaceutical composition comprise a cyanine carbamate as disclosed herein, or stereoisomer thereof, and a pharmaceutically acceptable carrier.
In some embodiments, a method of using a cyanine carbamate includes contacting a biological sample with a compound as disclosed herein; exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R1 from the compound to provide a cleaved compound; exposing the cleaved compound to a pH less than 8; subsequently exposing the cleaved compound to light having a wavelength greater than 700 nm; and detecting fluorescence from the cleaved compound. In some embodiments, the biological sample comprises the enzyme, and exposing the compound to the enzyme comprises contacting the biological sample comprising the enzyme with the compound; or the biological sample comprises the chemical trigger, and exposing the compound to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the compound; or exposing the compound to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the compound. In any of the foregoing or following embodiments, the biological sample may comprise an environment having a pH less than 7, thereby exposing the cleaved compound to the pH less than 7.
In any of the foregoing or following embodiments, the biological sample may comprise, or be suspected of comprising, a target; the compound comprises a group comprising a targeting agent that binds to the target; and detecting fluorescence from the cleaved compound indicates presence of the target in the biological sample. In some embodiments, the targeting agent is an antibody.
In any of the foregoing or following embodiments, contacting the biological sample with the compound may be performed in vivo. In some embodiments, contacting the biological sample in vivo comprises administering the compound or a pharmaceutical composition comprising the compound to a subject; and detecting fluorescence from the cleaved compound is performed via in vivo imaging.
The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a reaction scheme showing cleavage of a cyanine carbamate (CyBam-N ) to produce a norcyanine (Sulfo-NorCy7) and subsequent indolenine protonation of the norcyanine (NorCy7-[H+]).
FIG. 2 shows absorbance spectra of CyBam-Na, Sulfo-NorCy7, and Sulfo-NorCy7-[H+].
FIGS. 3A and 3B show the effects of pH on absorbance (3A) and fluorescence (3B) spectra of CyBam-Na and Sulfo-NorCy7.
FIGS. 4A and 4B are graphs showing conversion of CyBam-Na to Sulfo-NorCy7 by reaction with triphenyl phosphine at pH 5.2 over time (4 A) and the increased fluorescence after the conversion occurred (4B).
FIGS. 5A-5F are graphs comparing properties of two xanthene cyanines. FIGS. 5A and 5B show the absorbance spectra at pH 7.2 (5 A) and 4.5 (5B). FIGS. 5C and 5D show the emission spectra at pH 7.2 (5C) and 4.5 (5D) with an excitation wavelength of 640 nm. FIGS. 5E and 5F show the emission spectra at pH 7.2 (5E) and 4.5 (5F) with an excitation wavelength of 690 nm.
FIGS. 6A-6C are graph showing fluorescence intensity of CyBam-y-Glu (20 pM) after incubation with increasing concentrations of y-glutamyl transpeptidase (GGT, 0-400 U/L) (6A), rate of activation in the presence of GGT (0-400 U/L in PBS (pH 7.4) for 30 minutes (6B), and kinetics of Anorogenic probe activations at different concentrations of CyBam-y-Glu (2.5-50 pM) in PBS (pH 7.4, 37 °C) with 100 U/L GGT (6C). Mean ± SD of Auorescent signal from three independent experiments.
FIG. 7 is a graph showing activation of CyBam-y-Glu (20 pM) after incubation with GGT (100 U/L), leucine aminopeptidase (LAP; 800 U/L), pig-liver esterase (PLE; 800 U/L) at 37 °C for 30 mins in PBS pH 7.4 followed by pH adjustment to pH 5.2. Cathepsin B (CatB; 2.5 mg) was used in acetate buffer pH 5.2 for 30 mins at 37 °C.
FIG. 8 is a graph showing the inhibition of CyBam-y-Glu in the presence of inhibitors DON and GGsTop (1 mM). Mean ± SD of absorbance signal from at least three independent experiments.
FIG. 9 is a series of images showing cellular uptake of Sulfo-NorCy7 (20 pM, red channel) in SHIN-3 cells after 4 h incubation followed by organelle staining (green channel). The upper panels show uptake in mitochondria (Mitotracker Green) and the lower panels show uptake in lysosomes (Lysotracker Green).
FIG. 10 shows confocal images of fluorescence activation of CyBam-y-Glu (20 pM) and CyBam-N.C. (20 pM) showing in vitro uptake of CyBam-y-Glu in SHIN-3 cells.
FIG. 11 shows quantification of fluorescent signal after incubation of CyBam-y-Glu (20 mM) in presence of GGT inhibitors (DON, GGsTop) and CyBam-N.C. in SHIN-3 cells using flow cytometry. Geometric mean fluorescent intensity (± SD) of fluorescent signal in the cells is shown (n = 6 independent experiments).
FIG. 12 shows in vivo imaging of a SHIN-3-ZsGreen metastatic tumor model at 3h after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels, respectively. Fluorescent line graphs show correlation between fluorescent signal from GFP and Cy7 channel across the metastatic tumor in two different regions (A and B). Data points are displayed as mean ± SD, and the p-values were evaluated by student t-test (*** p-value < 0.001).
FIG. 13 shows brightfield, GFP channel, Cy7 channel, and merged images of the SHIN- 3 -Zs Green metastatic tumor model at Ih after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels respectively.
FIG. 14 shows brightfield, GFP channel, Cy7 channel, and merged images of the SHIN- 3 -Zs Green metastatic tumor model at 6h after injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels respectively.
FIG. 15 shows brightfield and Cy7 channel images of mice 4 h after injection with CyBam-y-Glu and CyBam-N.C (25 nM). Signal from tumors, liver and background in mice are
shown in red, blue and magenta dotted circles. Green pseudo colors are used to represent fluorescent signal from and Cy7 channel.
FIGS. 16A and 16B are graphs quantifying the fluorescence signal emitting from the tumors of FIG. 15 (16A) and tumor to background ratio in the mice (16B).
FIGS. 17A and 17B are graphs showing absorbance and fluorescence spectra of A-Me-NorCy7 (5 pM) in PBS pH 7.20 and acetate buffer pH 4.25 (ex. 690 nm) (17A), and determination of pKa in buffers ranging from pH 3.5 - pH 7.4 (17B).
FIG. 18 is graph showing flow cytometry quantification of in vitro uptake of norcyanine heptamethine cyanines (5 mM) in MDA-MB-468 after 1 h incubation.
FIGS. 19A-19F show confocal microscopy images of NorCy7 compounds (5 pM) in MDA-MB-468 cells after 6 h of incubation: A-Me-Pip-NorCy7 (19A), A-Me-NorCy7 (19B), H-NorCy7 (19C), Pip-NorCy7 (19D), OMe-NorCy7 (19E) and Sulfo-NorCy7 (19F). Nucleus and fluorescent signal from probes are shown in the left and center images, respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji.
FIGS. 20A and 20B show organelle localization of N-Me-NorCy7 (5 pM; red channel) in MDA-MB-468 cells after 6 h incubation followed by organelle staining (green channel) with lysosome (Lysotracker Green; 20A) and mitochondria (Mitotracker Green; 20B). Nucleus stained using NucBlue (blue channel). Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/ contrast using Fiji. Scale bar 10 pm.
FIG. 21 is a table calculating degree of labeling (DOL) for Pan-Sulfo-CyBam and Pan-N-Me CyBams cathepsin (VC) and non-cleavable (NC) linkers.
FIG. 22 shows chemical structures of two CyLBam antibody conjugates and two CyBam antibody conjugates.
FIG. 23 shows confocal images (63X) of Pan-VC-CyLBam, Pan-NC-CyLBam, Pan-VC-CyBam, and Pan-NC-CyBam in MDA-MB-468 (EGFR+) after 24 h incubation (23A). Fluorescent signal from the probe and nucleus (Hoechst) is shown in red and blue, respectively. Scale bar 10 pm.
FIG. 24 is a graph showing flow cytometry quantification of in vitro uptake in MDA-MB-468 (EGFR+) and MCF-7 (EGFR-) after 24 h incubation. All antibody conjugates were labeled at DOL 4. Geometric mean fluorescent intensity (± SD) of fluorescent signal in the cells is shown (n = 4 independent experiments; -10,000 cells counted).
FIG. 25 is confocal microscopy images of Pan-VC-CyLBam (A) Pan-NC-CyLBam (B), Pan-VC-CyBam (C) and Pan-NC-CyBam (D) probes in MDA-MB-468 cells. The probes were incubated for 24 h (50 pg; DOL 4). Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji. Scale bar 10 pm.
FIG. 26 is confocal microscopy images of Pan-VC-CyBam probe (50 pg; DOL 4) in MDA-MB-468 (A) and MCF-7 (B) cells after 24 h of incubation. Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The signal in red channel is enhanced to visualize the fluorescent signal from the probe. The images were processed with identical brightness/contrast using Fiji. Scale bar 8 pm.
FIG. 27 is confocal microscopy images of Pan-VC-CyLBam probe (50 pg; DOL 4) in MDA-MB-468 (A) and MCF-7 cells (B); and Pan-NC-CyLBam probe (50 pg; DOL 4) in MDA-MB-468 (C) and MCF-7 cells (D) after 24 h of incubation. Nucleus and Fluorescent signal from probes are pseudo colored in blue and red respectively. Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/contrast using Fiji. Scale bar 10 pm.
FIGS. 28A and 28B are in vivo imaging system fluorescent images 48 h post injection for probes (200 pg; DOL 4) intravenously injected in a xenograft model of female athymic nude mice implanted with MDA-MB-468 tumors (n = 3; tumors are highlighted in dotted circles) (28A); and a graph showing tumor-to-background ratios, the fluorescent signal of the tumor relative to an equal area in the neck measured at different time intervals (4, 48 and 168 h) (28B). Data points are displayed as mean ± SD, and the p-values were evaluated by the Student’s t-test (*** p-value < 0.001, **** p-value < 0.0001).
FIG. 29 shows side view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
FIG. 30 shows ventral view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48,
72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
FIG. 31 shows dorsal view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyBam (DOL 4) (upper images) and Pan-NC-CyBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 745/800 nm).
FIG. 32 shows side view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
FIG. 33 shows ventral view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
FIG. 34 shows dorsal view in vivo imaging following intravenous injection (200 pg in 100 pL PBS pH 7.2) of Pan-VC-CyLBam (DOL 4) (upper images) and Pan-NC-CyLBam (DOL 4) (lower images) in mice containing MDA-MB-468 xenograft tumors. Mice were imaged 4, 24, 48, 72 and 168 h time points. Tumors are shown in dotted circle. Images were captured at (ex/em filter 710/760 nm).
FIG. 35 shows chemical structures of four Pan-CyLBam conjugates - Pan-AA-CyLBam, Pan-S,S-CyLBam and Pan-S,SMe2-CyLBam.
FIG. 36 is a table showing calculation of DOL of Pan-CyLBam conjugates (Pan-CyLBam: VC, AA, S,S, S,SMe2 and NC) with cathepsin and glutathione (GSH) cleavable linkers.
FIG. 37 is a graph showing quantification of in vitro uptake of the Pan-CyLBam conjugates (50 pg; DOL 4) in MDA-MB-468 (EGFR+) and MCF-7 (EGFR-) after 24 h incubation. Geometric mean fluorescent intensity (± SD) of fluorescent signal in the cells is shown (n = 4 independent experiments; -10,000 cells counted).
FIG. 38 is a graph showing quantification of fluorescent signal in MDA-MB-231 cells after 6 and 24 h incubation with the Pan-CyLBam conjugates (50 pg). Geometric mean fluorescent
intensity (± SD) of fluorescent signal in the cells is shown (n = 3 independent experiments; -10,000 cells counted).
FIG. 39 shows fluorescent images following injection of the Pan-CyLBam conjugates (100 pg; DOL 4) in female athymic nude mice (n = 5) with MDA-MB-468 tumors at 48 h time point. Tumors are highlighted in dotted white circles.
FIG. 40 is a graph showing quantification of tumor-to-background ratio 48 hours post injection in the mice of FIG. 39.
FIG. 41 is a graph showing quantification of fluorescent signal of Pan-AA-CyLBam from liver and tumor in the mice of FIG. 39. Tumor-to-liver ratio (TLR) is depicted in insert. Data points are displayed as mean ± SD, and the p- values were evaluated by the Student’s t-test (** p- value < 0.01, *** p-value < 0.001).
FIG. 42 shows ventral view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2). Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
FIG. 43 shows side view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2). Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
FIG. 44 shows dorsal view in vivo imaging of mice at 4, 24 and 48 h after intravenous injection of Pan- CyLBam conjugates (100 pg in 100 pL PBS pH 7.2). Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S -CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
FIG. 45 shows ex vivo imaging of mice at 48 h after intravenous injection of Pan-CyLBam conjugates (100 pg in 100 pL PBS pH 7.2). Pan-VC-CyLBam (row A), Pan-AA-CyLBam (row B), Pan-S,S-CyLBam (row C), Pan-S,SMe2-CyLBam (row D), and Pan-NC-CyLBam (row E). Images were captured at (ex/em filter 710/760 nm).
FIGS. 46A and 46B are graphs showing ex vivo quantification of Pan-VC-CyLBam, Pan-AA-CyLBam, Pan-S,S- CyLBam, Pan-S,SMe2-CyLBam, and Pan-NC-CyLBam. tumor to liver ratio (46 A) and tumor to muscle ratio (46B). The p-values were evaluated by Student’s t-test (ns p- value > 0.05, * p-value < 0.05, *** p-value < 0.001).
FIG. 47 is a table showing calculation of DOL of m276-SL and IgG-CyLBams with cathepsin and GSH cleavable linkers.
FIG. 48 is a graph showing quantification of cellular uptake of m276-SL-S,SMe2-CyLBam, m276-SL-VC-CyLBam and m276-SL-NC-CyLBam (80 mg; DOL 4) in JIMT-1 cells following 24 h incubation. Geometric mean fluorescent intensity (± SD) of fluorescent signal in the cells is shown (n = 4 independent experiments; -10,000 cells counted).
FIG. 49 is a graph showing quantification of cellular uptake of m276-SL and IgG conjugated with VC-CyLBam, S,SMe2-CyLBam and NC-CyLBam linkers (80 pg; DOL 4) in JIMT-1 after 24 h incubation. Geometric mean fluorescent intensity ( ± SD) of fluorescent signal in the cells is shown (n = 4 independent experiments; -10,000 cells counted).
FIG. 50 is a graph showing tumor-to-background ratios at different time intervals after intravenous injection of m276-SL-S,SMe2-CyLBam and m276-SL- VC-CyLBam (100 pg; DOL - 4) in female athymic nude mice bearing orthotopic JIMT-1 tumors (n = 5).
FIG. 51 is fluorescence images of the mice of FIG. 50 72 h post injection. Tumors are highlighted in dotted circles.
FIG. 52 shows in vivo imaging of mice intravenously injected with m276-SL-VC-CyLBam (100 pg in 100 pL PBS pH 7.2) at different orientations, side view (panel A), dorsal view (panel B), and ventral view (panel C). The mice were imaged at 4, 24, 48, 72 and 168 h. Images were captured at (ex/em filter 710/760 nm).
FIG. 53 shows in vivo imaging of mice intravenously injected with m276-SL-S,SMe2-CyLBam (100 pg in 100 pL PBS pH 7.2) at different orientations, side view (panel A), dorsal view (panel B), and ventral view (panel C). The mice were imaged at 4, 24, 48, 72 and 168 h. Images were captured at (ex/em filter 710/760 nm).
FIGS. 54A-54C are graphs quantifying fluorescent signal from Pan-VC-CyLBam and Pan-NC-CyLBam (ex/em 710/760 nm): total fluorescent signal (54A), tumor to liver ratio (54B), and liver to background ratio (54C).
DETAILED DESCRIPTION
Fluorogenic cyanine carbamates are disclosed. Methods of making and using the compounds also are disclosed. The compounds include a carbamate group that may be cleaved by an enzyme or chemical trigger to produce a corresponding pH-responsive norcyanine. Following cleavage of the carbamate group, fluorescence intensity of the compound increases in a near-neutral or acidic environment (e.g., when the cleaved compound is protonated) when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce fluorescence, preferably in the near-infrared range.
Fluorogenic tum-ON probes that use near-infrared (NIR) wavelengths (-700-900 nm) have significant potential to provide insight into dynamics and localization of biological phenomena in complex tissue settings. Disclosed herein are fluorogenic cyanine carbamates that exhibit exceptional turn-ON ratios. In some embodiments, untargeted compounds enable in vivo imaging in a metastatic tumor model. In certain embodiments, mAb-conjugated variants provide a real-time, quantitative approach to determine the site and extent of antibody-drug-conjugate linker cleavage in complex model organisms. In particular implementations, inclusion of a basic amine in the cyanine carbamate molecule dramatically improves cellular photon output, likely due to enhanced lysosomal uptake and retention.
I. Definitions and Abbreviations
The following explanations of terms and abbreviations are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. As used herein, “comprising” means “including” and the singular forms “a” or “an” or “the” include plural references unless the context clearly dictates otherwise. The term “or” refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise.
Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features of the disclosure are apparent from the following detailed description and the claims.
The disclosure of numerical ranges should be understood as referring to each discrete point within the range, inclusive of endpoints, unless otherwise noted. Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, percentages, temperatures, times, and so forth, as used in the specification or claims are to be understood as being modified by the term “about.” Accordingly, unless otherwise implicitly or explicitly indicated, or unless the context is properly understood by a person of ordinary skill in the art to have a more definitive construction, the numerical parameters set forth are approximations that may depend on the desired properties sought and/or limits of detection under standard test conditions/methods as known to those of ordinary skill in the art. When directly and explicitly distinguishing embodiments from
discussed prior art, the embodiment numbers are not approximates unless the word “about” is recited.
Although there are alternatives for various components, parameters, operating conditions, etc. set forth herein, that does not mean that those alternatives are necessarily equivalent and/or perform equally well. Nor does it mean that the alternatives are listed in a preferred order unless stated otherwise.
Definitions of common terms in chemistry may be found in Richard J. Lewis, Sr. (ed.), Hawley’s Condensed Chemical Dictionary, published by John Wiley & Sons, Inc., 2016 (ISBN 978-1-118-13515-0). Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes VII, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); and other similar references.
In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
Aliphatic: A substantially hydrocarbon-based compound, or a radical thereof (e.g., Cetin, for a hexane radical), including alkanes, alkenes, alkynes, including cyclic versions thereof (cycloaliphatic), and further including straight- and branched-chain arrangements, and all stereo and position isomers as well. Unless expressly stated otherwise, an aliphatic group contains from one to twenty-five carbon atoms; for example, from one to fifteen, from one to ten, from one to six, or from one to four carbon atoms. An aliphatic chain may be substituted or unsubstituted. Unless otherwise specified, an aliphatic group can either be unsubstituted or substituted. An aliphatic group can be substituted with one or more substituents (up to two substituents for each methylene carbon in an aliphatic chain, or up to one substituent for each carbon of a -C=C- double bond in an aliphatic chain, or up to one substituent for a carbon of a terminal methine group). Exemplary substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amide, amino, aminoalkyl, aryl, arylalkyl, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, oxo, sulfonamide, sulfhydryl, thioalkoxy, or other functionality.
Alkyl: A hydrocarbon group having a saturated carbon chain. The chain may be branched, unbranched, or cyclic (cycloalkyl). Unless otherwise specified, the term alkyl encompasses substituted and unsubstituted alkyl.
Alkylaryl: An alkyl radical substituted with a terminal aryl group. One nonlimiting example of an alkylaryl group is -(CH2)n-aryl, such as benzyl. Unless otherwise specified, the aryl group may be substituted or unsubstituted. The alkyl radical may include substituents in addition to the aryl group.
Amino: A chemical functional group -N(R)R' where R and R' are independently hydrogen, alkyl, heteroalkyl, haloalkyl, aliphatic, heteroaliphatic, aryl (such as optionally substituted phenyl or benzyl), heteroaryl, alkylsulfano, or other functionality. A “primary amino” group is -NH2. “Mono-substituted amino” means a radical -N(H)R substituted as above and includes, e.g., methylamino, (l-methylethyl)amino, phenylamino, and the like. “Di-substituted amino” means a radical -N(R)R' substituted as above and includes, e.g., dimethylamino, methylethylamino, di(l-methylethyl)amino, and the like.
Antibody: A protein (or protein complex) that includes one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad of immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. In avian and reptilian species, IgY antibodies are equivalent to mammalian IgG.
The basic immunoglobulin (antibody) structural unit is generally a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” (about 50-70 kDa) chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms “variable light chain” (VL) and “variable heavy chain” (Vn) refer, respectively, to these light and heavy chains.
The structure of IgY antibodies is similar to the structure of mammalian IgG, with two heavy ("nu" chains; approximately 67-70 kDa) and two light chains (22-30 kDa). The molecular weight of an IgY molecule is about 180 kDa, but it often runs as a smear on gels due to the presence of about 3% carbohydrate. Heavy chains (H) of IgY antibodies are composed of four constant domains and one variable domain, which contains the antigen-binding site.
As used herein, the term “antibodies” includes intact immunoglobulins as well as a number of well-characterized fragments. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to target protein (or epitope within a protein or fusion protein) would also be specific binding agents for that protein (or epitope). These antibody fragments are defined as follows: (1) Fab, the
fragment which contains a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab’, the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab’ fragments are obtained per antibody molecule; (3) (Fab’)2, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab’)2, a dimer of two Fab’ fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody, a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Methods of making these fragments are routine (see, for example, Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999). As used herein, the term “antibodies” includes antibodies comprising one or more unnatural (i.e., non-naturally occurring) amino acids (e.g., p-acetyl-phenylalanine) to facilitate site-specific conjugation.
Antibodies for use in the methods of this disclosure can be monoclonal or polyclonal, and for example specifically bind a target such as the target antigen. Merely by way of example, monoclonal antibodies can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (Nature 256:495-97, 1975) or derivative methods thereof. Detailed procedures for monoclonal antibody production are described in Harlow and Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999.
Antigen: A compound, composition, or substance that can stimulate the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous immunogens. As used herein, a “target antigen” is an antigen (including an epitope of the antigen) that is recognized and bound by a targeting agent. “Specific binding” does not require exclusive binding. In some embodiments, the antigen is obtained from a cell or tissue extract. In some embodiments, the target antigen is an antigen on a tumor cell. An antigen need not be a full-length protein. Antigens contemplated for use include any immunogenic fragments of a protein, such as any antigens having at least one epitope that can be specifically bound by an antibody.
Aryl: A monovalent aromatic carbocyclic group of, unless specified otherwise, from 6 to 15 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings in which at least
one ring is aromatic (e.g., quinoline, indole, benzodioxole, and the like), provided that the point of attachment is through an atom of an aromatic portion of the aryl group and the aromatic portion at the point of attachment contains only carbons in the aromatic ring. If any aromatic ring portion contains a heteroatom, the group is a heteroaryl and not an aryl. Aryl groups are monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise specified, the term aryl encompasses substituted and unsubstituted aryl.
Biological sample: As used herein, a “biological sample” refers to a sample obtained from a subject (such as a human or veterinary subject) or other type of organism, such as a plant, bacteria or insect. Biological samples from a subject include, but are not limited to, cells, tissue, serum, blood, plasma, urine, saliva, cerebral spinal fluid (CSF) or other bodily fluid. In particular examples of the method disclosed herein, the biological sample is a tissue sample.
Chemical trigger: As used herein, the term “chemical trigger” refers to a non-enzyme compound capable of cleaving a carbamate group from a Anorogenic cyanine carbamate compound as disclosed herein. For example, triphenylphosphine is capable of cleaving a -C(O)-O-CH2-C6HSN3 group from a cyanine carbamate compound as disclosed herein.
Conjugatable moiety: A portion of a molecule that allows the molecule to be conjugated (i.e., coupled or bound) to another molecule, e.g., to a drug or targeting agent such as an antibody.
Drug: As used herein, the term “drug” refers to a substance which has a physiological effect when administered to a subject, and is intended for use in the treatment, mitigation, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. The term “small molecule drug” refers to a drug having a molecular weight < 1,000 Daltons.
Effective amount: As used herein, the term “effective amount” refers to an amount sufficient for detection in a biological sample, e.g., by Auorescence.
Enzyme: A protein molecule that is capable of catalyzing a chemical reaction. For example, galactosidase is an enzyme capable of hydrolyzing P-galactosides into monosaccharides through the breaking of a glycosidic bond.
Halogen: The terms halogen and halo refer to Auorine, chlorine, bromine, iodine, and radicals thereof.
Heteroaliphatic: An aliphatic compound or group having at least one heteroatom, i.e., one or more carbon atoms has been replaced with an atom having at least one lone pair of electrons, typically nitrogen, oxygen, phosphorus, silicon, or sulfur. Unless otherwise specified, heteroaliphatic compounds or groups may be substituted or unsubstituted, branched or unbranched,
cyclic (heterocycloaliphatic) or acyclic, and include "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" groups.
Heteroalkylaryl: As used in the term heteroalkylaryl refers to a heteroalkyl radical substituted with a terminal aryl group. Unless otherwise specified, the aryl group may be substituted or unsubstituted. The heteroalkyl radical may include substituents in addition to the aryl group.
Heteroaryl: An aromatic compound or group having at least one heteroatom, i.e., one or more carbon atoms in the ring has been replaced with an atom having at least one lone pair of electrons, typically nitrogen, oxygen, phosphorus, silicon, or sulfur. Unless otherwise specified, the term heteroaryl encompasses substituted and unsubstituted heteroaryl.
Ligand: A molecule that binds to a receptor, having a biological effect.
Near-infrared (near-IR, NIR): Wavelengths within the range of 650-2500 nm. NIR wavelengths for optical imaging of tissue may be divided into three windows - NIR-I, 650-950 nm; NIR-II, 1000-1350 nm (sometimes defined as 1000-1700 nm); and NIR-III, 1600-1870 nm. Unless otherwise specified, the terms “near-infrared” and “NIR” as used herein refer to wavelengths within the range of 650-1350 nm.
Norcyanine: As used herein, the term “norcyanine” refers to the product following cleavage of the carbamate group from a cyanine carbamate compound.
Pharmaceutically acceptable carrier: The pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. Remington: The Science and Practice of Pharmacy, The University of the Sciences in Philadelphia, Editor, Lippincott, Williams, & Wilkins, Philadelphia, PA, 21st Edition (2005), describes compositions and formulations suitable for pharmaceutical delivery of one or more targeting agent-drug conjugates as disclosed herein.
In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. In some examples, the pharmaceutically acceptable carrier may be sterile to be suitable for administration to a subject (for example, by parenteral, intramuscular, or subcutaneous injection). In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
Pharmaceutically acceptable salt: A biologically compatible salt of a disclosed conjugate, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like. Pharmaceutically acceptable acid addition salts are those salts that retain the biological effectiveness of the free bases while formed by acid partners that are not biologically or otherwise undesirable, e.g., inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, -lol uenesul Ionic acid, salicylic acid and the like. Pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for example, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharrn. Sci., 1977; 66:1-19, which is incorporated herein by reference.)
Specific binding partner: A member of a pair of molecules that interact by means of specific, non-covalent interactions that depend on the three-dimensional structures of the molecules involved. Exemplary pairs of specific binding partners include antigen/antibody, hapten/antibody, receptor/ligand, nucleic acid strand/complementary nucleic acid strand, substrate/enzyme, inhibitor/enzyme, carbohydrate/lectin, biotin/avidin (such as biotin/streptavidin), and virus/cellular receptor.
Substituent: An atom or group of atoms that replaces another atom in a molecule as the result of a reaction. The term "substituent" typically refers to an atom or group of atoms that replaces a hydrogen atom, or two hydrogen atoms if the substituent is attached via a double bond, on a parent hydrocarbon chain or ring. The term “substituent” may also cover groups of atoms having multiple points of attachment to the molecule, e.g., the substituent replaces two or more hydrogen atoms on a parent hydrocarbon chain or ring. In such instances, the substituent, unless otherwise specified, may be attached in any spatial orientation to the parent hydrocarbon chain or ring. Exemplary substituents include, for instance, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thioalkoxy groups.
Substituted: A fundamental compound, such as an aryl or aliphatic compound, or a radical thereof, having coupled thereto one or more substituents, each substituent typically replacing a hydrogen atom on the fundamental compound. Solely by way of example and without limitation, a substituted aryl compound may have an aliphatic group coupled to the closed ring of the aryl base, such as with toluene. Again solely by way of example and without limitation, a long-chain hydrocarbon may have a hydroxyl group bonded thereto.
Sulfonate-containing group: A group including SO3". The term sulfonate-containing group includes -SO3" and -RSO3" groups, where R is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
Target: An intended molecule to which a disclosed conjugate comprising a targeting agent is capable of specifically binding. Examples of targets include proteins and nucleic acid sequences present in tissue samples. A target area is an area in which a target molecule is located or potentially located.
Targeting agent: An agent that promotes preferential or targeted delivery to a target site, for example, a targeted location in a subject’s body, such as a specific organ, organelle, physiologic system, tissue, or site of pathology such as a tumor, area of infection, or area of tissue injury. Targeting agents function by a variety of mechanisms, such as selective concentration in a target site or by binding to a specific binding partner. Suitable targeting agents include, but are not limited to, proteins, polypeptides, peptides, glycoproteins and other glycoslyated molecules, oligonucleotides, phospholipids, lipoproteins, alkaloids, steroids, and nanoparticles. Exemplary
targeting agents include antibodies, antibody fragments, affibodies, aptamers, albumin, cytokines, lymphokines, growth factors, hormones, enzymes, immune modulators, receptor proteins, antisense oligonucleotides, peptides, avidin, nanobodies (small (15kDa) antigen-binding VHH fragments derived from heavy chain only antibodies present in camelids and cartilaginous fishes), nanoparticles, and the like. Particularly useful targeting agents are antibodies, peptides, nanobodies, nucleic acid sequences, and receptor ligands, although any pair of specific binding partners can be readily employed for this purpose.
II. Fluorogenic Cyanine Carbamates
Fluorogenic cyanine carbamate compounds are disclosed. The compounds include a carbamate group that may be cleaved by an enzyme or chemical trigger. Following cleavage of the carbamate group, the compound is fluorescent in an acidic environment (i.e., when the cleaved compound is protonated) when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce fluorescence.
In some embodiments, the fluorogenic cyanine carbamate has a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof:
The bond indicated by ” is an optional bond, which is present when Rx is present and absent when Rx is absent. L is substituted or unsubstituted conjugated alkenyl, each carbon having sp2 hybridization. R1 is substituted aryl or substituted heteroaliphatic, and the bond between the nitrogen atom and -C(O)-O-CH2-R1 is cleavable by an enzyme or chemical trigger. Y1 and Y2 independently are C(Rb)2, N(RC), S, O, or Se, wherein each Rb independently is aliphatic, H, deuterium, aryl, -(OCfFCfFjxOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each Rc independently is H, deuterium, aliphatic, or heteroaliphatic. R3 and R4 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring. R5-R10 independently are H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a
group comprising a conjugatable moiety, a targeting agent, or a drug. Rx is absent, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H, wherein if Rx is present, the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present. Suitable counterions include, but are not limited to, halide (fluoride, chloride, iodide, or bromide), hydroxy, carboxylate (e.g., formate, acetate), nitrate, hydrogen sulfate, hydrogen carbonate, dihydrogen phosphate, and hexafluorophosphate, among others.
In any of the foregoing or following embodiments, the recited groups may be substituted or unsubstituted, unless otherwise specified. For example, the term “aryl” encompasses both substituted and unsubstituted aryl groups. In some implementations, the substituent is further substituted. The substituent may be substituted with any substituent that does not interfere with cleavage of the carbamate group and/or near-infrared fluorescence of the cleaved compound. Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thioalkoxy groups, and combinations thereof. For instance, in one nonlimiting example, R1 is a substituted aryl group wherein the substituent is a substituted heteroaliphatic chain, e.g.,
L is substituted or unsubstituted conjugated alkenyl, each carbon having sp2 hybridization.
In some embodiments, L is substituted or unsubstituted Cn conjugated alkenyl where n is 3, 5, 7, or
In any of the foregoing or following embodiments, R2 and R2 independently are aryl, heteroaryl, heterocycloaliphatic, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug. Each Ra independently is H, halo, alkyl, or aryl.
In any of the foregoing or following embodiments, when L contains R11 and R12, but does not include R11 , then (i) R11 and R12 independently are H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R11 and R12 together with the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring.
In any of the foregoing or following embodiments, when L contains R11, R11 , and R12, then (i) R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R11 together with R12 and the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug or (iii) each of R11, R11 , and R12 independently is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (iv) R11, R11 , and R12 together with the atoms to which they are bound form a fused cycloaliphatic or heterocycloaliphatic ring system, each ring comprising 5-7 members
-CHRd-, -CH2CHRd-, -CHRdCH2-, or -NRd-, where Rd is H, alkyl, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug. In some embodiments, A and A' independently are -CHRd- or -NRd-. In certain implementations, A and A' independently are -CH2- or -N(CH3)-. When A and/or A' is -CH2-, the compound may hereinafter be referred to as a CyBam compound. When A and/or A' is -N(CH3)-, the compound may hereinafter be referred to as a CyLBam compound. In some embodiments, a CyLBam exhibits improved cellular permeability and lysosomal accumulation in vivo. Advantageously, presence of -N(CH3)- at A and/or A' dramatically improves cellular photon output, likely due to enhanced lysosomal uptake and retention.
In some implementations, A and/or A' may comprise a targeting agent or a conjugatable moiety. In certain embodiments, Rd is -(CH2)m-Re, -(CH2)mCH(NH2)-Re, -(CH2)mC(O)Re, -(CH2)mN(H)Re, -(CH2)mN(H)C(O)Re, -(CH2)mC(O)N(H)Re, -(CH2)mC(O)SRe, -C(O)Re, -C(O)N(H)Re, -C(O)N(H)(CH2CH2O)n(CH2)mC(O)Re, -N(H)C(O)Re, -N(H)Re, or -SRe, where m is
an integer > 1. Re is a targeting agent, -OH, -COOH, a phosphoramidite,
In some embodiments, the Anorogenic cyanine carbamate has a structure according to any one of Formulas II-IV, or a stereoisomer or pharmaceutically acceptable salt thereof:
R'-R12, R2, R11 , RX, Y1, and Y2 are as previously defined. In some implementations, Rx is absent.
If Rx is present, then the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present. In some implementations, R11 and/or R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring, and the Anorogenic cyanine carbamate has a structure according to formula Ila, Va, Vb, or Vc, or a stereoisomer or pharmaceutically acceptable salt thereof.
R^-R11, R2, R11 , Rx, A, A', Y1, and Y2 are as previously defined. In some embodiments, A and A' independently are -CHRd- or -NRd-, where Rd is H or alkyl. In certain implementations, A and A' independently are -CH2- or -N(CH3)-. In some implementations, Rx is absent. If Rx is present, then the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present.
In any of the foregoing or following embodiments, Y1 and Y2 independently may be C(Rb)2, N(RC), S, O, or Se, wherein each Rb independently is H, deuterium, aliphatic, aryl, -(OCH2CH2)XOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each Rc independently is H, deuterium, aliphatic, or heteroaliphatic. In some embodiments, Y1 and Y2 independently are C(Rb)2, where each Rb independently is aliphatic or aryl. In some implementations, each Rb independently is aliphatic, such as C1-C5 alkyl. In certain embodiments, Y1 and Y2 are -C(CH3)2-.
In any of the foregoing or following embodiments, R3 and R4 independently may be H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R3 and Y1 together with the atoms to which they are bound may form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound may form a 6-membered aryl ring. In some embodiments, R3 and R4 are H.
In some implementations, R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring. In such embodiments, the Anorogenic cyanine carbamate may have a structure according to any one of Formulas lib, Illa, IVa, or Vd, or a stereoisomer or pharmaceutically acceptable salt thereof:
R1, R2, R2 , R5-R12, R11 , and Rx are as previously defined. R13-R18 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug. In some implementations, R11 and/or R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring, and the Anorogenic cyanine carbamate has a structure according to formula lie, Ve, Vf, or Vg , or a stereoisomer or pharmaceutically acceptable salt thereof.
R1, R2, R2 , R5-Rn, R11 , R13-R18, RX, A, and A' are as previously defined.
In any of the foregoing or following embodiments, R2 and R2 independently are aryl, heteroaryl, heterocycloaliphatic, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each Ra independently is H, halo, alkyl, or aryl. In some
implementations, R2 and/or R2 is aryl. In certain embodiments, R2 and/or R2 is unsubstituted phenyl. In some implementations, R2 and/or R2 is phenyl substituted with -(CH2)PCO2H where p is an integer from 0 to 10 (e.g., -CO2H or -C2H4CO2H), an aryl group, or a group comprising a conjugatable moiety, a targeting agent (e.g., an antibody, a peptide, or a nanobody), or a drug. In some embodiments, the substituent is para to the attachment of R2 and/or R2 to the remainder of the molecule. In some embodiments, R2 and/or R2 is H, halo (e.g., chloro), -ORa, or -NRa 2, where each Ra independently is H, halo, alkyl, or aryl. In some implementations, when R2 and R2 are both present, one of R2 and R2 is H and the other of R2 and R2 is aryl, heteroaryl, heterocycloaliphatic, H, halo, -ORa, -NRa 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
or a targeting agent, where y is an integer > 1.
In any of the foregoing or following embodiments, R2 and/or R2 may be unsubstituted or substituted phenyl as previously described above, H, halo, -ORa, -NRa 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug. In any of the foregoing or following embodiments, R5 and R8 independently may be H or a sulfonate-containing group, such as -SO3" or
In any of the foregoing or following embodiments where the Anorogenic cyanine carbonate comprises a ring comprising A, a ring comprising A', or rings comprising A and A', A and A' independently may be -CH2- or -N(CH3)-. In some implementations, R3, R4, R6, R7, R9, R10, and R13-R18 are H. If present, R11 or R11 may also be H.
In any of the foregoing or following embodiments, R5-R10 independently may be H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a group comprising a conjugatable moiety, a targeting agent, or a drug. In any of the foregoing or following embodiments, R5 and R8
independently may be H, a sulfonate-containing group, or heteroahphatic. In some embodiments, i, n /~ » f~ \
, 8 “Hr _ “ ’
R3 and R8 independently are -SO3", 0 , 0 , H, or -OCH3. In some embodiments, R3, R4, R6, R7, R9, and R10 are H. In certain implementations, R3, R4, R6, R7, R9, R10, and R13-R18 are H.
In any of the foregoing or following embodiments, Rx may be absent, aliphatic, heteroaliphatic, aryl, heteroaryl, or H, wherein if Rx is present, the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present. In some embodiments, Rx is absent. In some implementations, Rx is aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H; in such implementations, the nitrogen to which Rx is attached has a +1 charge and the counterion X" is present. In certain implementations, Rx is alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, or H. For example, Rx may be H, C1-C10 straight, branched, or cyclo alkyl or alkenyl, C2-C10 straight, branched, or cyclo heteroalkyl or heteroalkenyl, phenyl, pyridinyl, pyrrolyl, pyrimidinyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, furyl, or thiophenyl. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl (2-methylpropyl), sec-butyl (butan-2-yl), tert-butyl, and the like. Exemplary heteroalkyl groups include, but are not limited to, alkoxy groups (methoxy, ethoxy, propoxy, cyclopropoxy, cyclobutoxy, and the like), as well as groups including nitrogen or sulfur heteroatoms. Exemplary cycloalkyl and cycloalkenyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Exemplary cycloheteroalkyl groups include, but are not limited to, piperidinyl, pyrrolidinyl, piperazinyl, furyl, tetrahydrofuryl, and morpholinyl groups.
In certain embodiments, the Anorogenic cyanine carbamate has a structure according to Formula IIA where R1 and Rx are as previously defined, R2 is substituted or unsubstituted phenyl; A is -CH2- or -N(CH3)-; Y1 and Y2 are C(CH3)2; R3, R4, R6, R7, R9, and R10 are H; and R5 and R8 are -SO3",
, , H, or -OCH3. In certain implementations, the compound has a structure according to any one of Formulas Ild-IIi, or a stereoisomer or pharmaceutically acceptable salt thereof, where R1 and R13 are as previously defined. In certain implementations, Rx is absent.
In any of the foregoing or following embodiments, Rx may be absent, and the Anorogenic cyanine carbamate may have a formula as shown in Table 1, wherein R^-R18, R2 , R11 , Y1, Y2, A, and A' are as previously defined.
Advantageously, the carbamate group, -C(O)OCH2R1, is cleavable by one or more enzymes or chemical triggers. R1 may be chosen to provide selectivity for a particular enzyme or chemical trigger. In any of the foregoing or following embodiments, R1 may be substituted aryl or substituted heteroaliphatic. In some embodiments, R1 is substituted phenyl or substituted heteroaliphatic. In some implementations, R1 is
-N3, -NO2, a heterocycle,
-O-heterocycloaliphatic, -O-heteroaliphatic, -O-aliphatic, -O-heteroalkylaryl, -O-alkylaryl, or -O-aryl, where R' is aliphatic and each R" independently is H or aliphatic. Rs is aliphatic, heteroaliphatic, heterocycloaliphatic, alkylaryl, or heteroalkylaryl. Rh is aliphatic. In any of the foregoing recitations, the heterocycle, heterocycloaliphatic, heteroaliphatic, alkyl, aryl, aliphatic, or heteroaliphatic portions may be substituted or unsubstituted. Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, acyl, aldehyde, amido, amino, aminoalkyl, aryl, arylalkyl, arylamino, carbonate, carboxyl, cyano, cycloalkyl, dialkylamino, halo, haloaliphatic (e.g., haloalkyl), haloalkoxy, heteroaliphatic, heteroaryl, heterocycloaliphatic, hydroxyl, isocyano, isothiocyano, oxo, sulfonamide, sulfhydryl, thio, and thioalkoxy groups, conjugatable groups, targeting agents, and combinations thereof. Aliphatic, heteroaliphatic, and alkyl moieties may be straight or branched chains. In one embodiment, -C(O)OCH2R1 may not be cleavable, and the compound may be utilized as a nonfluorescent control compound.
Several exemplary R1 groups are shown in Table 2.
In any of the foregoing or following embodiments, one of R 1 -R1 s, R2’ A, A', Y1, or Y2 may comprise a group comprising a targeting agent. In some embodiments, R2, R2 , A, or A' comprises the group comprising the targeting agent. In certain implementations, R1 comprises the targeting agent, and the targeting agent thus is cleaved from the compound upon exposure to the enzyme or chemical trigger. In any of the foregoing or following embodiments, the targeting agent may be an antibody, a peptide, or a nanobody. In some implementations, the targeting agent is an antibody. In certain examples, the antibody is panitumumab.
In any of the foregoing or following embodiments, one of R2-R18, R2 , R11 , A, A', Y1, or Y2 may comprise a group comprising a drug. Exemplary groups comprising a drug include, but are not limited to, groups having a formula -Li-C(O)-X1-drug, where Li is a linker moiety or is absent and X1 is O, N(H), or N(CH3). In one embodiment, Li is absent. In another embodiment, Li is O. In an independent embodiment, Li is aryl or heteroaryl substituted with at least one substituent comprising a substituted or unsubstituted aliphatic or heteroaliphatic moiety, wherein the aryl or heteroaryl ring is the site of attachment to the remainder of the conformationally restricted cyanine fluorophore and the substituent is bonded to the -C(O)-X1-drug moiety. In some embodiments, the group comprising a drug is:
independently are H, alkyl, -NO2, -NR*2, -NR1 , alkoxy, or sulfonate, wherein each R1 independently is H, halo, or alkyl. In certain embodiments, R19-R26 are H. In some examples, the group comprising a drug is -C(O)-X1-Drug. The drug can be any drug capable of conjugation to the remainder of the group. In some embodiments, the drug is a small-molecule drug, e.g., a drug having a molecular weight < 1,000 Daltons. In certain embodiments, the drug moiety is an anti-cancer drug.
III. Pharmaceutical Compositions
This disclosure also includes pharmaceutical compositions comprising at least one Anorogenic cyanine carbamate compound as disclosed herein. Some embodiments of the pharmaceutical compositions include a pharmaceutically acceptable carrier and at least one
fluorogenic cyanine carbamate. Useful pharmaceutically acceptable carriers and excipients are known in the art.
The pharmaceutical compositions comprising one or more fluorogenic cyanine carbamates may be formulated in a variety of ways depending, for example, on the mode of administration and/or on the location to be imaged. Parenteral formulations may comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like. Excipients may include, for example, nonionic solubilizers, such as Cremophor®, or proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition to be administered may also contain non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.
The form of the pharmaceutical composition will be determined by the mode of administration chosen. Embodiments of the disclosed pharmaceutical compositions may take a form suitable for virtually any mode of administration, including, for example, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, etc., or a form suitable for administration by inhalation or insufflation. Generally, embodiments of the disclosed pharmaceutical compositions will be administered by injection, systemically, or orally.
Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles. The compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent. The formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, and may contain added preservatives. The composition may take such forms as suspension, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. For example, parenteral administration may be done by bolus injection or continuous infusion. Alternatively, the fluorogenic cyanine carbamate may be in powder form for reconstitution with a suitable vehicle, e.g. sterile water, before use.
Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.
Oral formulations may be liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powder, tablets, or capsules). Oral formulations may be coupled with targeting ligands for crossing the endothelial barrier. Some fluorogenic cyanine carbamate formulations may be dried, e.g., by
spray-drying with a disaccharide, to form Anorogenic cyanine carbamate powders. Solid compositions prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, mannitol, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets may be coated by methods well known in the art with, for example, sugars, films or enteric coatings. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art.
Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, Cremophor® or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, preservatives, Aavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the Auorophore, as is well known.
For rectal and vaginal routes of administration, the Anorogenic cyanine carbamate(s) may be formulated as solutions (for retention enemas) suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
For nasal administration or administration by inhalation or insufAation, the Anorogenic cyanine carbamate(s) can be conveniently delivered in the form of an aerosol spray or mist from pressurized packs or a nebulizer with the use of a suitable propellant, e.g., dichlorodiAuoromethane, trichloro Auoromethane, dichlorotetraAuoroethane, Auorocarbons, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.
Certain embodiments of the pharmaceutical compositions comprising Anorogenic cyanine carbamates as described herein may be formulated in unit dosage form suitable for individual administration of precise dosages. The pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the Anorogenic cyanine carbamate. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.
The amount of Anorogenic cyanine carbamate administered will depend at least in part on the subject being treated, the target (e.g., the size, location, and characteristics of a tumor), and the manner of administration, and may be determined as is known to those skilled in the art of pharmaceutical composition and/or contrast agent administration. Within these bounds, the formulation to be administered will contain a quantity of the Anorogenic cyanine carbamate disclosed herein in an amount effective to enable visualization of the Anorogenic cyanine carbamate by suitable means after administration to the subject. In certain embodiments, the Anorogenic cyanine carbamate comprises a drug bound to the molecule, and the formulation to be administered will contain a quantity of the drug bound to the Anorogenic cyanine carbamate effective to provide a therapeutically effective dose of the drug to the subject being treated.
In some embodiments, the pharmaceutical composition includes a second agent other than the Anorogenic cyanine carbamate. The second agent may be, for example, an anti-tumor agent or an angiogenesis inhibitor.
IV. Uses
Embodiments of the disclosed Anorogenic cyanine carbamates are suitable for in vivo, ex vivo, or in vitro use. Advantageously, following cleavage of the carbamate group, the compound is Auorescent in an acidic or neutral pH environment when irradiated with targeted application of an effective quantity of light having a selected wavelength and a selected intensity to induce Auorescence.
In some embodiments, a method of using a Anorogenic cyanine carbamate as disclosed herein includes contacting a biological sample with the compound, exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R1 from the compound to provide a cleaved compound (hereinafter referred to as a “norcyanine”), exposing the norcyanine to a pH less than 8, subsequently exposing the norcyanine to light having a wavelength greater than 700 nm, and detecting Auorescence from the norcyanine. In some embodiments, the cyanine carbamate does not include an Rx substituent, and the norcyanine is exposed to a pH less than 7 to provide a protonated norcyanine. Both the initial compound and the norcyanine exhibit minimal absorbance and emission in the near-infrared range. However, exposing the norcyanine to a pH less than 8, or a pH less than 7, provides a shift in absorbance and dramatically increased Auorescence signal in the NIR range. In some embodiments, at a pH less than 8 or a pH less than 7, the norcyanine has a Auorescence intensity at least 100X greater than the cyanine carbamate or norcyanine, such as a Auorescence intensity that is at least 125X greater, at least 150X greater, or even at least 170X
greater than the cyanine carbamate or the norcyamne at a pH greater than 8 or a pH greater than 7. In certain implementations, fluorescence may be detected at pH ranges near neutral, e.g., pH 7-8, or 7-7.5. However, protonation provides a dramatic increase in fluorescence when the compound does not include an Rx substituent.
In some embodiments, the cyanine carbamate is a CyBam (a cyanine carbamate wherein the linker includes a 6-membered aliphatic ring where A or A' is -CH2-) or a CyLBam (a cyanine carbamate wherein the linker includes a 6-membered heteroaliphatic ring where A or A' is -N(CH3)-) as disclosed herein. In some embodiments, a CyLBam exhibits improved cellular permeability and lysosomal accumulation in vivo.
One generalized reaction scheme showing the carbamate group cleavage and subsequent indolenine protonation is shown below:
(protonated norcyanine)
In some embodiments, the cyanine carbamate has an absorbance maximum of 400-450 nm, whereas the resulting norcyanine has an absorbance maximum of 700-800 nm.
Cleavage of the carbamate group shifts Abs to 520 nm, and subsequent indolenine protonation further shifts Abs to 755 nm. The protonated norcyanine has a 170-fold increase in fluorescence signal (Xmax = -775 nm, xcitation = 710 nm) compared to the original compound.
The carbamate group is cleaved in situ by an enzyme or a chemical trigger. In one embodiment, the biological sample comprises the enzyme, and exposing the cyanine carbamate to
the enzyme comprises contacting the biological sample comprising the enzyme with the cyanine carbamate. In an independent embodiment, the biological sample comprises the chemical trigger, and exposing the cyanine carbamate to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the cyanine carbamate. In another independent embodiment, exposing the cyanine carbamate to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the cyanine carbamate.
The cleaved compound, or norcyanine, is exposed to a pH less than 8, such as pH less than 7. In some embodiments, the norcyanine does not include an Rx substituent and the norcyanine is protonated by exposure to a pH less than 7. In some implementations, the biological sample comprises an environment having a pH less than 7, thereby exposing the norcyanine to the pH less than 7. In certain implementations, the pH of the biological sample may be reduced, e.g., with a mild acid, to provide expose the compound to a pH less than 8 or a pH less than 7. In other implementations, sufficient fluorescence may be detectable at a neutral pH, e.g., a pH of 7-8 or 7-7.5.
In any of the foregoing or following embodiments, subsequently exposing the cleaved compound, or norcyanine, to light having a wavelength greater than 700 nm and detecting fluorescence from the norcyanine may comprise irradiating the biological sample, or a targeted portion of a subject comprising the biological sample, with targeted application of a quantity of light having a wavelength in the visible, far-red, or near-infrared range and a selected intensity, wherein the quantity of light is sufficient to produce fluorescence of the norcyanine, and detecting any fluorescence emitted by the norcyanine. Advantageously, the light has a wavelength at or near a maximum absorption wavelength of the norcyanine in an environment having a pH less than 8 or a pH less than 7. In some embodiments, the light has a wavelength at or near a maximum absorption wavelength of the protonated norcyanine. For example, the biological sample may be irradiated with light having a wavelength within a range of 600 nm to 2500 nm, such as from 600-900 nm, or 600-700 nm. In some embodiments, the light source is a laser. Suitable light intensities may range from 1 mW/cm2 to 1000 mW/cm2, such as 1-750 mW/cm2 or 300-700 mW/cm2, depending on the target site and method of application. Near-infrared light sources can be obtained from commercial sources, including Thorlabs (Newton, NJ), Laser Components, USA (Hudson, NH), ProPho tonix (Salem, NH) and others. In some embodiments, the effective quantity of far-red or NIR light is 10-250 J, such as 10-200 J, 10-150 J, or 10-100 J. In some embodiments, visualization may include techniques such as fluoroscopy, single-molecule localization microscopy (SMLM), photo-activated localization microscopy (PALM), stochastic optical reconstruction
microscopy (STORM), direct stochastic optical reconstruction microscopy (dSTORM), biplane imaging (BP), temporal radial-aperture based intensity estimation (TRABI), fluorescence resonance energy transfer (FRET), and combinations thereof.
In any of the foregoing or following embodiments, the carbamate group may be selected to provide desired stimuli-dependent information. In some embodiments, R1 is selected to provide cleavage of the carbamate group by a particular enzyme or chemical trigger. For example, a glutamate-substituted compound can be activated by y-glutamyl transpeptidase (GGT) with high selectivity in vitro and in a metastatic model of ovarian cancer. Table 3 provides several exemplary combinations of enzyme and/or chemical triggers and suitable R1 groups for those triggers. Table 3
In any of the foregoing or following embodiments, the biological sample may comprise, or be suspected of comprising a target. In such embodiments, the cyanine carbamate may comprise a group comprising a targeting agent that binds to the target, and detecting fluorescence from the norcyanine indicates presence of the target in the biological sample. In some embodiments, the targeting agent is an antibody, a nanobody, or a peptide. In certain implementations, the targeting agent is an antibody. In some examples, the antibody is panitumumab.
In any of the foregoing or following embodiments, contacting the biological sample with the cyanine carbamate may be performed in vivo. In some embodiments, contacting the biological sample in vivo comprises administering the cyanine carbamate or a pharmaceutical composition comprising the cyanine carbamate to a subject, and detecting fluorescence from the norcyanine is performed via in vivo imaging. The amount of the cyanine carbamate administered may be an amount effective to provide detectable fluorescence from the norcyanine. Administration is
performed by any suitable method, e.g., intravenous, intra-arterial, intramuscular, intratumoral, or subcutaneous injection, or oral, intranasal, or sublingual administration.
A suitable period of time for cleavage of the carbamate group from the cyanine carbamate is allowed to elapse. The suitable period of time may further include time for and subsequent protonation of the norcyanine. In some embodiments, the period of time ranges from a few minutes to several days. For instance, the period of time may be from 15 minutes to 7 days, such as from 30 minutes to 48 hours, 30 minutes to 24 hours, 30 minutes to 12 hours, 1 hour to 12 hours, or 3 hours to 12 hours.
The norcyanine is subsequently irradiated by targeted application of a quantity of light having a wavelength in the visible, far-red, or near-infrared range and a selected intensity to a target area of the subject, wherein the quantity of light is sufficient to excite the protonated cleaved compound. When irradiating a target area (e.g., an area proximate a tumor), the effective quantity of far-red or NIR light may be 1-250 J/cm2, such as 1-250 J/cm2, such as 5-250 J/cm2, 10-250 J/cm2, 10-200 J/cm2, 10-150 J/cm2, 10-100 J/cm2, or 30-100 J/cm2. Any fluorescence from the protonated cleaved compound in the targeted portion of the subject is detected, thereby diagnosing the subject as having the condition.
In any of the foregoing or following embodiments, certain cells within the biological sample may express enzymes or chemical triggers capable of cleaving the carbamate group from the compound. The norcyanine then may be taken up by the cell and protonated intracellularly. In one non-limiting example, the cleaved compound Sulfo-NorCy7 (below) may be taken up by ovarian cancer cells with strong lysosomal localization, and subsequently protonated in the lysosome. The protonated Sulfo-NorCy7 is detectable by excitation at 710 nm and subsequent fluorescence detection at 760-800 nm. Detection of the protonated compound may diagnose the subject as having ovarian cancer.
Sulfo-NorCy7
In certain embodiments, the subject has, or is suspected of having, a cancer characterized in part by overexpression of y-glutamyl transpeptidase, and R1 of the compound is
. Cancers characterized in part by overexpression of y-glutamyl
transpeptidase include, for example, ovarian cancer, cervical cancer, liver cancer, colon cancer, gastric cancer, astrocytic glioma, soft tissue sarcoma, melanoma, and leukemia.
In addition to diagnostic uses, embodiments of the disclosed compounds may be used in theranostic procedures and/or for research uses. For example, embodiments of the disclosed compounds may be used as activatable probes for in vivo imaging, including for optically guided surgical procedures. Additionally, the compounds may be used to non-invasively monitor enzymatic processes and other stimuli in real time in living organisms. When conjugated to a targeting agent, the compounds may also be useful as probes for detecting enzymatic activity at a particular cell type or location of interest. If the cell or location of interest does not express an enzyme or chemical trigger capable of cleaving the carbamate group from the compound, an amount of an effective enzyme or chemical trigger may be administered to the location of interest after the compound comprising the targeting agent has bound to the target cell or location of interest, thereby inducing cleavage of the carbamate group so that the cleaved compound may be protonated and visualized.
V. Representative Embodiments
Certain representative embodiments are exemplified in the following numbered paragraphs.
1. A compound according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof:
where R1 is substituted aryl or substituted heteroaliphatic; R2 is aryl, heteroaryl, heterocycloaliphatic, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each Ra independently is H, halo, alkyl, or aryl; Y1 and Y2 independently are C(Rb)2, N(RC), S, O, or Se, wherein each Rb independently is H, deuterium, aliphatic, aryl, -(OCFFCFbjxOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each Rc independently is H, deuterium, aliphatic, or heteroaliphatic; R3 and R4 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a
drug, or R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring;
R5-R10 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug; and R11 and R12 independently are H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R11 and R12 together with the atoms to which they are bound form a 5-7 membered cycloaliphatic or heterocycloaliphatic ring.
2. The compound of paragraph 1, where the compound has a structure according to Formula IA: where
, alkyl, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
3. The compound of paragraph 2, where: Y1 and Y2 independently are C(Rb)2, where each Rb independently is aliphatic or aryl; R2 is, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug; R5 and R8 independently are -SO3",
are H.
4. The compound of paragraph 3, where Y1 and Y2 are -C(CH3)2-.
5. The compound of paragraph 4, having a structure according to Formula IB, IC, or
ID:
6. The compound of paragraph 1, where the compound has a structure according to Formula II:
where R13-R18 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
7. The compound of paragraph 6, where the compound has a structure according to Formula II A:
absent, -CHRd-, -CH2CHRd-, -CHRdCH2-, or -NRd-, where Rd is H, aliphatic, aryl, or a group comprising a conjugatable moiety, a targeting agent, or a drug.
8. The compound of paragraph 7, where: R2 is phenyl, H, halo, -ORa, -NRa 2, or a group comprising a conjugatable moiety, a targeting agent, or a drug; R5 and R8 are -SO3",
s an integer > 1 ; and m is an integer > 1.
10. The compound of any one of paragraphs 1-9, wherein R1 is substituted phenyl or substituted heteroaliphatic.
11. The compound of paragraph 10, wherein: R1 is
, or
,
-O-alkylaryl, or -O-aryl, where R' is aliphatic and each R" independently is H or aliphatic; Rs is aliphatic, heteroaliphatic, heterocycloaliphatic, alkylaryl, or heteroalkylaryl; and Rh is aliphatic.
13. The compound of any one of paragraphs 1-12, wherein: R2 is unsubstituted phenyl,
, Rh, H, Cl, -ORa, or -NRa 2; Rh is -(CH2)m-Re, -(CH2)mCH(NH2)-Re, -(CH2)mC(O)Re,
-(CH2)mN(H)Re, -(CH2)mN(H)C(O)Re, -(CH2)mC(O)N(H)Re, -(CH2)mC(O)SRe, -C(O)Re, -N(H)C(O)Re, -N(H)Re, or -SRe; Re is -OH,
phosphoramidite, or a targeting agent, where y is an integer > 1 ; and m is an integer > 1.
14. The compound of paragraph 13, wherein R2 is unsubstituted phenyl.
15. The compound of any one of paragraphs 1-11 or 13, wherein one of R2-R18, A, Y1, or Y2 comprises a group comprising a targeting agent.
16. The compound of paragraph 15, wherein R2 or A comprises the group comprising the targeting agent.
17. The compound of paragraph 15 or paragraph 16, wherein the targeting agent comprises an antibody.
19. A pharmaceutical composition comprising a compound, or stereoisomer thereof, according to any one of paragraphs 1-18, and a pharmaceutically acceptable carrier.
20. A method, comprising: contacting a biological sample with a compound according to any one of paragraphs 1-18; exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R1 from the compound to provide a cleaved compound; exposing the cleaved compound to a pH less than 7 to provide a protonated cleaved compound; subsequently exposing the protonated cleaved compound to light having a wavelength greater than 700 nm; and detecting fluorescence from the protonated cleaved compound.
21. The method of paragraph 20, wherein: the biological sample comprises the enzyme, and exposing the compound to the enzyme comprises contacting the biological sample comprising the enzyme with the compound; or the biological sample comprises the chemical trigger, and exposing the compound to the chemical trigger comprises contacting the biological sample
comprising the chemical trigger with the compound; exposing the compound to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the compound.
22. The method of paragraph 20 or paragraph 21, wherein the biological sample comprises an environment having a pH less than 7, thereby exposing the cleaved compound to the pH less than 7.
23. The method of any one of paragraphs 20-22, wherein the enzyme or chemical trigger and R1 are selected from the following combinations: carboxy esterase (CES 1, 2) and
acetylcholinesterase (ACHe) and
butyrylcholinesterase (BCHe) and
aminopeptidase N and
cathepsin B and
cathepsin S and
cathepsin L and
cathepsin K and
pantetheinase (Vanin- 1) and
caspase 3/7 and
caspase 8 and
trysin and
chymotrypsin and
alkaline phosphatase and
fibroblast activating protein and
dipeptidyl peptidase 4 and
furin and
galactosidase and
granzymes and
nuraminidase and
leucine aminopeptidase and
legumain and
neutrophil elastase and
gamma glutamyltranspeptidase (GGT) and
tyrosinase and
lysyl oxidase and
NAD(P)H:quinone oxidoreductase isozyme 1 and
monoamine oxidase A or B and
cytochormide P450 and
nitro reductase and
hydrogen peroxide and
super oxide and
hydrogen sulfide or triphenyl phosphine and
hypochlorous acid and
peroxynitrite and
carbon monoxide and
selenol and
thiophenol and
glutathione, cysteine, or homocysteine
and
24. The method of any one of paragraphs 20-23, wherein: the biological sample comprises, or is suspected of comprising, a target; the compound comprises a group comprising a targeting agent that binds to the target; and detecting fluorescence from the protonated cleaved compound indicates presence of the target in the biological sample. 25. The method of paragraph 24, wherein the targeting agent is an antibody.
26. The method of any one of paragraphs 20-25, wherein contacting the biological sample with the compound is performed in vivo.
27. The method of paragraph 26, wherein: contacting the biological sample in vivo comprises administering the compound or a pharmaceutical composition comprising the compound to a subject; and detecting fluorescence from the protonated cleaved compound is performed via in vivo imaging.
28. The method of paragraph 27, wherein the subject has, or is suspected of having, a cancer characterized in part by overexpression of y-glutamyl transpeptidase, and R1 of the compound is
29. The method of paragraph 28, wherein the cancer comprises ovarian cancer, cervical cancer, liver cancer, colon cancer, gastric cancer, astrocytic glioma, soft tissue sarcoma, melanoma, or leukemia.
30. The method of any one of paragraphs 20-29, wherein the protonated cleaved compound has a fluorescence intensity at least 100X greater than the compound or cleaved compound.
VI. Examples
General Procedures
Synthesis. All reactions were carried out under an argon atmosphere. Reagents were purchased at a high commercial quality (typically 97 % or higher) and used without further purification, unless otherwise stated. !H NMR and 13C NMR spectra were recorded on Bruker spectrometers (at 400 or 500 MHz or at 100 or 125 MHz) and are reported relative to deuterated solvent signals (CDC13: 1 H NMR = 7.24, 13C NMR = 77.0, MeOD: 1 H NMR = 3.30, 13C NMR = 49.0, DMSO-d6: 1 H NMR = 2.50, 13C NMR = 39.5). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, dd = double doublet, dt = double triplet, dq = double quartet, m = multiplet, br = broad. Electrospray ionization mass spectrometry (ESI-MS) data were collected on triple-stage quadrupoleinstrument in a positive mode. Flash column chromatography was performed using reversed phase (100 A, 20- 40-micron particle size, RediSep® Rf Gold® Reversed-phase Cl 8 or C18Aq) and silica on a CombiFlash® Rf 200i (Teledyne Isco, Inc.). LC/MS was performed using a Shimadzu LCMS-2020 SingleQuadrupole utilizing a Kinetex 2.6 pm C18 100 A (2.1 x 50 mm) column obtained from Phenomenex, Inc(Torrance, CA). Runs employed a gradient of 0-90% MeCN/H2O with 0.1% formic acid over 4.5 min at a flow rate of 0.2 mL/min. Preparatory HPLC was performed on Waters HPLC equipped with Waters 515 HPLC Pump, Waters 2998 Photodiode Array Detector, Waters 2545 Binary Gradient Module and Waters 2767 Sample Manager. The HPLC was installed with Luna 10 pm C18 column (100 x 30 mm) and each run employed 10-95% or 60-95% CH3CN/H2O gradient with 0.1% TFA over 10 mins. Absorbance curves were obtained on a Shimadzu UV-2550 spectrophotometer operated by UVProbe 2.32 software. Fluorescence traces were recorded on a PTI QuantaMaster steady state spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, and a 0.1 s integration rate. Analytical LC analyses were collected from Agilent 1260 Infinity Quaternary LC module using Poroshell 120 EC-C18 2.7 pM (4.6 x 50 mm) column in 5-95% CH3CN/water gradient with 0.1% formic acid over 25 minutes.
Microplates were read on Synergy Mx microplate reader. All statistical analyses were carried out by Graphpad Prism version 9.0 (Graphpad Software).
Absorbance and Fluorescence Measurements. Absorbance curves were obtained on a Shimadzu UV- 2550 spectrophotometer operated by UVProbe 2.32 software. Fluorescence traces were recorded on a PTIQuantaMaster steady-state spectrofluorometer operated by FelixGX 4.2.2 software, with 5 nm excitation and emission slit widths, and a 0.1 s integration rate.
Determination of Molar Absorption Coefficients. Molar absorption coefficients (e) were determined in PBS (pH 7.2) or acetate buffer (pH 4.5) using Beer’s law, from plots of absorbance vs. concentration (1 - 10 pM). Spectra were recorded with disposable micro-UV-Cuvette holder with 10 mm path length, with absorbance at the highest concentration < 0.20. Three independent readings were taken at each concentration.
Absolute Fluorescence Quantum Yields. Absolute fluorescence quantum yields (OF) were measured in PBS (pH 7.2), acetate buffer (pH 4.5), or methanol + 0.1% formic acid using a Horiba fluorimeter QM-8075-11-C equipped with R928 PMT point detector and an integrating sphere to determine photons absorbed and emitted by a sample. Probe was excited at 710 nm and emission was collected from 730-850 nm or 730-900 nm. Measurements were carried out a concentration with optical density of less than 0.1 in buffer or solvent and self-absorption corrections were performed using the instrument software.
Determination of pKa. Absorption and emission spectra were recorded in different buffers (pH 3.00 to pH 10.0) using a spectrophotometer and fluorometer, respectively. Following buffers were used in the study: Citrate buffers (pH 3.05 - 3.50), acetate buffers (pH 3.75 to 5.75) and PBS (20 mM, pH 6.00 - 10.0).
Kinetics of release by Staudinger reaction. CyBam-N (10 pM) and PPh (10 eq) added in PBS: MeOH (1:1) at pH 7.4 or pH 5.2. A spectral scan reading was taken after every 5 min for 1 h. monitored at different intervals using microplate reader (300 - 800 nm). Three independent experiments were carried out.
GGT probe. All the assays were conducted at 37 °C for 30 mins unless otherwise stated. The pH was adjusted to pH 5.2 after completion of the assay as described below. The absorbance was measured using plate reader and fluorescence was measured using a fluorimeter.
1. Kinetics of Activation. CyBam-y-Glu (20 pM) was dissolved PBS buffer (IX, pH = 7.4) at increasing concentration of GGT (0 - 800 U/L) at 37 °C. KM was calculated after incubating CyBam-y-Glu (2.5 - 50 pM) with 100 U/L.
2. Inhibition of GGT. 6-Diazo-5-oxo-L-norleucine (DON; 1 mM) and GGsTop (0.5 mM) were incubated with GGT (100 U/L) for 1 h prior to addition of CyBam-y-Glu (20 pM).
3. Specificity against GGT. CyBam-y-Glu (20 pM) was incubated with GGT (100 U/L), LAP (leucine amino peptidase; 800 U/L) and PLE (pig liver esterase; 800 U/L).
4. pH and cell culture media stability. CyBam-y-Glu (20 pM) was incubated with DMEM with 10% FBS, 100% FBS and pH (4.5, 5.5, 6.5 and 7.5) for 18 h. The stability of the compound was monitored by observing the absorbance of the probe every 1 h.
5. Activity at different pH. Different pH (6.0, 6.5, 7.0, 7.5 and 8.0) was generated using Gibco PBS (IX). The probes were incubated for 30 mins with GGT (100 U/L).
Fluorescent Imaging in Live Cells. Briefly, 25,000 cells were seeded on Greiner Bio-One CELLview™ Cell Culture Slides and allowed to adhere overnight.
Fluorescent Imaging in Live Cells of NorCy7 Compounds: 15,000 cells/well (MDA-MB-468) were seeded on Greiner Bio-One CELLview™ Cell Culture Slides (10 compartments and allowed to adhere overnight. Cells in NorCy7 (5 pM) were incubated with for 6 h in media (with FBS), followed by wash with DPBS (twice). Nucleus was stained with NucBlue™ Live Ready Probes (Invitrogen; 1 drop/ 500 pL) for 15 min. Live cell microscopy was carried out in DMEM phenol red free media. The images were captured using two different lasers: nucleus (405, blue channel) and NorCy7 library (700 nm, red channel).
Subcellular Localization. Sulfo-NorCy7 (20 pM) in RPMI media was incubated for 4 h followed by addition of Lysosome (Lysotracker Green DND 26; Invitrogen), Mitochondria (Mitotracker Green FM; Invitrogen) for 1 h. Afterwards, the cells were washed with PBS (pH 7.4) and nucleus was stained with NucBlue™ Live Ready Probes (Invitrogen) for 15 mins. Following concentrations of probes were used in the study: Mitotracker Green (500 nM), Lysotracker Green (75 nM) and NucBlue (1 drop/500 pL). Live cell microscopy was carried out in DMEM phenol red free media. The images were captured using three different lasers: nucleus (405, blue channel), mitochondria and lysosome (488 nm, green channel) and Sulfo-NorCy7 (640 nm, red channel).
2V-Me-NorCy7 (10 pM) in DMEM/10%FBS media was incubated for 6 h followed by addition of Lysosome (Lysotracker Green DND 26; Invitrogen), Mitochondria (Mitotracker Green FM; Invitrogen) for 1 h. Afterwards, the cells were washed with DPBS (pH 7.2) and nucleus was stained with NucBlue™ Live Ready Probes (Invitrogen) for 15 mins. Following concentrations of probes were used in the study: Mitotracker Green (500 nM), Lysotracker Green (75 nM) and NucBlue (1 drop/500 pL). Live cell microscopy was carried out in DMEM phenol red free media.
The images were captured using three different lasers: nucleus (405, blue channel), mitochondria and lysosome (488 nm, green channel) and 2V-Me-NorCy7 (640 nm, red channel).
Competition experiment. The cells were divided in three groups: Group 1 contained untreated cells, Group 2 contained blocked probes and Group 3 contained nonselective and non-cleavable probe. Group 2 was treated with DON (1 mM) and GGsTop (1 mM), 1 h prior to study. CyBam-y-Glu (20 pM) was incubated in Group 1 and 2, whereas CyBam-N.C was incubated in Group 3. After 3 h the cells were washed, and nucleus was stained as described above. The media was changed to HBSS for live cell study.
Flow Cytometry Analysis. 300,000 cells/well were seeded on 12 well plate (Coming Costar). The cells were treated with compounds, described as below, follow by cleavage using cell dissociation free buffer and spun down at 200 ref using centrifuge. The cells were suspended in DMEM, phenol red free and live cells counting was performed on flow cytometer. Geometric mean fluorescence intensity was measured at least in three independent trials (at least 10,000 cells counted). Flow cytometry data was processed using FlowJo. CyBam-y-Glu: The cells were divided in three groups: Group 1 was untreated, Group 2 contained blocked probes and Group 3 contained nonselective and non-cleavable probe. Group 2 was treated with DON (1 mM) and GGsTop (1 mM), 1 h prior to study. CyBam- y-Glu (20 pM) was incubated in Group 1 and 2, whereas CyBam-N.C was incubated in Group 3. After 3 h the cells were washed twice with PBS (pH 7.4).
Enzyme and Protein Assays, y- Glutamyltranspeptidase from equine kidney (Type VI, 5-12 units/mg solid), leucine aminopeptidase, microsomal from porcine kidney (Type IV-S, 10-40 units/mg protein), Cathepsin B from human liver and Esterase from porcine liver (>15 units/mg solid) were purchased from Millipore Sigma.
Cytotoxicity Assay. 5000 SHIN-3 cells/well were seeded on 96 well plate and allowed to adhere overnight. Stock solutions of Sulfo-NorCy7and CyBam-y-Glu (20 mM in DMSO) were diluted with protein-free medium (PFHM-II) to make desired final concentrations varying from 0.01 to 80 pM. The cells were incubated with the desired concentration for 72h. The cell viabilities were calculated using alamarBlue assay. Briefly, 10 pL of alamarBlue™ Cell Viability Reagent (Invitrogen) was incubated for 1 h and fluorescence was measured with excitation at 560 nm and emission wavelength at 590 nm with a Microplate Reader. The viability of each cell line in response to the treatment with tested compounds was calculated as: % dead cells = 100 - (OD treated/OD control) x 100.
5000 cells/well (MDA-MB-468 and MCF-7) were seeded on 96 well plate and allowed to adhere overnight. Stock solutions (10 mM in DMSO) of all six compounds in NorCy7 library were
diluted in media for each respective cell lime to make desired final concentrations varying of 1 , 5 and 10 pM. The cells were incubated with the desired concentration for 24h. The cell viabilities were calculated using alamarBlue assay. Briefly, 10 pL of alamarBlue™ Cell Viability Reagent (Invitrogen) was incubated for 1 h and fluorescence was measured with excitation at 560 nm and emission wavelength at 590 nm with a Microplate Reader. The viability of each cell line in response to the treatment with tested compounds was calculated as: % dead cells = 100 - (OD treated/OD control) x 100.
ROS generation. PC-3 cells (250,000) were seeded in 12 well plate (Coming Costar) and allowed to adhere overnight. The cells were divided in five groups: Group 1 - doxorubicin (20 pM), Group 2 CyBam- B(OHji (20 pM), Group 3 CyBam-P(OPh)2 (20 pM), Group 4 coincubation of CyBam-B(OH)2 (20 pM) + doxorubicin (20 pM) and Group 5 coincubation of CyBam-P(OPh)2 (20 pM) + doxorubicin (20 pM). The groups were incubated with compounds for 12 hours. Afterwards, cells were washed with PBS twice, cleaved from plate using cell dissociation free buffer and spun down at 200 ref using centrifuge. Geometric mean fluorescence intensity was measured in four independent trials (-10,000 cells counted). Flow cytometry data was processed using FlowJo.
Cellular assays. SHIN-3 cells were generously provided by Dr. Hisataka Kobayashi. MDA-MB-468 and PC-3 were bought from ATCC. SHIN-3 cells were cultured in Roswell Park Memorial Institute media (RPMI) containing 10% FBS and 1% PS. MDA-MB-468 cells were grown in Dulbecco's Modified Eagle'smedium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-dtreptomycin (PS). PC-3 cells were grown in F-12K media containing 10% FBS and 1%PS. Cells were grown in a cell culture incubator at 37°C in a humidified atmosphere containing 5% CO2. Cells were grown in T-75 or T-175 culture flask till 70% confluency before splitting into next passage.
MDA-MB-468, MDA-MB-231 and JIMT-1 cells were grown in Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (PS). MCF-7 cells were grown in Eagle's Minimal Essential Medium (EMEM) containing 10% fetal bovine serum (FBS), 1% penicillin- streptomycin (PS) and 1% L-glutamine. Cells were grown in a cell culture incubator at 37 °C in a humidified atmosphere containing 5% CO2. Cells were grown in T-75 or T-175 culture flask till 70% confluency before splitting into next passage following trypsinization with 5% trypsin-EDTA. The cells were evaluated for molecular testing of biological materials by animal health diagnostic laboratory at Frederick National Laboratory for Cancer Research. The results confirmed the absence of the
following agents within the cells: Ectromelia virus (ECT), Mouse rotavirus (EDIM), Lymphocytic coriomeningitis virus (LCMV), Lactic dehydrogenase elevating virus (LDHV), Mouse adenovirus (MAD), Mouse cytomegalovirus (MCMV), Mouse hepatitis virus (MHV), Mouse norovirus (MNV), Mouse parvovirus (MPV), Minute virus of mice (MVM), Mycoplasma spp. (MYCO), Polyoma virus (POLY), Pneumonia virus of mice (PVM), Reovirus 3 (REO3), Sendai virus (SEN), Theiler's murine encephalomyelitis virus (TMEV).
Flow Cytometry was performed at Flow Cytometry Core (CCR) using BD LSRII. The fluorescence signal in the near infrared region was excited using 633 nm laser (18 mW) and emission detected on APC-Cy7 detectors (780/60). The flow cytometry data was processed using FlowJo software. Geometric mean fluorescent intensity was calculated in APC-Cy7 channel.
Confocal imaging was carried out at Optical Microscopy and Image Analysis Lab (OMAL) on Andor spinning disk confocal microscope on Leica DMi8 base. DAPI was imaged at Blue channel (excitation 405 nm, emission 450/50 nm) and Cy7 fluorophores were images at red channel (excitation 640 or 710 nm, emission 810/90). The images were taken at 63x/1.4 oil immersed objective. The images were processed using Fiji software. The images were taken at 63x/1.4 oil immersed objective. The images were processed using Fiji software.
SHIN-3 metastatic tumor model. Animal experiments were approved by the Institutional Animal Care and Use Committee of the NIH and conducted in compliance with the Guide for the Care and Use of Laboratory Animal Resources and the National Research Council. The tumors were implanted by intraperitoneal injection of 2 x 106 SHIN- 3 -Zs Green cells suspended in 300pl of PBS into female athymicnude mice (Athymic NCr-nu/nu, strain #553). Experiments with tumor-bearing mice were performed afterl5 days of implantation of SHIN-3-ZsGreen models, when disseminated peritoneal implants grew to about 1 mm in size. 100 |1M of 300 |1L (30 nmol) was injected intraperitoneally, and mice were sacrificed at 1, 3 and 6 h time interval. Acquisition for GFP signal (ZsGreen): Excitation: band-pass filter from 445 - 490 nm; Emission long-pass filter over 515 nm; Acquisition: 500 - 720 nm in 10 nm steps. Acquisition for Cy7 channel signal (probe): Excitation: band-pass filter from 710 - 760 nm; Emission long- pass filter over 800 nm; Acquisition: 780 - 950 nm in 10 nm steps. Fluorescence images were automatically acquired in 10 nm increments with constant exposure. The images, which consisted of an autofluorescence spectrum and the spectra from GFP and Cy7 channel, were reconstructed using Maestro software, based on their unique spectral patterns.
In vivo studies: Studies were performed according to Animal Care and Use committee guidelines at Frederick National Laboratory for Cancer Research (Frederick, MD). Frederick
National Laboratory for Cancer Research is accredited by American Association for Accreditation of Laboratory Animal Care (AAALAC) International and follows the Public Health Service Policy for the Care and use of Laboratory Animals. Animal care was provided in accordance with the procedures outlined in the “Guidefor Care and Use of Laboratory Animals” (National Research Council; 2011; National Academies Press; Washington, D.C.).
Fluorescence was longitudinally monitored employing the IVIS spectrum imager (PerkinElmer Inc, Waltham, MA). Images were acquired and processed using Living Image software. Mice body temperature were maintained constant at 37 °C during the imaging procedure with a heated pad located under the anesthesia induction chamber, imaging table, and post procedure recovery cage. All mice were anesthetized in the induction chamber with 3% isoflurane with filtered (0.2 pm) air at 1 liter/minute flow rate for 3-4 minutes and then modified for imaging to 2% with 02 as a carrier with a flow rate of 1 liter/minute. Static 2D images were acquired with the following parameters: excitation filter 745 ± 15 nm, emission filter 800 ± 10 nm, f/stop2, medium binning (8x8) and auto exposure (typically 1-60 seconds or 1-120 seconds). 4-7- week-old female athymic nude mice were purchased from Charles River Laboratories International, Inc. (Frederick, MD).
MDA-MB-468 tumor model. 5xl06 human breast cancer cells (MDA-MB-468) in 100 pL of Hanks Balanced Salt Solution (HBSS) were subcutaneously injected in the right flank of the mice. Tumors were monitored daily until they reach 4-6 mm in the longest diameter or 25-35 mm3. In vivo studies were initiated 10 days post cell injection of the mice.
JIMT-1 tumor model. 5xl06 human breast cancer cells (JIMT-1) in 100 pL of MatrigekPBS (1:1) were injected subcutaneously in the inguinal memory fat pad of mice. Tumors were monitored daily until they reached 200-250 mm3. In vivo studies were initiated 21 days post cell injection.
Data Analysis Living Image software was used for image analysis. Using white light images, the tumors were identified, and regions of interest (ROI) were drawn over the tumor, liver, and ear (used as background) to quantify in vivo data. Fitted ROIs were drawn over each organ to quantify ex vivo data. Total radiance efficiency within each ROI was normalized by the corresponding area of the ROI. This normalized radiance efficiency was used to calculate ratios (tumor to background, tumor to liver and liver to background). Statistics (unpaired 2-tail Student’s t-test) were carried out using Prism 9.
Panitumumab, m276-SL and IgG conjugation. 1 mg of 25 mg/mL of antibody and 10X of CyBam and CyLBams (10 mM stock in DMSO) was added to 300 pL of PBS (pH 7.2) in 1.5
mL Eppendorf tube. The mixture was covered in aluminum foil and stirred for 2 h on orbital shaker. The reaction mixture was eluted through a pH 7.4 PBS equilibrated Zeba spin DS column (7K MWCO, Thermo Fisher Scientific) to remove unreacted free dye. This was followed by buffer exchange and further purification using slide- A-Lyzer MINI Dialysis Devices (10K MWCO, 0.5mL, Thermofisher) in PBS (IX, pH 7.4). The buffer was replaced twice, at 1 and 3 h time interval. Purified conjugate was collected in 0.5 mL Eppendorf. The antibody conjugates were concentrated using Amicon® Ultra Centrifugal Filter Devices (10k MWCO; Millipore Sigma) by centrifuging at 10,000 rom for 10 mins. The degree of labeling (DOL; dye to antibody ratio) was determined by measuring absorption at 280 nm and 430 nm. A correction factor of 0.03 at 280 nm was used in the calculations. DOL and protein concentrations were measured by the following equations. The antibody conjugates were stored at 4 °C. No changes in absorbance spectra were monitored over 28 days.
Eq. 1. DOL = (A43o/£dye)/[(A28O - 0.03 X A430)]/ Sprotein
Eq. 2. protein cone (mg/mL) = [(A280 - 0.03 x A430)/ ^protein] x MWprotein x dilution factor Fluorescent Imaging in Live Cells with Pan Conjugates: 15,000 cells/well (MDA-MB-468 or MCF-7) were seeded on Greiner Bio-One CELLview™ Cell Culture Slides (10 compartments and allowed to adhere overnight. Compounds in Panitumumab conjugates (50 pg; DOL 4) were incubated with for 24 h in respective media (with FBS), followed by wash with DPBS (twice). Nucleus was stained with NucBlue™ Live Ready Probes (Invitrogen; 1 drop/ 500 pL) for 15 min. Live cell microscopy was carried out in DMEM phenol red free media. The images were captured using two different lasers: nucleus (405, blue channel) and Cy7 (640 nm, red channel).
Flow Cytometry Analysis of Panitumumab, m276-SL and IgG Conjugates. 300,000 cells/well were seeded on 12 well plate (Corning Costar). The cells were treated with Panitumumab conjugates (50 pg; DOL 4), m276-SL or IgG (80 pg; DOL 4) for 6 and 24 h (as required), followed by wash with cold DPBS (twice). The cells were cleaved using Gibco™ Cell Dissociation Buffer, enzyme- free, PBS. and were centrifuged at 200 ref using Eppendorf centrifuge 5424R. The cells were resuspended in cold DPBS and cells were counted on flow cytometer. Geometric mean fluorescence intensity was measured at least in three independent trials (~ 10,000 cells counted).
Flow Cytometry Analysis of NorCy7 compounds. 300,000 cells/well were seeded on 12 well plate (Coming Costar). The cells were treated with NorCy7 library (5 pM) for 1, 3 and 6 h, followed by wash with cold DPBS (twice). The cells were cleaved using Gibco™ Cell Dissociation Buffer, enzyme-free, PBS. and were centrifuged at 200 ref using Eppendorf centrifuge 5425. The
cells were resuspended in cold DPBS and cells were counted on flow cytometer. Geometric mean fluorescence intensity was measured at least in three independent trials (~ 10,000 cells counted).
Example 1
Compound Synthesis
Compound SI. To a 20 mL microwave vial, Vilsmeier reagent (400 mg, 1.11 mmol), phenyl boronic acid (269.6 mg, 2.22 mmol) and K3PO4 (236.2 mg, 2.11 mmol) were added sequentially. Pd(PPh3)4 (45mg, 0.038 mmol) was added in glove box and the vial was sealed. Subsequently, degassed DMF:H2O (5:1) was added to the solution and heated at 90 °C for 18 h. The solvent was removed and filtered through celite to remove inorganic compounds. Crude mixture was taken forward to next step.
Sulfo-NorCy7. Compounds S2 was synthesized according to literature procedure (Park et al., Bioconjug Chem 2012, 23(3):350-362). To a 100 mL round bottom flask, SI (800 mg, 2.19 mmol), S2 (1.1 g, 4.39 mmol) and sodium acetate (NaOAc, 360 mg, 4.39 mmol) were added sequentially in 20 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 6 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on reversed phase chromatography (0-50% MeCN:H2O). (320 mg, 21%). !H NMR (500 MHz, DMSO) 57.62 - 7.55 (m, 5H), 7.53 (dd, J = 8.0, 1.6 Hz, 2H), 7.21 (dd, J = 6.4, 2.9 Hz,
2H), 7.07 - 6.97 (m, 4H), 6.10 (d, J = 14.1 Hz, 2H), 2.59 (t, J = 6.3 Hz, 4H), 1.92 (p, J = 6.2 Hz, 2H), 1.23 (s, 12H). 13C NMR (126 MHz, DMSO) 5 160.8, 144.7, 141.7, 140.2, 138.4, 134.5, 130.7, 130.4, 130.1, 128.9, 128.7, 127.8, 126.6, 120.4, 116.7, 114.4, 111.0, 49.05, 36.25, 26.91, 25.01, 21.48. HRMS (ESI) calculated for C36H37N2O6S2 [M+H]+ 657.2088; observed: 657.2094.
The dye exhibited two forms in biologically relevant conditions, an unprotonated quenched form, Sulfo-NorCy7 (Zabs = 520 nm @ pH 7.4) and a protonated fluorescent form, Sulfo- NorCy7-[H+] (Zabs = 755 nm @ pH 4.5), with a pKa of 5.2. After examining several conditions, it was determined that exposure of Sulfo-NorCy7 and 4-nitrophenyl carbonates to NaH or CS2CO3 in DMF afforded the corresponding carbamate products.
CyBam-Ns was prepared from Sulfo-NorCy7 and 1 in reasonable yield following purification by reversed-phase chromatography (Scheme 1).
Scheme 1
Compound 1 was synthesized according to a known procedure (van Brakel et al. , Bioconjug Chem 2008, 19(3):714-718). To a 5 mL microwave vial, Sulfo-NorCy7 (20 mg, 0.030 mmol), NaH (1.4 mg, 0.061 mmol) were added sequentially to dry DMF (1.5 mF) and stirred for 1 h. S3 (19 mg, 0.060 mmol) was dissolved in dry DMF (1.5 mL) and added dropwise over 10 mins. Reaction progress was monitored by LC/MS. After 2 h, the reaction was complete by LC/MS and was quenched using H2O (1 mL). The resulting mixture was purified by reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to give CyBam-Ns as purple amorphous solid (12.5 mg, 50%). 1 H NMR (500 MHz, DMSO) 57.79 (d, J = 1.6 Hz, 1H), 7.70 - 7.65 (m, 2H), 7.64 - 7.58 (m, 5H), 7.47 - 7.44 (m, 2H), 7.41 (d, J = 1.8 Hz, 1H), 7.30 (d, J = 13.1 Hz, 1H), 7.22 (td, J = 7.5, 7.0, 1.8 Hz, 4H), 6.70 (d, J = 15.8 Hz, 1H), 6.36 (d, J = 13.0 Hz, 1H), 5.38 (s, 2H), 2.61 (t, J = 6.2 Hz, 2H), 2.30 (t, J = 6.2 Hz, 2H), 1.86 - 1.80 (m, 2H), 1.29 (s, 6H), 1.09 (s, 6H). 13C NMR (125 MHz, DMSO) 5 183.4, 153.8, 152.2, 148.1, 145.2, 143.5, 140.2, 139.5, 138.5, 138.3, 136.8, 133.8, 132.3, 131.5, 130.0, 129.1, 128.6, 128.5, 126.8, 125.9, 120.5, 119.9, 119.8, 119.6, 119.2, 116.8, 115.7, 115.0, 114.5, 108.4, 68.38, 52.01, 45.09, 29.03, 26.91, 24.90, 24.74, 24.68, 21.39. HRMS (ESI) calculated for C44H42N5O8S2 [M+H]+ 832.2468; observed: 832.2469.
Compound S4. Compound S3 was prepared according to a known procedure (Huang et al., J Med Chem 2017, 60(21):8847-8857). To a 20 mL microwave vial, S3 (100 mg, 0.20 mmol) and 4-nitrophenyl chloroformate (45 mg, 0.22 mmol) were added sequentially to dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (57 pL, 0.40 mmol) was added dropwise, and the solution was stirred for 12 h. The resulting white precipitate were filtered, and the solvent was evaporated. The product was purified by normal phase chromatography (ethyl acetate (EtO Ac) .’hexanes; 0 - 100%, 24 g SiCh). Product containing fractions were combined, evaporated, and triturated with ether to give compound S4 as a white amorphous solid (100 mg, 77% yield). 1 H NMR (500 MHz, CDC13) 5 8.33 - 8.20 (m, 4H), 7.81 - 7.71 (m, 3H), 7.60 (dt, J = 17.1, 8.7 Hz, 5H), 7.39 (q, J = 8.8, 7.0 Hz, 4H), 7.31 (d, J = 7.2 Hz, 2H), 5.61 (d, J = 8.1 Hz, 2H), 5.24 (s, 2H), 4.51 - 4.37 (m, 4H), 4.20 (t, J = 6.8 Hz, 2H), 3.76 (s, 3H), 3.49 (d, J = 4.2 Hz, 1H), 2.38 (dt, J = 28.9, 10.2 Hz, 4H), 2.17 (s, 2H), 1.99 - 1.88 (m, 2H). 13C NMR (125 MHz, CDC13) 5 172.2, 170.3, 155.5, 152.4, 145.3, 143.7, 143.4, 141.3, 129.8, 127.8, 127.1, 127.0, 125.3, 125.0, 124.9, 121.7, 120.1, 120.0, 119.7, 70.68, 67.21, 53.14, 52.80, 47.18, 33.90, 30.01. HRMS (ESI) calculated for C35H32N3O10 [M+H]+ 654.2082; observed: 654.2096.
CyBam-v-Glu: To a 5 mL microwave vial, Sulfo-NorCy7 (30 mg, 0.046 mmol) and CS2CO3 (30 mg, 0.092) were added sequentially to dry DMF (2 mL) and stirred for 3 h. Compound S4 (60 mg, 0.092 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 10 mins. The reaction mixture was monitored at different intervals using LC/MS. After 3 h, the reaction was quenched using H2O (1 mL). The crude product concentrated and then dissolved in 20% piperidine
in DMF (1 mL). After 1 h, the solvent was evaporated and LiOH (1.1 mg; 0.046 mmol) was added to THF:H2O (1:1) on ice. The reaction was monitored by LC/MS. After 1 h the reaction was complete and the crude mixture was purified by reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to provide CyBam- y -Glu as a purple amorphous solid (13 mg, 29%). 1 H NMR (500 MHz, DMSO) 5 8.29 (d, J = 5.4 Hz, 3H), 7.67 (t, J = 8.5 Hz, 3H), 7.58 - 7.54 (m, 3H), 7.50 (d, J = 8.6 Hz, 2H), 7.42 (d, J = 1.8 Hz, 1H), 7.38 (d, J = 1.8 Hz, 1H), 7.37 (s, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 7.19 (d, J = 1.7 Hz, 1H), 7.17 (t, J = 1.5 Hz, 1H), 6.61 (d, J = 16.1 Hz, 2H), 6.14 (d, J = 12.8 Hz, 2H), 5.32 (s, 2H), 2.37 (t, J = 1.9 Hz, 1H), 2.28 (t, J = 5.9 Hz, 3H), 2.15 - 2.08 (m, 4H), 1.81 (s, 3H), 1.13 (d, J = 42.3 Hz, 12H). 13C NMR (125 MHz, DMSO) 5 184.1, 171.3, 170.3, 152.3, 145.1, 139.9, 139.6, 139.1, 138.5, 136.9, 133.5, 130.3, 130.1, 130.1, 128.9, 128.1, 126.1, 120.3, 119.8, 119.5, 117.9, 115.6, 114.9, 113.2, 108.5, 68.62, 52.16, 52.00, 44.71, 31.99, 28.87, 26.08, 24.99, 24.19. HRMS (ESI) calculated for C49H51N4O11S2 [M+H]+ 935.2992; observed: 935.2990.
Compound S6. Compound S5 was synthesized according to known procedure (Blaser et al., Helvetica Chimica Acta 2001, 84(7):2119-2131). To 20 mL microwave vial, S5 (500 mg, 1.99 mmol) and 4-nitrophenyl chloroformate (400 mg, 2.38 mmol) were added sequentially in dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (550 pL, 4.00 mmol) was added dropwise and the solution was stirred for 12 h. White precipitate were filtered, and the solvent was evaporated. The crude mixture redissolved in CH2CI2 and purified by normal phase silica column (EtOAcm-hexane; 0 - 100%, 24 g SiCL) to give S7 white color product (620 mg, 74% yield). !H NMR (500 MHz, DMSO) 5 10.01 (s, 1H), 8.32 (d, J = 8.6 Hz, 2H), 7.67 - 7.52 (m, 5H), 7.38 (dd, J = 24.2, 8.3 Hz, 3H), 5.24 (s, 2H), 4.71 (s, 1H), 3.60 (s, 4H), 2.51 (s, 3H), 1.84 (s, 3H).13C NMR
(125 MHz, DMSO) 5 173.52, 171.22, 155.76, 152.43, 145.64, 140.17, 129.93, 129.43, 125.88, 123.09, 119.49, 119.41, 70.77, 51.75, 46.70, 35.70, 33.08, 20.77. HRMS (ESI) calculated for C20H21N2O6 [M+H]+ 417.1288; observed: 417.1292.
CyBam-N.C. To a 5 mL microwave vial, Sulfo-NorCy7 (30 mg, 0.046 mmol) and NaH (2.1 mg, 0.092) were added sequentially in dry DMF (2 mL) and stirred for 30 min. Compound S7 (38.2 mg, 0.092 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 10 mins. The reaction mixture was monitored at different intervals using LC/MS. After 1 h, the reaction was quenched using H2O (1 mL). The crude mixture was concentrated. The resulting mixture was dissolved in THF:H2O (1:1), cooled to 4 °C, and LiOH (1.1 mg; 0.046 mmol) was added . The reaction monitored by LC/MS. After 1 h the reaction was complete. The crude mixture was purified by reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to provide CyBam-N.C as purple amorphous solid (8.0 mg, 17%). 1 H NMR (500 MHz, DMSO) 57.62 (dd, J = 8.6, 6.4 Hz, 3H), 7.52 (dd, J = 9.5, 1.6 Hz, 2H), 7.50 - 7.43 (m, 5H), 7.43 - 7.39 (m, 2H), 7.36 (dd, J = 8.5, 1.8 Hz, 1H), 7.30 (d, J = 1.8 Hz, 1H), 7.27 (d, J = 8.1 Hz, 2H), 7.12 - 7.06 (m, 4H), 6.52 (d, J = 16.1 Hz, 3H), 6.03 (d, J = 12.8 Hz, 2H), 5.23 (s, 2H), 2.32 (t, J = 7.4 Hz, 2H), 2.23 (t, J = 7.4 Hz, 2H), 2.13 (d, J = 5.4 Hz, 2H), 1.79 - 1.74 (m, 2H), 1.70 (d, J = 6.6 Hz, 3H), 1.08 (s, 5H), 1.00 (s, 5H). 13C NMR (125 MHz, DMSO) 5 184.1, 174.6, 171.3, 158.5, 152.3, 145.1, 140.2, 139.7, 139.3, 138.5, 137.0, 133.4, 130.4, 130.2, 129.8, 128.9, 128.0, 126.0, 125.8, 119.8, 119.5, 119.4, 118.4, 114.9, 108.5, 68.69, 52.19, 44.68, 35.92, 33.42, 28.86, 24.95, 24.07, 20.94. HRMS (ESI) calculated for C49H50N3O11S2 [M+H]+ 920.2809; observed: 920.2880.
Compound S8 (reported in J Mater Chem B 2017, 5:5278-5283, Chem Commun 2020, 56:5819-5822, and Dyes and Pigments 2004, 61:103-107, without synthetic details). Compound S7 was synthesized according to known procedure (Wolf et al., J Org Chem 2020, 85(15):9751-9760). To a 20 mL microwave vial S7 (327.8 mg, 0.93 mmol) and Vilsmeier reagent (150 mg, 0.46 mmol) were added sequentially in dry ethanol (20 mL). The solution was heated at 70 °C for 6 h. The
reaction was cooled, and solvent was evaporated. The crude mixture was redissolved in H2O and purified over reversed phase chromatography (0-50% MeCN:H2O) to provide S8 as green amorphous solid (150 mg, 38%). ' H NMR (500 MHz, DMSO) 5 8.26 (d, 7= 13.9 Hz, 2H), 7.81 (d, 7 = 1.6 Hz, 2H), 7.66 (dd, 7= 8.2, 1.6 Hz, 2H), 7.40 (d, 7= 8.4 Hz, 2H), 6.34 (d, 7 = 14.1 Hz, 2H), 4.22 (t, 7= 7.3 Hz, 4H), 2.71 (t, 7= 6.0 Hz, 4H), 2.21 (t, 7 = 7.3 Hz, 4H), 1.90 - 1.82 (m, 2H), 1.74 (p, 7= 7.5, 7.0 Hz, 5H), 1.68 (s, 12H), 1.56 (p, 7 = 7.4 Hz, 4H), 1.41 - 1.35 (m, 4H). 13C NMR (125 MHz, DMSO) 5 174.8, 172.8, 148.4, 145.9, 143.3, 142.5, 140.9, 127.0, 126.7, 120.3, 111.1, 102.4, 49.47, 44.22, 33.92, 27.87, 27.21, 26.29, 26.08, 24.66, 20.82. LRMS: calculated for C42H53CIN2O10S2 [M+H]+ 843.2; observed: 843.2.
Compound S9. To a 10 mL microwave vial resorcinol (26mg, 0.24 mmol) and K2CO3 (49.2, 0.36 mmol) were added sequentially in dry DMF (5 mL). The solution was stirred at 25 °C for 15 mins followed by addition of S8 (100 mg, 0.11 mmol). The solution was first stirred at 25 °C for 30 mins and then heated at 60 °C for 1.5 h. The reaction was cooled, and solvent was evaporated. The crude mixture was redissolved in H2O and purified over reversed phase chromatography (0-50% MeCN:H2O) to provide S9 as blue amorphous solid (30.1 mg, 47%). !H NMR (500 MHz, DMSO) 5 8.57 (d, J = 14.7 Hz, 2H), 7.74 (dd, J = 8.3, 1.6 Hz, 1H), 7.58 (s, 2H), 7.50 (d, 7 = 8.5 Hz, 1H), 6.96 (d, 7= 2.4 Hz, 1H), 6.86 (dd, 7= 8.5, 2.2 Hz, 1H), 6.59 (d, 7 = 4.0 Hz, 1H), 6.49 (d, 7 = 14.8 Hz, 2H), 4.37 (t, 7 = 7.3 Hz, 2H), 2.74 - 2.68 (m, 3H), 2.68 - 2.63 (m, 2H), 2.21 (t, 7 = 7.3 Hz, 2H), 1.84 (t, 7= 6.0 Hz, 2H), 1.75 (s, 6H), 1.59 - 1.52 (m, 2H), 1.45 - 1.35 (m, 3H). 13C NMR (125 MHz, DMSO) 5 174.8, 161.7, 154.6, 147.5, 141.9, 141.7, 135.1, 129.7, 126.8, 126.3, 120.4, 114.9, 114.4, 112.6, 102.4, 50.60, 44.94, 33.86, 28.76, 27.94, 27.49, 26.00, 24.62, 20.45. HRMS (ESI) calculated for C31H34NO7S [M+H]+ 564.2046; observed: 564.2050.
Compound S10. To a 5 mL microwave vial S9 (10 mg, 0.021 mmol) was dissolved in dry DMF (2 mL). Acetyl chloride (2.49 pL, 0.035 mmol) and El N (7.41 pL. 0.053 mmol) were added sequentially and solution stirred at 25 °C for 1 h. The crude mixture was purified by reversed phase Prep HPLC (10-95% MeCN:H2O,0.1% TFA) to provide S10 as blue amorphous solid (6.2 mg,
8.85 (d, 7 = 15.0 Hz, 1H), 8.08 (d, 7 = 1.6 Hz, 1H), 8.02 (dd, 7= 8.4, 1.7 Hz, 1H), 7.66 (dd, 7 = 8.4, 1.5 Hz, 1H), 7.58 (d, 7 = 8.4 Hz, 1H), 7.45 - 7.40 (m, 2H), 7.15 (dd, 7 = 8.5, 2.2 Hz, 1H), 6.63 (d, 7 = 14.9 Hz, 2H), 4.43 (t, 7 = 7.5 Hz, 2H), 2.84 (t, 7 = 5.9 Hz, 2H), 2.77 (t, 7= 6.1 Hz, 2H), 2.37 (s, 3H), 2.01 (s, 1H), 2.00 - 1.94 (m, 4H), 1.87 (s, 6H), 1.78 - 1.71 (m, 3H), 1.58 - 1.52 (m, 3H). 13C NMR (125 MHz, MeOD) 5 179.4, 175.6, 169.1, 161.2,
146.9, 144.5, 142.2, 132.4, 129.9, 128.1, 127.02, 120.2, 119.7, 119.3, 115.1, 112.6, 109.5, 104.8, 50.94, 45.02, 33.07, 28.83, 27.07, 26.73, 25.82, 24.14, 23.59, 20.08, 19.50. HRMS (ESI) calculated for C33H36NO8S [M+H]+ 606.2155; observed: 606.2156.
CyBam-B(OH)2. Compound Sil was synthesized according to a known procedure Skarbek et al., Bioorg Chem 2019, 91:103158). To a 5 mL microwave vial, Sulfo-NorCy7 (30 mg, 0.045 mmol), NaH (2.1 mg, 0.091 mmol) were added sequentially to dry DMF (1.5 mL) and stirred for 1 h. Sil (36.5 mg, 0.091 mmol) was dissolved in dry DMF (1.5 mL) and added dropwise over 10 mins. Reaction progress was monitored by LC/MS. After 2 h, the reaction was complete by LC/MS and was quenched using H2O (1 mL). The resulting mixture was purified by reversed phase HPLC (60- 95% MeCN:H2O, 0.1% TFA) to give CyBam-B(OH)2 as purple amorphous solid (13.5 mg, 37%). NMR (500 MHz, MeOD) 57.81 (dd, J = 9.9, 1.6 Hz, 2H), 7.68 (dd, J = 8.4, 3.2 Hz, 3H), 7.53 - 7.45 (m, 6H), 7.40 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.30 (d, J = 13.1 Hz, 1H), 7.26 - 7.23 (m, 1H), 7.20 (dd, J = 8.1, 6.5 Hz, 2H), 7.04 (dd, J = 6.6, 2.9 Hz, 2H), 6.53 (d, J = 15.6 Hz, 1H), 6.45 (d, J = 13.0 Hz, 1H), 5.29 (s, 2H), 2.45 (t, J = 6.2 Hz, 2H), 2.19 (t, J = 6.2 Hz, 2H), 1.72 (t, J = 6.2 Hz, 2H), 1.21 (s, 6H), 1.03 (s, 6H). 13C NMR (125 MHz, MeOD) 5 184.5, 158.6,
155.0, 153.1, 152.1, 145.0, 142.8, 141.2, 140.9, 140.7, 139.2, 138.0, 137.0, 136.5, 136.0, 134.1,
134.0, 133.9, 133.5, 133.2, 129.5, 128.5, 128.3, 128.0, 127.1, 127.0, 126.3, 125.6, 120.4, 119.6,
115.2, 114.3, 109.6, 108.4, 68.87, 66.76, 51.60, 45.09, 38.99, 28.22, 24.41, 24.38, 24.35, 20.99.
Compound S13. Compound S12 was synthesized according to known procedure (Chem Commun (Camb) 2017, 53(10): 1653- 1656). To 20 mL microwave vial, S5 (250 mg, 0.77 mmol) and 4-nitrophenyl chloroformate (171 mg, 0.85 mmol) were added sequentially in dry THF (10 mL) and stirred on ice for 30 mins. Triethylamine (600 pL, 1.54 mmol) was added dropwise and the solution was stirred for 12 h. The solvent was removed, the crude mixture redissolved in
CH2CI2 and purified by normal phase silica column (EtOAcm-hexane; 0 - 100%, 24 g SiCh) to give S7 white color product (320 mg, 84% yield). !H NMR (500 MHz, MeOD) 5 8.31 - 8.27 (m, 1H), 7.93 (ddt, J = 12.7, 7.1, 1.4 Hz, 4H), 7.66 - 7.62 (m, 2H), 7.56 (td, J = 7.5, 3.7 Hz, 4H), 7.46 - 7.38 (m, 4H), 7.27 (dd, J = 8.7, 1.4 Hz, 2H), 5.23 (s, 2H). 13C NMR (125 MHz, MeOD) 5 155.6, 152.4, 151.0, 150.94, 145.4, 132.8, 132.8, 131.8, 131.5, 131.4, 130.3, 129.9, 129.2, 128.7, 128.7, 128.6,
128.5, 124.8, 121.8, 120.7, 120.6, 69.61. HRMS (ESI) calculated for C26H21NO7P [M+H]+ 490.1057; observed: 490.1050.
CyBam-P(OPh)2. To a 5 mL microwave vial, Sulfo-NorCy7 (30 mg, 0.045 mmol), NaH (2.1 mg, 0.091 mmol) were added sequentially to dry DMF (1.5 mL) and stirred for 1 h. S13 (45 mg, 0.091 mmol) was dissolved in dry DMF (1.5 mL) and added dropwise over 10 mins. Reaction progress was monitored by LC/MS. After 2 h, the reaction was complete by LC/MS and was quenched using H2O (1 mL). The resulting mixture was purified by reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to give CyBam-P(OPh)2 as purple amorphous solid (15.5 mg, 38%). ' H NMR (500 MHz, MeOD) 57.85 - 7.80 (m, 6H), 7.72 - 7.67 (m, 1H), 7.60 - 7.57 (m, 2H), 7.56 - 7.51 (m, 3H), 7.50 (dd, J = 6.1, 4.2 Hz, 4H), 7.45 (td, J = 7.6, 3.6 Hz, 5H), 7.37 - 7.33 (m, 2H), 7.23 (dd, J = 8.5, 1.3 Hz, 2H), 7.12 - 7.09 (m, 2H), 6.57 (d, J = 15.6 Hz, 1H), 6.49 (d, J = 13.0 Hz, 1H), 5.24 (s, 2H), 2.51 (t, J = 6.1 Hz, 2H), 2.31 (t, J = 6.2 Hz, 2H), 1.83 - 1.76 (m, 2H), 1.26 (s, 6H), 1.05 (s, 6H). 13C NMR (125 MHz, MeOD) 5 184.6, 155.2, 153.1, 151.9, 151.2, 151.1, 145.0, 142.8, 141.3, 140.8, 140.7, 139.1, 138.0, 137.0, 136.2, 134.1, 132.9, 132.9, 131.9, 131.8, 131.8,
131.5, 131.4, 130.9, 130.8, 130.7, 130.3, 129.6, 129.2, 128.7, 128.7, 128.6, 128.5, 128.3, 128.3,
128.2, 127.0, 125.6, 120.8, 120.8, 120.4, 119.6, 115.1, 114.2, 109.4, 108.3, 68.00, 51.67, 45.06,
28.17, 24.44, 24.35, 21.02. HRMS (ESI) calculated for C56H52N2O10PS ’ [M+H]+ 1007.2828; observed: 1007.2796.
Compound S2. Compound SI was synthesized according to literature procedure (Reynolds, et al., J Org Chem 1977, 42(5): 885-888). To a 20 mL microwave vial, SI (400 mg, 2.32 mmol), phenylboronic acid (562.7 mg, 4.65 mmol) and K3PO4 (493.6 mg, 2.32 mmol) were added sequentially. Pd(PPh3)4 (95 mg, 0.081 mmol) was added in glove box and the vial was sealed under nitrogen. Subsequently, degassed DMF:H2O (5:1; 12 mL) was added to the solution and heated at 90 °C for 18 h. The solvent was removed and filtered through celite to remove inorganic compounds. Crude mixture was taken forward to next step.
Compound S3, S4 and SulfoNorCy7 were synthesized according to a previous published procedure (Usama et al., JACS 2021, 143(150:5674-5679).
Compound S5. To a 20 mL microwave vial compound S3 (1200 mg, 5.04 mmol) and
POCh (1.4 mL, 15.1 mmol) were refluxed for 2 h. The reaction was cooled on ice for 15 mins and n-hexane (10 mL) was added to remove excess POCI3. The supernatant was removed carefully. The red thick red liquid was dried under high vacuum overnight to get solid compound (S5). The crude mixture was carried into to the next steps without purification.
Compound S6. To a 20 mL microwave vial compound S5 (500 mg; 1.94) was dissolved in MeCN (10 mL) and cooled down to 5 °C on ice for 15 mins. Piperidine (960 pL; 9.73 mmol) and EtsN (1 mL) were added sequentially on ice. The reaction mixture was stirred on ice for 15 mins, followed by at room temperature for 1 h. The solvent was removed, and crude reaction mixture passed through celite to remove salts. The crude was purified by normal phase chromatography (0-10% MeOFPCFhCh) to give S6 as mustard yellow solid (495 mg, 84% over two steps). Rf value = 0.6 (
) 57.82 (t, J = 1.1 Hz, 1H), 7.68 - 7.64 (m, 2H), 2.88 (t, J = 5.5 Hz, 4H), 2.28 (s, 3H), 1.56 - 1.51 (m, 4H), 1.38 - 1.32 (m, 3H), 1.31 (s, 6H).
13C NMR (125 MHz, DMSO) 5 193.1, 157.6, 147.4, 132.3, 128.2, 121.5, 120.1, 54.41, 47.03, 25.12, 23.32, 22.53, 15.90. HRMS (ESI) calculated for C16H23N2O2S [M+H]+ 307.1475; observed: 307.1467.
Compound S7. To a 20 mL microwave vial compound S5 (1000 mg; 3.89 mmol) was dissolved in MeCN (10 mL) and cooled down to 5 °C on ice for 15 mins. 1 -methylpiperazine (2.15 mL; 19.5 mmol) and Et3N (2 mL) were added sequentially on ice. The reaction mixture was stirred on ice for 15 mins, followed by at room temperature for 1 h. The solvent was removed, and crude reaction mixture passed through celite to remove salts. The crude was purified by normal phase chromatography (0-10% MeOH:CH2C12) to give S7 as mustard yellow solid (500 mg, 84% over two steps). Rf value = 0.3 (10% MeOH/DCM).
NMR (400 MHz, DMSO) 57.81 (d, J = 1.6 Hz, 1H), 7.69 - 7.62 (m, 2H), 2.87 (s, 4H), 2.32 (t, J = 4.9 Hz, 4H), 2.27 (s, 3H), 2.09 (s, 3H), 1.30 (s, 6H). 13C NMR (101 MHz, DMSO) 5 193.23, 157.75, 147.47, 131.56, 128.47, 121.64, 120.15, 54.43, 53.90, 46.22, 45.71, 22.52, 15.90. HRMS (ESI) calculated for C16H24N3O2S [M+H]+ 322.1584; observed: 322.1571.
Pip-NorCy7. To a 20 mL microwave vial, S6 (1.75 g, 3.51 mmol) S2 (250 mg, 1.10 mmol) and TsOH (603.72 mg, 3.51 mmol) were added sequentially in 20 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 18 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on normal phase chromatography (0-10% MeOH:CH2C12) to give Pip- NorCy7 (240 mg, 27%). Rf value = 0.3 (10% MeOH/DCM). 1 H NMR (500 MHz, MeOD) 57.64 - 7.57 (m, 4H), 7.52 (qd, J = 4.9, 1.7 Hz, 3H), 7.21 - 7.13 (m, 3H), 7.13 - 7.06 (m, 3H), 6.12 (d, J = 14.0 Hz, 2H), 3.23 (p, J = 1.6 Hz, 5H), 2.86 (t, J = 5.5 Hz, 8H), 2.61 (t, J = 6.2 Hz, 4H), 1.98 - 1.90 (m, 2H), 1.39 - 1.31 (m, 5H), 1.26 (s, 12H). 13C NMR (125 MHz, MeOD) 5 173.2, 163.1, 147.2, 145.4, 141.4, 138.2, 132.8, 130.9, 128.9, 128.4, 124.5, 121.8, 111.2, 48.85, 46.76, 25.94, 24.95, 24.68, 23.13, 21.11. HRMS (ESI) calculated for C46H55N4O4S2 [M+H]+ 791.3659; observed: 791.3687.
/V-Me-Pip-NorCy7. To a 20 mL microwave vial, S7 (1.5 g, 4.67 mmol) S2 (500 mg, 2.34 mmol) and TsOH (1.2 g, 7.1 mmol) were added sequentially in 20 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 18 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on normal phase chromatography (0-20% MeOH:CH2C12) to give -Me-pip- NorCy7 (410 mg, 20%). Rf value = 0.2 (10% MeOH/DCM).
MHz, MeOD) 57.75 (dd, J = 8.2, 1.8 Hz, 3H), 7.65 - 7.58 (m, 3H), 7.31 - 7.27 (m, 3H), 7.27 - 7.19 (m, 4H), 6.25 (d, J = 14.0 Hz, 2H), 3.98 - 3.86 (m, 4H), 3.61 - 3.52 (m, 4H), 3.23 (s, 4H), 2.90 (s, 6H), 2.72 (t, J = 6.2 Hz, 4H), 2.07 - 2.00 (m, 3H), 1.37 (s, 12H). 13C NMR (125 MHz, MeOD) 5 163.7, 146.0, 141.7, 138.1, 133.2, 129.9, 129.3, 129.2, 128.4,
128.3, 121.9, 117.1, 114.8, 111.5, 52.54, 48.86, 43.31, 41.99, 25.91, 24.67, 21.06. HRMS (ESI) calculated for C46H57N2O6S2 [M+H]+ 821.3877; observed: 821.3878.
24% yield
Compound S8. In a 500 mL round bottom flask, DMF/CH2CI2 (18 mL/18 mL) was cooled down on ice for 20 mins. POCI3 (16.29 mL, 174.1 mmol) was added dropwise over 10 mins to the solution and reaction mixture was stirred for 1 h on ice. N-Methyl-4-piperidone (5.43 mL, 44.24 mmol) was added dropwise over 10 mins and the solution was heated at 70 °C for 6 h. The excess
POCh was quenched by adding distilled H2O (20 mL) dropwise on ice. The solvent was removed on rotavap. Ethanol (20 mL) and aniline (6 mL) were premixed and poured in the solution. Thick slurry solution was stirred at room temperature for 30 mins followed by addition of cone. HC1 (7 mL). The precipitate is filtered and washed with ethyl acetate and ether to give compound S8 as a reddish black solid (8.2 g, 70% yield). 1 H NMR (400 MHz, DMSO) 57.46 - 7.34 (m, 15H), 7.20 (t, J = 7.1 Hz, 3H), 4.65 (s, 4H), 4.21 (s, 4H), 2.99 (s, 6H). 13C NMR (100 MHz, DMSO) 5 186.8, 145.2, 141.2, 137.7, 130.2, 130.1, 130.1, 128.4, 123.8, 123.7, 118.04 116.7, 116.7, 99.07, 50.94, 50.31, 41.78, 41.68. LRMS (ESI) calculated for CI4HI6C1N2O and C20H21CIN3 [M+H]+ 263.0 and 338.1; observed: 263.1 and 338.2.
Compound S9. To a 20 mL microwave vial, S8 (400 mg, 1.51 mmol), phenyl boronic acid (371 mg, 3.04 mmol) and K3PO4 (637 mg, 3.01 mmol) were added sequentially. Pd(PPh3)4 (61 mg, 0.042 mmol) was added in glove box and the vial was sealed under nitrogen. Subsequently, degassed DMF:H2O (5:1; 12 mL) was added to the solution and heated at 90 °C for 18 h. The solvent was removed and filtered through celite to remove inorganic compounds. The crude reaction mixture was purified on normal phase chromatography (0-15% MeOH:CH2Cl2) to give compound S9 (110 mg, 24%). Rf value = 0.4 (10% MeOH/DCM). ' H NMR (500 MHz, DMSO) 5 7.50 - 7.39 (m, 4H), 7.29 - 7.20 (m, 4H), 7.20 - 7.14 (m, 2H), 7.07 (t, J = 7.4 Hz, 1H), 6.81 (d, J = 7.8 Hz, 3H), 6.68 (d, J = 8.0 Hz, 2H), 6.21 (d, J = 11.9 Hz, 1H), 4.11 (d, J = 5.3 Hz, 1H), 3.46 (d, J = 27.2 Hz, 4H), 3.18 (d, J = 5.0 Hz, 3H). 13C NMR (125 MHz, DMSO) 5 158.9, 153.3, 149.1,
142.8, 136.7, 130.7, 130.5, 129.9, 129.9, 129.8, 129.7, 129.5, 128.7, 128.3, 125.9, 125.2, 120.9,
120.8, 116.2, 114.5, 113.2, 53.70, 53.06, 49.07, 45.81. LRMS (ESI) calculated for C20H21N2O and C26H26N3 [M+H]+ 305.1 and 380.2; observed: 305.2 and 380.3.
/V-Me-NorCy7. To a 20 mL microwave vial, S9 (110 mg, 0.36 mmol) 2,3,3-trimethylindolenine (174 mg, 1.08 mmol) and TsOH (1.2 g, 7.1 mmol) were added sequentially in 15 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 18 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on normal phase chromatography (0-20% MeOH:CH2Cl2). (140 mg, 75%). !H NMR (500 MHz, MeOD) 57.70 - 7.66 (m, 3H), 7.41 (d, J = 7.5 Hz, 2H), 7.37 - 7.34 (m, 2H), 7.34 -
7.30 (m, 2H), 7.28 (d, J = 5.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 6.07 (d, J = 14.6 Hz, 1H), 4.69 (d, J = 14.1 Hz, 2H), 4.20 (d, J = 14.7 Hz, 2H), 3.27 (s, 3H), 1.37 (s, 12H). 13C NMR (125 MHz, MeOD) 5 176.8, 156.1, 144.9, 140.9, 140.7, 135.6, 129.8, 129.0, 128.8, 128.4, 124.8, 122.2, 118.4, 117.1, 114.8, 111.9, 51.26, 49.61, 41.83, 25.49. HRMS (ESI) calculated for C36H38N3 [M+H]+ 512.3060; observed: 512.3071.
H-NorCy7. To a 20 mL microwave vial, S2 (200 mg, 0.93 mmol) 2,3,3-trimethylindolenine (594 mg, 3.73 mmol) and TsOH (643 mg, 3.73 mmol) were added sequentially in 15 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 18 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on normal phase chromatography (0-10% MeOH:CH2Ch) to give a green amorphous solid (143 mg, 77%). Rf value = 0.3 (10% MeOH/DCM). 1 H NMR (500 MHz, MeOD) 57.65 - 7.58 (m, 4H), 7.33 (d, J = 7.4 Hz, 3H), 7.26 (dd, J = 7.4, 5.0 Hz, 4H), 7.17 (s, 2H), 7.13 (d, J = 7.5 Hz, 2H), 7.05 (d, J = 7.8 Hz, 2H), 2.67 (t, J = 5.1 Hz, 4H), 2.05 - 1.99 (m, 2H), 1.30 (s, 12H). 13C NMR (125 MHz, MeOD) 5 141.3, 140.5, 138.7, 130.6, 129.8, 129.6, 128.2, 128.1, 127.9, 123.7, 122.3, 122.1, 117.8, 115.5, 111.6, 110.9, 54.41, 42.37, 26.09, 25.62, 24.62, 21.20, 17.29, 15.86, 11.74. HRMS (ESI) calculated for C36H37N2 [M+H]+ 497.2951; observed: 497.2949.
OMe-NorCy7. To a 20 mL microwave vial, S2 (250 mg, 1.11 mmol) 2,3,3-trimethyl-5-methoxy-3h-indole (664 mg, 3.51 mmol) and TsOH (604 mg, 3.51 mmol) were added sequentially in 15 mL of absolute ethanol. The reaction mixture was heated at 70 °C for 18 h. The flask was cooled on ice to room temperature and solvent was removed. The crude reaction mixture was purified on normal phase chromatography (0-10% MeOH:CH2C12) to give OME-NorCy7 as green amorphous solid (220 mg, 33%). Rf value = 0.2 (10% MeOH/DCM). 1 H
NMR (500 MHz, DMSO) 57.52 - 7.46 (m, 3H), 7.14 - 7.10 (m, 2H), 7.03 (d, J = 2.6 Hz, 2H), 6.95 (d, 7= 8.6 Hz, 2H), 6.85 (d, 7= 14.3 Hz, 2H), 6.75 (dd, 7 = 8.6, 2.6 Hz, 2H), 5.97 (d, 7 = 14.3 Hz, 2H), 3.66 (s, 6H), 2.48 (t, 7= 6.1 Hz, 4H), 1.84 (q, 7 = 6.0 Hz, 2H), 1.12 (s, 12H). 13C NMR (125 MHz, DMSO) 5 157.2, 138.9, 135.4, 130.1, 129.4, 128.8, 128.3, 113.76, 112.6, 109.8, 56.10, 49.24, 27.00, 24.88, 21.55. HRMS (ESI) calculated for C38H41N2O2 [M+H]+ 557.3163; observed:
VC-CyBam. To a 10 mL microwave vial Sulfo-NorCy7 (60 mg, 0.091 mmol) and CS2CO3 (59.44 mg, 0.183) were added sequentially to dry DMF (3 mL) and stirred for 1 h. Subsequently,
Boc-Val-Cit-PABA- PNB (140 mg, 0.183 mmol, obtained from BroadPharm, Cat:BP-24175) was dissolved in dry DMF (3 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored at different intervals using LC/MS. After 6 h, the reaction was quenched using H2O (1 mL). The crude product concentrated and then dissolved in TFA:CH2Ch (1 mL) on ice. After 1 h, the solvent was evaporated, followed by addition of glutaric anhydride (4.30 mg, 0.037 mmol) and DIPEA (7.45 pL, 0.056 mmol) in dry DMF. The reaction
mixture was stirred at room temperature. The reaction was monitored by LC/MS. After 3 h the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyBam as amorphous purple solid (28 mg, 30% yield). ' H NMR (500 MHz, DMSO) 5 8.08 (d, J = 7.6 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 1.6 Hz, 1H), 7.49 (dd, J = 7.8, 1.8 Hz, 2H), 7.45 - 7.42 (m, 2H), 7.37 (dd, J = 8.5, 1.8 Hz, 1H), 7.32 - 7.28 (m, 2H), 7.13 (d, J = 4.0 Hz, 1H), 7.09 (dt, J = 6.0, 1.5 Hz, 2H), 6.54 (d, J = 16.0 Hz, 2H), 6.05 (d, J = 13.0 Hz, 2H), 5.23 (s, 1H), 4.40 - 4.35 (m, 2H), 3.33 (d, J = 5.6 Hz, 3H), 3.29 (t, J = 5.5 Hz, 3H), 2.82 (s, 1H), 2.66 (s, 2H), 2.22 (t, J = 7.4 Hz, 2H), 2.15 (dt, J = 14.9, 7.4 Hz, 7H), 2.10 - 2.05 (m, 2H), 1.92 (dq, J = 12.8, 6.6 Hz, 2H), 1.49 (dd, J = 7.4, 4.1 Hz, 2H), 1.39 (dq, J = 6.4, 3.1, 2.7 Hz, 3H), 1.33 (dd, J = 6.9, 3.1 Hz, 3H), 1.20 - 0.98 (m, 12H), 0.83 - 0.75 (m, 6H). 13C NMR (125 MHz, DMSO) 5 184.2, 174.8, 174.7, 174.6, 172.4, 171.8, 171.2, 170.2,
162.8, 159.6, 152.3, 145.1, 139.9, 139.8, 139.2, 138.6, 137.1, 133.5, 130.5, 130.1, 130.0, 128.6,
120.6, 119.7, 119.5, 118.3, 115.9, 114.9, 113.6, 58.08, 53.64, 52.12, 46.25, 44.74, 36.26, 34.74,
33.50, 33.47, 33.21, 31.98, 31.24, 30.88, 28.89, 26.56, 25.79, 24.54, 24.22, 21.31, 20.83, 20.42,
19.72, 18.68. HRMS (ESI) calculated for C60H70N7O14S2 [M+H]+ 1176.4417; observed: 1176.4434.
VC-CyBam-NHS. To a 10 mL microwave vial, VC-CyBam (10 mg, 0.0085 mmol), TSTU (7.7 mg, 0.025 mmol) and DIPEA (4.4 pL, 0.025 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyBam-NHS as amorphous purple solid (8.6 mg, 80% yield). HRMS (ESI) calculated for C64H73N8O16S2 [M+H]+ 1273.4580; observed: 1273.4579.
NC-CyBam-NHS. Compound NC-CyBam was synthesized according to our reported procedure. 2 To a 10 mL microwave vial, NC-CyBam (5.0 mg, 0.0065 mmol), TSTU (5.9 mg, 0.019 mmol) and DIPEA (2.5 pL, 0.019 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give
N.C-CyBam-NHS as amorphous purple solid (4.1 mg, 72% yield). HRMS (ESI) calculated for C53H53N4O13S2 [M+H]+ 1017.3045; observed: 1017.3031.
VC-CyLBam. To a 10 mL microwave vial 2V-Me-NorCy7 (30 mg, 0.059 mmol) and
CS2CO3 (38 mg, 0.11 mmol) were added sequentially to dry DMF (2 mL) and stirred for 1 h. Subsequently, Boc-Val-Cit-PABA- PNB (140 mg, 0.18 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored using LC/MS and quenched using H2O (1 mL). The crude product concentrated and then dissolved in TFA:CH2C12 (1 mL) on ice. After 1 h, the solvent was evaporated, followed by addition of glutaric anhydride (2.5 mg, 0.022 mmol) and DIPEA (5.7 pL, 0.033 mmol) in dry DMF. The reaction mixture was stirred at room temperature and was monitored by LC/MS. After 3 h the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyLBam as amorphous dark blue solid (7.9 mg, 60% yield). JH NMR (500 MHz, MeOD) 5 8.04 - 7.96 (m, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.80 - 7.74 (m, 1H), 7.74 - 7.59 (m, 4H), 7.55 - 7.47 (m, 3H), 7.44 (t, J = 7.0 Hz, 1H), 7.38 (ddd, J = 19.0, 10.7, 5.6 Hz,
3H), 7.32 (d, J = 8.6 Hz, 1H), 7.30 - 7.22 (m, 2H), 7.21 - 7.15 (m, 1H), 6.95 (t, J = 20.2 Hz, 2H), 6.72 (t, J = 16.7 Hz, 1H), 5.39 (d, J = 11.5 Hz, 1H), 5.32 (d, J = 11.4 Hz, 1H), 5.24 (dd, J = 11.4, 8.8 Hz, 1H), 4.85 - 4.72 (m, 2H), 4.65 (t, J = 14.7 Hz, 2H), 4.58 - 4.53 (m, 1H), 4.51 (dp, J = 13.4,
4.5, 3.5 Hz, 1H), 4.26 (d, J = 6.2 Hz, 1H), 4.18 (dd, J = 10.3, 7.3 Hz, 2H), 4.00 (d, J = 14.4 Hz, 1H), 3.17 (dq, J = 14.6, 7.2 Hz, 3H), 3.07 (s, 1H), 3.02 (s, 1H), 2.96 (s, 1H), 2.46 - 2.38 (m, 3H), 2.38 - 2.28 (m, 3H), 2.01 - 1.87 (m, 4H), 1.69 - 1.54 (m, 4H), 1.40 - 1.28 (m, 6H), 1.22 (d, J = 5.0 Hz, 2H), 1.13 - 1.03 (m, 5H), 1.03 - 0.89 (m, 4H). 13C NMR (125 MHz, MeOD) 5 183.6, 175.7, 175.5,
175.5, 175.1, 174.6, 174.5, 174.4, 173.3, 173.1, 172.8, 171.9, 171.4, 163.5, 152.2, 144.7, 144.6,
140.9, 139.9, 139.6, 138.8, 138.7, 135.3, 135.2, 133.6, 133.4, 130.1, 129.8, 129.5, 129.1, 128.9,
128.5, 127.7, 127.5, 127.2, 124.6, 122.6, 122.5, 122.1, 121.8, 121.5, 121.4, 119.8, 119.5, 117.5,
117.3, 115.8, 114.9, 112.6, 105.1, 104.9, 60.2, 60.1, 59.78, 59.18, 54.50, 53.90, 53.80, 53.73, 52.28, 45.86, 45.77, 38.54, 35.59, 34.21, 33.81, 32.75, 32.71, 32.64, 32.42, 30.20, 30.11, 30.06, 29.90,
28.78, 28.62, 28.56, 28.29, 28.19, 26.99, 23.15, 20.80, 20.22, 19.89, 18.49, 18.47, 18.44, 18.41,
17.80, 17.68, 17.57, 17.37. HRMS (ESI) calculated for CeoHviNsOs [M+H]+/2 516.2731; observed: 516.2740.
VC-CyLBam-NHS. To a 10 mL microwave vial, VC-CyLBam (8.0 mg, 0.0077 mmol), TSTU (4.7 mg, 0.015 mmol) and DIPEA (4.05 pL, 0.023 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give VC-CyLBam-NHS as amorphous dark blue solid (6.5 mg, 75% yield). LRMS (ESI) calculated for C64H74N9O10 [M+H]+ 1128.5; observed: 1128.4.
(840 mg, 4.46 mmol) and HATU (1.69 g, 4.46 mmol) were added sequentially in dry THF and stirred on ice for 10 mins. Subsequently, 4-aminobenzyl alcohol (500 mg. 4.06 mmol) and DIPEA (1.4 mL, 8.1 mmol) were sequentially added to the reaction mixture and stirred for 12 h. Afterwards, the solvent was evaporated, and crude mixture was dissolved in EtOAc. The organic layer was washed twice with 1 N HC1, sat. NaHCO and brine. The organic layer was dried over Na2SO4 and dried to get product as yellow fluffy power (1.11 g, 82%). !H NMR (500 MHz, DMSO) 57.56 - 7.51 (m, 2H), 7.24 - 7.19 (m, 2H), 5.09 (t, J = 5.7 Hz, 1H), 4.43 (d, J = 5.7 Hz, 2H), 2.70 (s, 1H), 2.33 (t, J = 7.4 Hz, 2H), 2.25 (t, J = 7.4 Hz, 2H), 1.80 (q, J = 7.4 Hz, 2H), 1.41 (s, 9H). 13C NMR (125 MHz, DMSO) 5 170.3, 168.8, 136.2, 135.4, 125.2, 117.1, 77.90, 60.96, 53.26,
33.53, 32.45, 26.12, 18.85. HRMS (ESI) calculated for C18H28N3O5 [M+H]+ 366.2023; observed: 366.2031.
Compound Sil. To a 20 mL microwave vial, S10 (300 mg, 1.02 mmol) and 4-nitrophenyl chloroformate (308 mg, 1.53 mmol) were added sequentially to dry THF (15 mL) and stirred on ice for 30 mins. Triethylamine (285 pL, 0.40 mmol) was added dropwise, and the solution was stirred for 12 h. The resulting white precipitate was filtered, and the solvent was evaporated. The product was purified by normal phase chromatography (EtO Ac .’hexanes; 0 - 100%) to give compound Sil as a white amorphous solid (276 mg, 58% yield). Rf value = 0.5 (1:1 EtOAc/n-hexane). !H NMR (500 MHz, DMSO) 5 8.35 - 8.30 (m, 2H), 7.67 - 7.62 (m, 2H), 7.61 - 7.56 (m, 2H), 7.43 - 7.38 (m, 2H), 5.24 (s, 2H), 2.36 (t, J = 7.4 Hz, 2H), 2.26 (t, J = 7.4 Hz, 2H), 1.84 - 1.77 (m, 2H), 1.41 (s, 9H). 13C NMR (125 MHz, DMSO) 5 170.3, 169.1, 153.6, 150.3, 143.5, 138.1, 127.8, 127.3, 123.6, 120.9, 117.3, 77.91, 68.63, 33.56, 32.40, 26.11, 18.76. HRMS (ESI) calculated for C25H31N4O9 [M+H]+ 531.2086; observed: 531.2089.
Compound S12. To a 10 mL microwave vial 2V-Me-NorCy7 (30 mg, 0.059 mmol) and CS2CO3 (38.23 mg, 0.11) were added sequentially to dry DMF (2 mL) and stirred for 1 h. Subsequently, compound Sil (53 mg, 0.12 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored using LC/MS and quenched using H2O (1 mL). The reaction mixture was purified by reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to give S12 as amorphous dark blue solid (18 mg, 41% yield). 1 H NMR (500 MHz, DMSO) 57.73 (d, J = 8.4 Hz, 1H), 7.71 - 7.57 (m, 5H), 7.53 - 7.48 (m, 1H), 7.48 - 7.35 (m, 6H), 7.35 - 7.26 (m, 2H), 7.26 - 7.18 (m, 2H), 7.18 - 7.11 (m, 2H), 6.62 (d, J = 16.4 Hz, 1H), 6.55 (d, J = 13.2 Hz, 1H), 5.37 (d, J = 1.7 Hz, 1H), 5.28 (d, J = 11.7 Hz, 1H), 4.65 (dd, J = 17.8, 4.6 Hz, 2H), 4.39 (d, J = 14.4 Hz, 1H), 4.22 (d, J = 14.4 Hz, 1H), 3.18 (s, 2H), 2.36 (td, J = 7.4, 3.8 Hz, 3H), 2.28 - 2.23 (m, 2H), 1.83 - 1.76 (m, 3H), 1.42 - 1.37 (m, 12H), 1.16 (dd, J = 30.0, 8.8 Hz, 8H). 13C NMR (125 MHz, DMSO) 5 182.9, 174.6, 172.4, 172.4,
171.6, 171.3, 155.5, 153.3, 152.3, 146.8, 142.9, 141.7, 140.1, 139.3, 139.1, 136.1, 134.3, 134.1,
132.8, 130.5, 130.1, 129.9, 129.9, 129.8, 129.4, 129.1, 129.1, 128.3, 128.3, 126.3, 124.9, 124.3,
123.3, 123.1, 122.1, 121.8, 120.5, 120.1, 119.8, 119.6, 119.5, 119.4, 117.4, 116.1, 115.1, 112.8,
105.7, 80.04, 68.66, 57.58, 56.71, 52.48, 50.05, 45.56, 45.33, 35.78, 35.71, 34.54, 34.47, 34.44,
31.76, 29.24, 29.00, 28.23, 28.22, 27.51, 23.46, 23.43, 23.36, 20.92, 20.88. HRMS (ESI) calculated for C53H59N4O5 [M+H]+ 831.4; observed: 831.4.
NC-CyLBam. To a 10 mL microwave vial compound S12 was dissolved in TFA:CH2C12 (1 mL) on ice and stirred for 1 h. Afterwards the solvent was evaporated and crude product was
purified over reversed phase HPLC (60-95% MeCN:H2O, 0.1% TFA) to give NC-CyLBam as amorphous dark blue solid (11.5 mg, 62% yield). !H NMR (500 MHz, DMSO) 57.62 (d, J = 8.2 Hz, 2H), 7.60 - 7.48 (m, 6H), 7.41 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.31 (t, J = 7.8 Hz, 3H), 7.29 - 7.22 (m, 3H), 7.18 (td, J = 7.5, 1.3 Hz, 1H), 7.13 - 7.08 (m, 3H), 7.06 - 6.99 (m, 2H), 6.51 (d, J = 16.4 Hz, 1H), 6.44 (d, J = 13.1 Hz, 1H), 5.25 (d, J = 11.8 Hz, 1H), 5.19 (s, 1H), 4.55 (d, J = 7.6 Hz, 2H), 3.07 (s, 2H), 2.27 (td, J = 7.4, 3.5 Hz, 4H), 2.18 (dt, J = 10.6, 7.3 Hz, 4H), 1.71 (q, J = 7.4 Hz, 4H), 1.09 - 1.03 (m, 8H). 13C NMR (125 MHz, DMSO) 5 182.9, 174.6, 174.6, 171.7, 171.4, 155.4, 153.5, 152.3, 146.9, 142.9, 141.7, 140.1, 139.3, 139.1, 136.1, 134.1, 132.7, 130.5,
130.1, 129.9, 129.8, 129.4, 129.1, 128.3, 128.3, 126.3, 124.9, 124.3, 123.3, 123.2, 122.1, 121.8,
120.6, 120.2, 119.6, 119.4, 117.5, 116.1, 115.2, 105.7, 68.66, 57.51, 56.79, 52.49, 50.09, 45.33,
35.92, 35.85, 33.43, 33.43, 33.35, 29.24, 29.01, 23.42, 23.35, 20.85, 20.83. HRMS (ESI) calculated for C49H51N4O5 [M+H]+ 775.3854; observed: 775.3864.
NC-CyLBam-NHS. To a 10 mL microwave vial, NC-CyLBam (6 mg, 0.0077 mmol), TSTU (4.7 mg, 0.015 mmol) and DIPEA (4.05 pL, 0.023 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give NC-CyLBam-NHS as amorphous dark blue solid (6.5 mg, 86% yield). LRMS (ESI) calculated for C53H54N5O7 [M+H]+ 871.39; observed: 871.4.
Compound S13. To a 100 mL round bottom flask Boc-Ala-Ala-OH (1.0 g, 3.84 mmol, obtained from Chemlmpex: Cat 04505) and HATU (1.64 g, 4.23 mmol) were added sequentially in dry THF and stirred on ice for 10 mins. Subsequently, 4-aminobenzyl alcohol (568.3 mg. 4.61 mmol) and DIPEA (1.25 mL, 7.69 mmol) were sequentially added to the reaction mixture and stirred for 12 h. Afterwards, the solvent was evaporated, and crude mixture was dissolved in EtOAc. The organic layer was washed twice with 1 N HC1, sat. NaHCO and brine. The organic layer was dried over Na2SC>4 and dried to get compound S13 as yellow fluffy power (1.18 g, 85%). JH NMR (500 MHz, DMSO) 57.57 - 7.52 (m, 2H), 7.26 - 7.22 (m, 2H), 5.11 (t, J = 5.7 Hz, 1H), 4.44 (d, J = 5.8 Hz, 2H), 3.99 (t, J = 7.2 Hz, 1H), 1.38 (s, 9H), 1.31 (d, J = 7.1 Hz, 3H), 1.19 (d, J = 7.1 Hz, 3H). 13C NMR (125 MHz, DMSO) 5 173.01, 171.44, 155.67, 137.95, 127.35, 119.37,
78.58, 63.03, 50.16, 49.32, 28.66, 18.74, 18.47. HRMS (ESI) calculated for C18H28N3O5 [M+H]+ 366.2023; observed: 366.2031.
Compound S14. To a 20 mL microwave vial, S13 (200 mg, 0.54 mmol) and 4-nitrophenyl chloroformate (160 mg, 0.82 mmol) were added sequentially to dry THF (15 mL) and stirred on ice for 30 mins. Triethylamine (153 pL, 1.09 mmol) was added dropwise, and the solution was stirred for 12 h. The resulting white precipitate was filtered, and the solvent was evaporated. The product was purified by normal phase chromatography (MeOH:CH2Ci2; 0 - 10%) to give compound S14 as a white amorphous solid (276 mg, 77% yield). Rf value = 0.4 (10% MeOH/DCM). !H NMR (500 MHz, DMSO) 5 10.06 (s, 1H), 8.35 - 8.29 (m, 2H), 8.03 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.60 - 7.55 (m, 2H), 7.43 (d, J = 8.3 Hz, 2H), 6.99 (d, J = 7.4 Hz, 1H), 5.25 (s, 2H), 4.41 (t, J = 7.1 Hz, 1H), 4.00 (t, J = 7.3 Hz, 1H), 1.39 (s, 9H), 1.32 (d, J = 7.1 Hz, 4H). 13C NMR (125 MHz, DMSO) 5 173.1, 171.8, 155.8, 155.7, 152.4, 145.6, 139.8, 129.9, 129.8, 125.9, 123.1, 119.6, 119.5, 78.57, 70.71, 65.39, 50.10, 49.42, 28.67, 18.62, 18.48, 15.65. HRMS (ESI) calculated for C25H31N4O9 [M+H]+ 531.2086; observed: 531.2089.
Compound S15. To a 10 mL microwave vial 2V-Me-NorCy7 (30 mg, 0.059 mmol) and CS2CO3 (38 mg, 0.11) were added sequentially to dry DMF (2 mL) and stirred for 1 h. Subsequently, compound S14 (62.23 mg, 0.12 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored using LC/MS and quenched using H2O (1 mL). The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S15 as amorphous dark blue solid (26 mg, 52% yield). 1 H NMR (500 MHz, DMSO) 5 8.12 - 8.03 (m, 1H), 7.73 (q, J = 10.7, 9.4 Hz, 2H), 7.64 (dq, J = 19.4, 7.9, 6.8 Hz, 3H), 7.52 (d, J = 7.4 Hz, 1H), 7.48 - 7.33 (m, 5H), 7.29 (q, J =
7.2 Hz, 2H), 7.21 (p, J = 7.6, 7.0 Hz, 2H), 7.12 (q, J = 7.7, 6.2 Hz, 1H), 6.98 (t, J = 12.1 Hz, 1H), 6.62 (d, J = 16.6 Hz, 1H), 6.55 (d, J = 13.2 Hz, 1H), 5.36 (d, J = 11.6 Hz, 1H), 5.30 (d, J = 12.9 Hz, 1H), 4.72 - 4.59 (m, 3H), 4.39 (q, J = 14.0, 13.5 Hz, 2H), 4.01 (q, J = 8.5, 8.0 Hz, 2H), 3.67 - 3.59 (m, 1H), 3.15 (dq, J = 14.5, 3.7 Hz, 2H), 1.38 (s, 5H), 1.33 (dd, J = 18.0, 6.7 Hz, 9H), 1.26 (q, J =
7.3 Hz, 6H), 1.22 - 1.13 (m, 9H). 13C NMR (125 MHz, DMSO) 5 182.8, 173.2, 173.1, 172.2,
171.9, 155.7, 155.4, 153.8, 152.3, 146.9, 142.6, 141.5, 139.7, 139.3, 139.1, 136.1, 134.2, 130.5,
130.2, 130.1, 129.9, 129.4, 129.1, 128.3, 128.2, 126.7, 126.3, 124.9, 124.3, 123.4, 123.3, 122.2,
122.1, 120.7, 120.5, 120.4, 119.7, 119.6, 119.5, 118.1, 116.1, 115.6, 113.3, 78.61, 78.58, 78.55,
68.64, 54.02, 52.47, 50.13, 49.49, 45.33, 45.31, 42.27, 29.23, 29.03, 28.66, 28.64, 28.61, 23.46,
23.43, 23.36, 18.57, 18.53, 18.49, 18.46, 18.41, 17.19, 12.91 HRMS (ESI) calculated for C55H62N6O6 [M+H]+ 903.4804; observed: 903.4830.
AA-CyLBam. To a 10 mL microwave vial compound S15 (15 mg, 0.019 mmol) was dissolved in TFA:CH2C12 (1 mL) on ice and stirred for 1 h. Afterwards the solvent was evaporated, followed by addition of glutaric anhydride (4.3 mg, 0.037 mmol) and DIPEA (0.5 pL, 0.03 mmol) in dry DMF (2 mL). The reaction mixture was stirred at room temperature and was monitored by LC/MS. After 3 h the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give AA-CyLBam as amorphous dark blue solid (10.2 mg, 58% yield). JH NMR (500 MHz, DMSO) 5 8.05 (dd, J = 7.0, 2.5 Hz, 1H), 8.02 (d, J = 7.2 Hz, 1H), 7.95 (ddd, J = 15.5, 8.0, 4.4 Hz, 2H), 7.65 (t, J = 8.6 Hz, 2H), 7.59 - 7.53 (m, 3H), 7.53 - 7.48 (m, 1H), 7.41 (q, J = 3.1 Hz, 1H), 7.34 - 7.28 (m, 3H), 7.28 - 7.22 (m, 3H), 7.19 - 7.14 (m, 1H), 7.10 (q, J = 7.8 Hz, 2H), 7.01 (dt, J = 16.3, 6.1 Hz, 2H), 6.50 (d, J = 16.5 Hz, 1H), 6.43 (dd, J =
13.1, 4.2 Hz, 1H), 5.23 (dd, J = 11.8, 7.0 Hz, 1H), 4.27 (qd, J = 7.2, 4.4 Hz, 4H), 4.17 - 4.12 (m,
2H), 3.03 (d, J = 16.3 Hz, 2H), 2.13 - 2.02 (m, 6H), 1.60 (dt, J = 11.6, 7.4 Hz, 4H), 1.24 - 1.17 (m, 5H), 1.15 - 1.02 (m, 12H). 13C NMR (125 MHz, DMSO) 5 182.8, 174.7, 174.6, 174.6, 172.9, 172.8, 172.8, 172.6, 172.5, 172.4, 172.3, 172.3, 172.2, 172.1, 171.8, 162.7, 155.4, 155.3, 153.6,
152.2, 146.9, 142.7, 141.4, 139.6, 139.6, 139.4, 139.3, 139.1, 136.1, 134.3, 134.1, 132.6, 130.5,
130.1, 130.1, 129.9, 129.4, 129.2, 129.1, 128.3, 128.2, 126.2, 124.9, 124.3, 124.2, 123.3, 123.1,
122.1, 122.1, 120.6, 120.3, 120.1, 119.7, 119.6, 119.4, 117.7, 116.1, 115.3, 113.1, 105.6, 68.66,
52.47, 49.68, 49.64, 49.54, 48.87, 48.80, 48.77, 48.65, 45.35, 45.32, 36.25, 34.62, 34.60, 34.55,
34.45, 33.45, 33.42, 33.39, 31.24, 29.24, 29.02, 28.87, 23.46, 23.43, 23.37, 23.34, 22.97, 21.03,
21.00, 20.92, 18.52, 18.38, 18.35, 18.33, 18.28, 18.21, 18.09. LRMS (ESI) calculated for
C55H59N6O7 [M+H]+ 915.4 observed: 915.3.
AA-CyLBam-NHS. To a 10 mL microwave vial, AA-CyLBam (10 mg, 0.014 mmol), TSTU (8.7 mg, 0.028 mmol) and DIPEA (4.50 pL, 0.028 mmol) were added sequentially to dry DMF (3 mL). The progress of the reaction was monitored by LC/MS. After 1 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give AA-CyLBam-NHS as amorphous dark blue solid (6.8 mg, 70% yield). LRMS (ESI) calculated for C59H64N7O9 [M+H]+ 1014.3; observed: 1014.4.
M-Me-!torCy7
Compound S17. Compound S16 was synthesized according to reported literature procedures (Suma et al., JACS 2017, 139(11):4009-4018; Skakuj et al., JACS 2018, 140(4): 1227-1230). To a 10 mL microwave vial 2V-Me-NorCy7 (30 mg, 0.059 mmol) and CS2CO3 (38 mg, 0.11) were added sequentially to dry DMF (2 mL) and stirred for 1 h. Subsequently, compound S16 (41 mg, 0.12 mmol) was dissolved in dry DMF (2 mL) and added dropwise over 15 mins. The reaction mixture was stirred overnight. The reaction mixture was monitored using LC/MS and quenched using H2O (1 mL). The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S17 as amorphous dark blue solid (26 mg, 60% yield). JH NMR (500 MHz, DMSO) 5 8.42 (dt, J = 4.9, 1.3 Hz, 2H), 8.37 (dt, J = 4.9, 1.4 Hz, 1H), 7.74 (td, J = 7.8, 1.9 Hz, 2H), 7.69 (q, J = 1.7 Hz, 2H), 7.56 (dt, J = 9.6, 1.3 Hz, 3H), 7.38 - 7.34
(m, 2H), 7.28 (dd, J = 7.5, 1.4 Hz, 1H), 7.24 - 7.20 (m, 3H), 7.12 (dd, J = 7.4, 1.1 Hz, 1H), 7.08 - 7.03 (m, 2H), 6.61 (d, J = 16.3 Hz, 1H), 6.31 (d, J = 13.1 Hz, 1H), 4.52 (t, J = 5.9 Hz, 3H), 4.21 - 4.02 (m, 4H), 3.29 (s, 2H), 3.06 (s, 3H), 1.09 (d, J = 28.3 Hz, 12H). 13C NMR (125 MHz, DMSO) 5
182.9, 157.8, 154.1, 152.1, 150.1, 150.1, 146.8, 143.0, 138.6, 138.2, 136.6, 134.4, 130.4, 129.4,
128.9, 128.2, 126.5, 125.4, 124.9, 122.2, 120.1, 120.1, 117.6, 115.3, 106.4, 64.69, 52.44, 45.14, 42.66, 36.90, 29.07, 23.45. LRMS (ESI) calculated for C44H45N4O2S2 [M+H]+ 725.2; observed: 725.3.
5.5-CyLBam. To a 10 mL microwave vial S17 (10 mg, 0.013 mmol) and
3-mercaptopropionic acid (2.31 pL, 0.027) were added sequentially to dry DMF (2 mL) and stirred for 2 h. The reaction mixture was monitored using LC/MS and purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S,S-CyLBam as amorphous dark blue solid (8.6 mg, 86% yield). 1 H NMR (500 MHz, DMSO) 57.76 (d, J = 8.0 Hz, 1H), 7.67 - 7.64 (m, 2H), 7.60 (s, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.41 (dd, J = 7.4, 1.3 Hz, 1H), 7.36 - 7.32 (m, 2H), 7.30 - 7.24 (m, 3H), 7.22 - 7.18 (m, 1H), 7.14 - 7.09 (m, 2H), 7.06 (s, 1H), 6.68 (d, J = 16.3 Hz, 2H), 6.38 (d, J = 13.2 Hz, 2H), 4.61 (t, J = 6.1 Hz, 2H), 4.25 - 4.13 (m, 4H), 3.22 (t, J = 6.1 Hz, 2H), 3.14 (s, 3H), 2.94 (t, J = 7.0 Hz, 2H), 2.66 (t, J = 7.0 Hz, 2H), 1.16 (d, J = 28.1 Hz, 12H). 13C NMR (125 MHz, DMSO) 5 182.9, 173.1, 162.7, 154.1, 153.7, 152.2, 146.9, 142.7, 139.2, 139.1, 136.6, 136.1, 134.1, 130.1, 130.2, 130.1, 129.4, 128.9, 128.3, 128.1, 126.6, 126.5, 126.1, 125.4, 124.9, 122.9, 122.1,
120.6, 120.5, 120.4, 118.1, 116.3, 116.2, 115.7, 113.4, 106.3, 64.75, 52.44, 51.28, 50.79, 45.13,
42.68, 36.25, 36.22, 34.02, 33.57, 33.49, 31.24, 29.05, 23.43. HRMS (ESI) calculated for
C45H52N3O4S2 [M+H]+ 762.3394; observed: 762.3389.
5.5-CyLBam-NHS. To a 10 mL microwave vial, S,S-CyLBam (5 mg, 0.007 mmol), TSTU (8.7 mg, 0.014 mmol) and DIPEA (2.40 pL, 0.014 mmol) were added sequentially to dry DMF (2 mL). The progress of the reaction was monitored by LC/MS. After 2 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S,S- -Me-CyBam-NHS as amorphous dark blue solid (4.5 mg, 84% yield). HRMS (ESI) calculated for C42H46N3O4S2 [M+H]+ 720.2924; observed: 720.2935.
S,SMe2-CyLBam. To a 10 mL microwave vial S17 (10 mg, 0.013 mmol) and 4-mercapto-4- methylpentanoic acid (2.31 pL, 0.027 obtained from BroadPharm, Cat:BP-22000) were added sequentially to dry DMF (2 mL) and stirred for 2 h. The reaction mixture was monitored using LC/MS and purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S,SMe2-CyLBam as amorphous dark blue solid (23 mg, 70% yield). !H NMR (500 MHz, DMSO) 57.78 - 7.76 (m, 1H), 7.66 (td, J = 7.3, 1.5 Hz, 2H), 7.62 - 7.59 (m, 1H), 7.46 - 7.41 (m, 2H), 7.36 - 7.32 (m, 2H), 7.31 - 7.24 (m, 3H), 7.23 - 7.18 (m, 2H), 7.14 - 7.10 (m, 1H), 7.07 (s, 1H), 6.67 (s, 1H), 6.40 (d, J = 1.8 Hz, 1H), 4.59 (t, J = 6.0 Hz, 3H), 4.24 - 4.14 (m, 3H), 3.18 (t, J = 6.1 Hz, 2H), 3.14 (s, 3H), 2.39 - 2.34 (m, 1H), 2.34 - 2.25 (m, 2H), 2.10 - 2.05 (m, 1H), 1.88 - 1.83 (m, 1H), 1.83 - 1.73 (m, 2H), 1.31 (s, 2H), 1.26 (d, J = 15.6 Hz, 6H), 1.21 (d, J = 12.6 Hz, 6H), 1.14 (s, 5H). 13C NMR (125 MHz, DMSO) 5 182.9, 174.9, 174.7, 154.2, 153.3, 152.2, 146.8, 143.0, 139.2, 139.1, 136.6, 134.5, 130.4, 130.1, 129.4, 128.9, 128.3, 128.2, 126.5, 126.3, 126.2, 125.4, 124.9, 122.9, 122.1, 120.4, 120.1, 119.8, 117.5, 116.36, 115.2, 112.8, 106.3, 65.04, 56.82, 52.44, 51.27, 51.13, 51.00, 50.77, 45.15, 44.21, 42.68, 42.64, 42.28, 41.18, 37.78, 35.96, 32.55, 30.72, 30.52, 30.05, 29.05, 28.75, 28.13, 27.53, 27.45, 23.45. LRMS (ESI) calculated for C45H52N3O4S2 [M+H]+ 762.3; observed: 762.3.
S,SMe2-CyLBam-NHS. To a 10 mL microwave vial, S,SMe2-CyLBam (5 mg, 0.007 mmol), TSTU (8.7 mg, 0.014 mmol) and DIPEA (2.40 pL, 0.014 mmol) were added sequentially to
dry DMF (2 mF). The progress of the reaction was monitored by LC/MS. After 2 h, the reaction was complete. The reaction mixture was purified by reversed phase HPLC (10-95% MeCN:H2O, 0.1% TFA) to give S,SMe2-CyLBam- NHS as amorphous dark blue solid (4.1 mg, 75% yield). HRMS (ESI) calculated for C42H46N3O4S2 [M+H]+ 859.3; observed: 859.3.
Example 2 Characterization ofCyBam Ns
A disulfonated heptamethine norcyanine, CyBam-Ns, was synthesized as described in
CyBam -Ns allowed examination of the tum-ON chemistry using a chemical trigger. Azide reduction, involving aza-ylide formation and hydrolysis, was hypothesized to initiate 1,6 elimination and carbamic acid hydrolysis to result in unmasking of the pH-sensitive norcyanine (FIG. 1). CyBam-Ns exhibited minimal absorbance and emission in the NIR range at either neutral (pH 7.2) or acidic pH (pH 4.5) (FIG. 2). Examining the absorbance profiles of CyBam-Ns and Sulfo-NorCy7 at both neutral and acidic pH revealed three readily distinguishable species as shown in FIG. 2. FIGS. 3A and 3B show the absorbance (300-800 nm) and fluorescence (720-850 nm) spectra, respectively, with 710 nm excitation of CyBam-Ns (10 pm) and Sulfo-NorCy7 (10 pm) at pH 7.2 (PBS) and pH 4.5 (acetate buffer) The pKa of Sulfo-NorCy7 was determined as 5.4 by absorbance and 5.2 by fluorescence. The photophysical properties of the three species are summarized in Table 4. The stability of CyBam-Ns at physiological pH values ranging from 4.5-7.5 and in serum was evaluated and little degradation (< 5%) was observed over 24 h.
Table 4
The fluorogenic response of CyBam-N was investigated by incubating with triphenyl phosphine (PPI13) at pH 5.2 (FIGS. 4A and 4B). The reaction of CyBam-N (10 mM; 1 eq) and PPI13 (100 mM; 10 eq) in PBS:MeOH (1:1), pH 5.2, was monitored at 5-minute intervals (n = 3). Complete conversion to Sulfo-NorCy7-[H+] occurred within 60 mins of PPI13 addition. Rapid conversion to Sulfo-NorCy7-[H+] was observed (FIG. 4A) with a dramatic 170-fold increase in the fluorescence signal (FIG. 4B). This reaction could also be carried out at neutral pH to provide the neutral form Sulfo-NorCy7.
The magnitude of the turn-ON response of CyBams was compared to xanthene cyanines, which are far-red probes that have been broadly employed for in vivo fluorogenic imaging. A sulfonated, acetylated variant, compound S10, was prepared as described in Example 1 and compared to the xanthene cyanine, compound S9. The absorbance spectra of both compounds are shown at pH 7.2 (PBS, FIG. 5A) and pH 4.5 (acetate buffer, FIG. 5B). Compound S9 exhibited turn-ON ratios of 15 and 1.5 over compound S10 were obtained at pH 7.2 (FIG. 5C) and pH 4.5 (FIG. 5D), respectively, with an excitation of 640 nm. Compound S9 exhibited tum-ON ratios of 13 and 8 over compound S10 were obtained at pH 7.2 (FIG. 5E) and pH 4.5 (FIG. 5F), respectively, with an excitation of 690 nm. The critical distinction is the absorption profile in the OFF state. The acetylated xanthene cyanine exhibited substantial long-wavelength absorption, which leads to significant emission from the quenched state (FIG. 5A). In contrast, CyBams exhibit minimal absorption in the NIR region at either neutral or acidic pHs.
Example 3
Cellular and In Vivo Imaging with CyBam-y-Glu and Sulfo-NorCy7
To investigate the utility of CyBams for cellular and in vivo imaging, a validated Anorogenic trigger with significant translational potential was used. y-Glutamyl transpeptidase (GGT) is a cell-surface-bound enzyme involved in maintaining cellular glutathione (GSH) and cysteine homeostasis (Wickham et al., Anal Biochem 2011, 414(2):208-214). Additionally, it has been shown to act as a biomarker of several malignant tumors (including liver, cervical, and ovarian) and overexpression of GGT has been correlated with metastases (Schafer et al., Acta Oncol 2001, 40(4):529-535; Yao et al., Cancer 2000, 88(4):761-769; Luo et al., Oncotarget 2017, 8(4):67651-67662; Hanigan, et al., Cancer Res 1994, 54(l):286-290). A cleavable glutamate was installed on CyBam-v-Glu as described in Example 1.
After confirming the stability of CyBam-y-Glu, the probe was evaluated in enzymatic assays. A GGT-dependent increase in Auorescent signal was observed (FIG. 6) with a Michaelis constant (KM = 16 mM) similar to those obtained with other GGT probes. GGT converts CyBam-y-Glu to the corresponding norcyanine via 1,6-elimination. CyBam-y-Glu was determined to be specifically activated by GGT and did not show any significant signal when incubated with representative proteases and esterases (FIG. 7). The selectivity of CyBam-y-Glu was determined using established GGT inhibitors. GGT (100 U/L) was pre-blocked with covalent inhibitors DON and GGsTop (1 mM) for 1 h in PBS (pH. 7.4) followed by incubation with CyBam-y-Glu (20 pM) at 37 °C. A 60% and 80% decrease in Auorescent signal in the presence of DON and GGsTop, respectively, was observed, confirming the selectivity of the probe (FIG. 8).
CyBam-y-Glu and the corresponding non-cleavable variant CyBam-N.C were examined in cellular assays and in vivo imaging experiments. A SHIN-3 ovarian cancer cell line that has been previously shown to overexpress GGT was used (Urano et al., Sci Transl Med 2011, 3(110): 1 lOral 19). CyBam-y-Glu exhibited minimal toxicity, demonstrated by incubating SHIN-3 cells with 1-40 pM of the compound for 72 h. Cell viability was measured as described in the experimental procedures. Sulfo-NorCy7 (Example 2) also was evaluated and found to have minimal toxicity.
Sulfo-NorCy7 exhibited significant cellular uptake in SHIN-3 cells with strong lysosomal localization, consistent with prior results and the requirement for chromophore protonation (FIG. 9). The upper panels show uptake in mitochondria (Mitotracker Green) and the lower panels show uptake in lysosomes (Lysotracker Green). Overlap in the green and red channel was analyzed using fluorescent line graph in the green and the red channel. Nucleus stained using NucBlue (blue channel). Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/ contrast using Fiji.
The cellular activation and selectivity of CyBam-y-Glu with and without incubation with GGT inhibitors was evaluated. Using confocal microscopy and flow cytometry, a strong fluorescent signal was observed in cells treated with CyBam-y-Glu. By contrast, minimal fluorescence signal was observed in cells that were treated with either CyBam-N.C or preincubated with GGT inhibitors (FIGS. 10 and 11). FIG. 10 shows confocal images of fluorescence activation of CyBam-y-Glu (20 mM) and CyBam-N.C (20 mM). Fluorescent signal from the probe and nucleus (Hoechst) is shown in red and blue, respectively. Images were taken using a 63X oil immersed lens (N.A 1.4). FIG. 11 shows quantification of fluorescent signal after incubation of CyBam-y-Glu (20 mM) in presence of GGT inhibitors (DON, GGsTop) and CyBam-N.C. in SHIN-3 cells using flow cytometry.
CyBam-y-Glu was evaluated in a metastatic tumor model of ovarian cancer. This model entails intraperitoneal injection of SHIN-3-ZsGreen cells, resulting in formation of a significant primary tumor in the greater omentum and locally disseminated metastases (Urano et al., Sci Transl Med 2011, 3(110: 1 lOral 19). CyBam-y-Glu (30 nmol) was injected intraperitoneally in mice which were euthanized after 1, 3, and 6 h and both the primary tumor and local metastases were imaged. Excellent colocalization between CyBam-y-Glu and the ZsGreen signal suggests that the probe was activated and taken up selectively by tumor cells, with significant signal at all three time points (FIGS. 12-14). FIG. 12 shows imaging of the SHIN-3-ZsGreen metastatic tumor model at 3h after
injection with CyBam-y-Glu (30 nmol). Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels, respectively. The fluorescent line graphs show correlation between fluorescent signal from GFP and Cy7 channel across the metastatic tumor in two different regions (A and B). FIGS. 13 and 14 show brightfield, GFP channel, Cy7 channel, and merged images of a SHIN-3-ZsGreen metastatic tumor model at Ih and 6 h, respectively, after injection with CyBam-y-Glu (30 nmol). After 1 h, the mouse was euthanized, and tumors (omental cake and metastatic) were imaged. GFP ex 445 - 490 nm, em 500 - 720 nm; Cy7 ex 710 - 760 nm, em 780 - 950 nm. Green and red pseudo colors are used to represent signal from the GFP and Cy7 channels respectively. These results indicate that CyBams have significant potential for use as activatable probes for in vivo imaging, including for optically guided surgical procedures. The extensive optical instrumentation in place for heptamethine cyanines makes this prospect more enticing.
CyBam-y-Glu and CyBam-N.C (25 nM) were injected (in sterile IX PBS pH 7.4) intravenously in mice containing MDA-MB-468 xenograft tumors. Mice were imaged after 4 h in bright field and Cy7 channel (ex/em filter 745/800 nm) (FIG. 15). Signal from tumors, liver and background in mice are shown in red, blue and magenta dotted circles. Green pseudo colors are used to represent fluorescent signal from and Cy7 channel. FIGS. 16A and 16B show quantification of fluorescent signal emitting from tumors (16A) and tumor to background ratio in mice by drawing ROIs (16B); p-values were evaluated by student t-test (*** p-value < 0.001).
The data shows that CyBam-y-Glu has a turn-ON ratio that dramatically exceeds those found with existing far-red Anorogenic probes, particularly in acidic conditions. Unlike existing far-red Anorogenic probes, the cationic chromophore is only formed through cleavage of the carbamate group and subsequent protonation of the resulting norcyanine, leading to an exceptional turn-ON ratio (>150X). The CyBam is selectively activated upon protonation in the lysosome.
Example 4 Optimization of Norcyanine Signal
While the sulfonated norcyanine, Sulfo-NorCy7 can provide high contrast imaging, relatively high concentrations (20 - 40 mM) were required for sufficient in vitro signal.
This requirement might be problematic for mAb targeted imaging because probe concentrations are intrinsically limited by antigen levels. Microscopy studies indicated that the cellular signal of Sulfo-NorCy7 was predominately from the lysosome - an observation consistent with probe protonation and a pXa between 4 and 5. Poor lysosomal accumulation might be responsible for the modest cellular fluorescence of this probe. It was hypothesized that improving cellular permeability and, perhaps, introducing a lysosomal targeting element could improve the fluorescent output.
To approach this problem, a small panel of chemically diverse norcyanines was designed and synthesized. These compounds contain a C4’-phenyl-substituent appended to the polymethine chromophore, which has been found to improve synthetic accessibility, photostability, and serum stability. To test the question of cell permeability alone, two hydrophobic derivatives, OMe-NorCy7 and H-Nor-Cy7 were included. Commonly used lysotracker probes contain tertiary amines, suggesting this functional group can promote lysosomal targeting (Xu et al., Angew Chem Int Ed Engl 2016, 55(44):13658-13699; Zhu et al., Acc Chem Res 2016, 49(10):2115-2126; Choi et al., Molecules 2021, 26(1)). To determine whether might apply to norcyanines, we prepared indolenine-substituted sulfonamide derivatives modified with both the hydrophobic piperidine (Pip-NorCy7) and the tertiary amine-containing X-Me piperazine (N-Me-Pip-NorCy7) substituents. Another “lysotracker-like” derivative, N-Me-NorCy7, in which the central ring system contains an A-methyl substituent also was prepared. The syntheses are described in Example 1.
The photophysical properties and cellular uptake of the probes was investigated. All six probes exhibited absorbance and emission maxima above 700 nm, similar extinction coefficients and quantum yields, and pk'ys between 4.4 and 5.2 (see, e.g., FIGS. 17A and 17B). The results are summarized in Table 5.
Table 5
a acetate buffer (pH 4.5); bMeOH:acetate buffer pH 4.5 (2:1); cMeOH:acetate buffer pH 3.75 (2:1); dMeOH + 0.1% formic acid for all compounds.
The NorCy7 series was determined to have minimal toxicity in MDA-MB-468 and MCF-7 cells. Signal in MDA-MB-468 cells was quantified at 1, 3 and 6 h time points with flow cytometry using the APC-Cy7 channel. At all three time points, the uptake of the six norcyanines follows the rank order: 2V-Me-NorCy7 > -Me-Pip-NorCy7 » Pip-NorCy7, OMe-NorCy7, H-Nor-Cy7 » Sulfo-NorCy7. FIG. 18 shows flow cytometry quantification of in vitro uptake of the compounds (5 mM) in MDA-MB-468 after 1 h incubation. Geometric mean fluorescent intensity (+ SD) of fluorescent signal in the cells is shown (n = 4 independent experiments; -10,000 cells counted). The 2V-Me-NorCy7 and -Me-Pip-NorCy7 exhibited 187-fold and 72-fold higher uptake, respectively, in MDA-MB-468 cells after only 1 h incubation compared to previously used Sulfo-NorCy7. The fluorescent signal remained constant at the 1 , 3 and 6 h time points suggesting efficient uptake and high retention of tertiary amine substituted norcyanines (2V-Me-NorCy7 and 2V-Me-Pip-NorCy7). In contrast, the signal from Sulfo-NorCy7 increased steadily overtime and was ~3-fold higher after 6 h relative to 1 h. Using confocal microscopy, the subcellular localization of the 2V-Me-NorCy7 was confirmed to be lysosomal, with dramatically higher signal than SulfoNorCy7 (FIGS. 19A-19F). FIGS. 20A and 20B show organelle localization of 2V-Me-NorCy7 (5 pM; red channel) in MDA-MB-468 cells after 6 h incubation followed by organelle staining (green channel) with lysosome (Lysotracker Green; 20A) and mitochondria
(Mitotracker Green; 20B). Nucleus stained using NucBlue (blue channel). Confocal imaging carried out at 63X oil immersed lens with 1.4 NA. The images were processed with identical brightness/ contrast using Fiji. Scale bar 10 pm. The relatively modest signal of the three hydrophobic derivatives, Pip-NorCy7, OMe-NorCy7, and H-NorCy7, indicates that the tertiary amine, the lysotracker-mimicking feature, is important for fluorescent signal enhancement. Overall, this data indicates that incorporation of a single basic amine dramatically enhances cellular uptake and lysosomal localization of norcyanines. The enhanced cellular signal and synthetic accessibility led the selection of 2V-Me-NorCy7 to compare to the previously described Sulfo-NorCy7 in developing activable mAb conjugates.
Example 5 Norcyanine-mAb Conjugates and Targeting
The impact of norcyanine modification on the signal of mAb conjugates was assessed. 2V-Me-NorCy7 was converted to the cyanine lysosome-targeting carbamate (CyLBam) variant by attaching a cathepsin cleavable dipeptide (valine-citrulline, VC) and a non-cleavable (NC) glutaric anhydride linker substituted with a lysine reactive NHS ester (see Example 1 for synthesis details). As a comparison, Sulfo-NorCy7 was converted to the corresponding CyBam molecules. The four probes were conjugated to the FDA-approved anti-Epidermal Growth Factor Receptor (EGFR) antibody Panitumumab (Pan) at pH 7.4 (degree of labeling (DOL) ~4; FIG. 21). The resulting conjugates were purified by both spin column and dialysis to ensure that no free small molecule remained. The inventors’ prior work had shown that similar conjugates maintain the in vitro and in vivo targeting properties of the parent mAb (Gorka et al., Acc Chem Res 2018, 51 (12) :3226-3235 ; Usama et al., Curr Opin Chem Biol 2021, 63:38-45).
The series of Pan probes was compared in cellular assays. The four conjugates, Pan-VC-CyLBam, Pan-NC-CyLBam, Pan-VC-CyBam, Pan-NC-CyBam, (FIG. 22) were tested in MDA-MB-468 (EGFR+) and MCF-7 (EGFR-) cells (Mamor et al., Cancer Res 2003, 63(12):3154-61 ; Bhattacharyya et al. , Medchemcomm 2014, 5(9): 1337- 1346). The fluorescent signal emitting from Pan-VC-CyLBam was 50-fold higher than Pan-VC-CyBam after incubation with MDA-MB-468 cells for 24 h (FIGS. 23, 24). Validating the role of receptor- mediated uptake, the fluorescent signal of both probes was lower in MCF-7 cells (by 7.5-fold for the CyLBam and 4.5-fold for the CyBam (FIG. 24). As expected, the non-cleavable probes, Pan-NC-CyLBam and Pan-NC-CyBam, did not exhibit any significant fluorescent signal in either cell line. Confocal
microscopy confirmed the trends observed by flow cytometry, as well as the lysosomal uptake of the released norcyanine (FIGS. 25-27).
The conjugates (200 mg) were injected intravenously into female athymic nude mice with MDA-MB-468 xenograft tumors (25-35 mm3). The mice were imaged at 4, 24, 48, 72, and 168 h post-injection using an In Vivo Imaging System (IVIS) (FIG. 28A and FIGS. 29-34). After 24 h, a strong fluorescent signal was observed in tumors injected with Pan-VC-CyLBam and the signal persisted over 168 h, with tumor-to-background ratios (TBRs) between 4 and 5 (FIG. 28B). In contrast, the Pan-VC-CyBam group had lower TBRs (1-2) at all time points - similar to the two non-cleavable probes, Pan-NC-CyLBam and Pan-NC-CyBam. Significant liver signal was observed with the two probes containing the protease cleavable linker (Pan-VC-CyLBam and Pan-VC-CyBam) at early time points (4 h and 24 h), and the fluorescent signal decreased afterwards.
The selective hepatic signal of Pan-VC-CyBam and its time-dependent disappearance suggests that the released Sulfo-NorCy7 is rapidly cleared through hepatobiliary pathways. Thus, the reduced tumor signal observed with this probe likely reflects lower tumor retention (compared to V-Me-NorCy7) and subsequent clearance. Overall, these results suggest that the improved cellular retention of V-Me-NorCy7, first observed in vitro, extends to an in vivo setting.
Example 6 Quantitative Comparison of Antibody-Drug-Conjugate Linkers
A small panel of probes was designed to compare two commonly used cathepsin-cleavable peptide linkers, valine-citrulline, Pan-VC-CyLBam (Example 5, FIG. 22) and alanine-alanine, Pan-AA-CyLBam, and two disulfides, one hindered gem-dimethyl-substituted variant, Pan-S,SMe2-CyLBam and one primary disulfide, Pan-S,S-CyLBam (FIGS. 35, 36). As a control, the non-cleavable probe, Pan-NC-CyLBam (Example 5, FIG. 22), was also employed.
The signals of the panel of conjugates were examined in cells expressing variable levels of EGFR. The fluorescent signal from linker cleavage was quantified using flow cytometry at 6 and 24 h post-incubation (FIG. 37). At the 6 h time point, Pan-S,S-CyLBam exhibited the highest fluorescent signal in EGFR+ MDA-MB-468 cells. The other three cleavable probes had only modest fluorescent signal after 6 h, but the signal increased substantially after 24 h. Pan-VC-CyLBam had the highest fluorescent signal among the cleavable probes after 24 h, indicating the most extensive linker cleavage. All 5 conjugates exhibited low levels of probe signal at 6 and 24 h in the EGFR- cell lines (MCF-7 and MDA-MB-231, FIGS. 37, 38), albeit with
slightly higher signal with the Pan-S,S-CyLBam probe. Significantly, if these data were used in isolation, it would be difficult to differentiate these linkers and assess the optimal agent for further study.
With the goal of investigating differences between these linkers in an organismal context, the NIR spectroscopic properties of these probes was then harnessed for in vivo imaging. The full series of probes (100 mg dose, half the dose of the studies above), were administered to female athymic nude mice implanted with MDA-MB-468 tumors and imaged at regular intervals up to 48 h (FIG. 39). With the disulfide probes, Pan-S,SMe2-CyLBam and Pan-S,S-CyLBam, significant tumor signal was not observed, and the TBR was similar to the non-cleavable Pan-NC-CyLBam control. In contrast, strong tumor signal was observed from the cathepsin-sensitive probes, Pan-VC-CyLBam and Pan-AA-CyLBam (FIGS. 40-44), with the TBR reaching as high as 4.5 after 48 h. These studies indicated that cathepsin-cleavable linkers provide dramatically higher tumor activation relative to hindered or non-hindered disulfides. Importantly, as only modest differences are observed using the cellular methods described above, this key distinction was only apparent with in vivo imaging.
In addition to tumor uptake, these data also provide significant insight into off-target cleavage pathways. As observed above, conjugates with cleavable linkers exhibit significant liver signal at early time points (4 and 24 h, FIG. 42). While likely due to a combination of liver uptake/cleavage and probe clearance through hepatobiliary pathways, this approach can provide quantitative insight into off target cleavage. With Pan-AA-CyLBam as an example, the liver signal decreased overtime but increased in the tumor (FIG. 41), which leads to an increase in the tumor-to-liver ratio over time (FIG. 41, inset). The in vivo imaging results were corroborated with an ex vivo assessment, performed 48 h post injection. As expected, the TMR (tumor-to-muscle ratio) revealed an identical trend to that observed in vivo (FIGS. 45, 46A, 46B).
Finally, to test the generality of the approach, CyLBams were tested against an alternative cancer target. The cell surface protein CD276, also known as B7 homolog H3 (B7H3), is overexpressed in both tumor cells and tumor vasculature of multiple solid tumor types (Qin et al. , Onco Targets Ther 2013, 6:1667-73; Zang et al., Mod Pathol 2010, 23(8): 1104-12; Brunner et al., Gynecol Oncol 2012, 124(1): 105-11; Seaman et al., Cancer Cell 2007, 11(6):539-54). VC and S,SMe2 linkers were selected for comparison. The CD276 targeting antibody, m276-SL, reported previously, and non-cleavable NC control m276-SL conjugates were prepared, as well as a non-binding mAb IgG control (DOL 4, FIG. 47). In initial in vitro testing using a CD276+ JIMT-1
triple negative breast cancer cell line, both cleavable m276-SL conjugates showed high levels of cleavage, with little activation using the control non-binding IgG antibody (FIGS. 48, 49).
Protease-cleavable m276-SL-VC-CyLBam and the disulfide-cleavable m276-SL-S,SMe2-CyLBam conjugates were compared in JIMT-1 tumors (200-250 mm3) grown orthotopically in the mammary fat pad. As observed in the studies above, only the protease-cleavable m276-SL-VC-CyLBam conjugate exhibited a TBR greater than 5 (5.2 after 48 h), while the disulfide m276-SL-S,SMe2-CyLBam probe exhibited much lower tumor signal (FIGS. 50-53, 54A-54C).
These initial studies in this model serve to both validate the generality of the CyBam imaging strategy, as well as the observation that protease-cleavable linkers outperform disulfide linkers in solid tumor models.
The mode of action of ADCs is complex. Optimal efficacy depends on target binding, internalization, and, finally, lysosomal catabolism to initiate payload release. While the linker domain plays a central role in determining the efficacy and selectivity of ADCs, it is challenging to directly assess the site and extent of linker cleavage using conventional methods. This is an important issue because off-target cleavage of ADCs contributes significantly to ADC toxicity (Masters et al., Invest New Drugs 2018, 36:121-135). The optical imaging approach detailed here provides a general means to analyze linker chemistry across cellular, tissue, and body-wide scales. This work identified probes suitable for mAb-targeted activatable imaging. Installation of a tertiary amine into the norcyanine framework dramatically improved cellular and in vivo signal compared to sulfonated CyBams, likely due to enhanced lysosomal uptake and retention. It is likely that these “lysotracker-like” norcyanines and the resulting CyLBam probes will have applications in other settings, including their use as activity-based sensing agents.
These examples have shown that quantitative comparisons of linker chemistries can be obtained by varying the linker component. In addition to linker chemistry, the properties of the payload molecule (e.g. charge, hydrophobicity) are also important aspects of tumor targeting. While the norcyanine probe is a hydrophobic, sp2-rich small molecule, so too are many ADC payloads. Further variations of the cyanine component could provide additional insights into the role of pay load properties on tumor and normal tissue distributions. CyLBam imaging could provide insights that directly inform the development of ADCs. These studies have suggested significant differences between protease cleavable dipeptides and disulfides in terms of tumor cleavage, which is likely due to instability of disulfides in circulation. Prior studies looking at various cysteine mutants have found the site of mAb labeling can have dramatic effects on disulfide
stability (Ohri et al., Bioconjug Chem 2018, 29(2):473-485). This approach is well positioned to investigate these and related homogenous labeling strategies.
In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims
1. A compound according to Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof:
where
L is substituted or unsubstituted Cn conjugated alkenyl, each carbon having sp2 hybridization, where n is 7, 3, 5, or 9;
R1 is substituted aryl or substituted heteroaliphatic, and the bond between the nitrogen atom and -C(O)-O-CH2-R1 is cleavable by an enzyme or chemical trigger;
Y1 and Y2 independently are C(Rb)2, N(RC), S, O, or Se, wherein each Rb independently is aliphatic, H, deuterium, aryl, -(OCFFCFFjxOH where x is an integer > 2, trityl, or a group comprising a conjugatable moiety, a targeting agent, or a drug, and each Rc independently is H, deuterium, aliphatic, or heteroaliphatic;
R3 and R4 independently are H, aliphatic, amino, a sulfonate-containing group, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring, and R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring;
R5-R10 independently are H, a sulfonate-containing group, aliphatic, heteroaliphatic, amino, or a group comprising a conjugatable moiety, a targeting agent, or a drug; and
Rx is absent, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or H, wherein if Rx is present, the nitrogen to which Rx is attached has a +1 charge and a counterion X’ is also present.
2. The compound of claim 1, where L is:
R2 and R2 independently are aryl, heteroaryl, heterocycloaliphatic, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug, where each Ra independently is H, halo, alkyl, or aryl; and
(i) R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and, if present, R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (ii) R11 together with R12 and the atoms to which they are bound forms a 5-7 membered cycloaliphatic or heterocycloaliphatic ring and R11 is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug or (iii) each of R11, R11 , and R12 independently is H, aliphatic, heteroaliphatic, or a group comprising a conjugatable moiety, a targeting agent, or a drug, or (iv) R11, R11 , and R12 together with the atoms to which they are bound form a fused cycloaliphatic or heterocycloaliphatic ring system, each ring comprising 5-7 members.
7. The compound of claim 6, where:
Y1 and Y2 independently are C(Rb)2, where each Rb independently is aliphatic or aryl;
R2 is, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug;
A is -CH2- or -N(CH3)-; and
R3, R4, R6, R7, R9, and R10 are H.
8. The compound of any one of claims 4-6, where:
Y1 and Y2 independently are C(Rb)2, where each Rb independently is aliphatic or aryl;
R2 and R2 independently are phenyl, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug;
A and A' independently are -N(CH3)- or -CH2-; and R3, R4, R6, R7, R9, and R10 are H.
9. The compound of any one of claims 4-8, where A or A' is -N(CH3)-.
10. The compound of any one of claims 1-9, where Y1 and Y2 are -C(CH3)2-.
112
13. The compound of any one of claims 1-6 or 9, wherein:
R3 and Y1 together with the atoms to which they are bound form a 6-membered aryl ring; and
R4 and Y2 together with the atoms to which they are bound form a 6-membered aryl ring.
113
16. The compound of claim 14, where the compound has a structure according to any one of Formulas lie Ve, Vf, or Vg :
114
17. The compound of claim 16, where the compound has a structure according to formula lie':
where R2 is phenyl, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug;
A is -CH2- or -N(CH3)-; and
R3, R4, R6, R7, R9, R10, and R13-R18 are H.
18. The compound of claim 16, where:
R2 is phenyl, H, halo, -ORa, -NRa2, or a group comprising a conjugatable moiety, a targeting agent, or a drug;
A and A' independently are -CH2- or -N(CH3)-; and R3, R4, R6, R7, R9, R10, and R13-R18 are H.
19. The compound of any one of claims 4-9, 13, or 16-18, wherein
A is -CHRd-, -CH2CHRd-, -CHRdCH2-, or -NRd-;
Rd is -(CH2)m-Re, -(CH2)mCH(NH2)-Re, -(CH2)mC(O)Re, -(CH2)mN(H)Re,
20. The compound of any one of claims 1-19, wherein R1 is substituted phenyl or substituted heteroaliphatic.
21. The compound of claim 20, wherein:
-O-heterocycloaliphatic, -O-heteroaliphatic, -O-aliphatic, -O-heteroalkylaryl, -O-alkylaryl, or -O-aryl, where R' is aliphatic and each R" independently is H or aliphatic;
Rs is aliphatic, heteroaliphatic, heterocycloaliphatic, alkylaryl, or heteroalkylaryl; and Rh is aliphatic.
116
24. The compound of claim 23, wherein R2 is unsubstituted phenyl.
25. The compound of any one of claims 2-23, wherein one of R^R18, R2 , A, A', Y1, or Y2 comprises a group comprising a targeting agent.
26. The compound of claim 24, wherein R1, R2, R2 , A, or A' comprises the group comprising the targeting agent.
27. The compound of claim 25 or claim 26, wherein the targeting agent comprises an antibody, a peptide, or a nanobody.
28. The compound of any one of claims 1, 2, 4, 5, 8-11, 13 14, 16, or 18-27, wherein Rx is absent.
31. A pharmaceutical composition comprising a compound, or stereoisomer thereof, according to any one of claims 1-30, and a pharmaceutically acceptable carrier.
32. A method, comprising: contacting a biological sample with a compound according to any one of claims 1-30; exposing the compound to an enzyme or a chemical trigger capable of cleaving -C(O)OCH2R1 from the compound to provide a cleaved compound; exposing the cleaved compound to a pH less than 8; subsequently exposing the cleaved compound to light having a wavelength greater than
700 nm; and detecting fluorescence from the cleaved compound.
33. The method of claim 32, wherein the compound does not comprise Rx and exposing the cleaved compound to a pH less than 8 comprises exposing the cleaved compound to a pH less than 7 to provide a protonated cleaved compound.
34. The method of claim 32 or claim 33, wherein: the biological sample comprises the enzyme, and exposing the compound to the enzyme comprises contacting the biological sample comprising the enzyme with the compound; or the biological sample comprises the chemical trigger, and exposing the compound to the chemical trigger comprises contacting the biological sample comprising the chemical trigger with the compound; or exposing the compound to the enzyme or chemical trigger comprises adding the enzyme or the chemical trigger to the biological sample and the compound.
35. The method of any one of claims 32-34, wherein the biological sample comprises an environment having a pH less than 7, thereby exposing the cleaved compound to the pH less than 7.
36. The method of any one of claims 32-35, wherein the enzyme or chemical trigger and R1 are selected from the following combinations: carboxyesterase (CES 1 , 2) and acetylcholinesterase (ACHe) and butyrylcholinesterase (BCHe) and aminopeptidase N and cathepsin B and
122
125
cytochormide P450 and nitro reductase and glutathione, cysteine, or homocysteine and
hydrogen peroxide and super oxide and hydrogen sulfide or triphenyl phosphine and hypochlorous acid and peroxynitrite and carbon monoxide and selenol and thiophenol and
126
37. The method of any one of claims 32-36, wherein: the biological sample comprises, or is suspected of comprising, a target; the compound comprises a group comprising a targeting agent that binds to the target; and detecting fluorescence from the cleaved compound indicates presence of the target in the biological sample.
38. The method of claim 37, wherein the targeting agent is an antibody, a peptide, or a nanobody.
39. The method of claim 37 or claim 38, wherein one of Rj-R18, R2 A, A', Y1, or Y2 comprises the targeting agent.
40. The method of claim 39, wherein one of R1, R2, R2 , A, or A' comprises the targeting agent.
41. The method of any one of claims 32-40 wherein contacting the biological sample with the compound is performed in vivo.
42. The method of claim 41, wherein: contacting the biological sample in vivo comprises administering the compound or a pharmaceutical composition comprising the compound to a subject; and detecting fluorescence from the cleaved compound is performed via in vivo imaging.
44. The method of claim 43, wherein the cancer comprises ovarian cancer, cervical cancer, liver cancer, colon cancer, gastric cancer, astrocytic glioma, soft tissue sarcoma, melanoma, or leukemia.
45. The method of any one of claims 32-44, wherein the compound does not comprise
Rx, the cleaved compound is exposed to a pH less than 7 to provide a protonated cleaved compound, and the protonated cleaved compound has a fluorescence intensity at least 100X greater than the compound or cleaved compound in an unprotonated state.
129
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163165511P | 2021-03-24 | 2021-03-24 | |
US63/165,511 | 2021-03-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022203930A1 WO2022203930A1 (en) | 2022-09-29 |
WO2022203930A9 true WO2022203930A9 (en) | 2023-04-27 |
Family
ID=81325047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/020708 WO2022203930A1 (en) | 2021-03-24 | 2022-03-17 | Fluorogenic cyanine carbamates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022203930A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017027721A1 (en) * | 2015-08-12 | 2017-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near-ir light-cleavable conjugates and conjugate precursors |
WO2018183960A1 (en) * | 2017-03-30 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Protease-activated contrast agents for in vivo imaging |
JP2021513988A (en) * | 2018-02-15 | 2021-06-03 | チルドレンズ ナショナル メディカル センターChildren’S National Medical Center | Heptametin cyanine for use as a fluorescent marker for the biliary and renal systems |
WO2020041743A1 (en) * | 2018-08-23 | 2020-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Water soluble novel cyanine fluorophore with tunable properties between near ir and swir region for in vivo imaging |
-
2022
- 2022-03-17 WO PCT/US2022/020708 patent/WO2022203930A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022203930A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy | |
AU2014228504B2 (en) | Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection | |
EP3655408B1 (en) | Conformational restriction of cyanine fluorophores in far-red and near-ir range | |
JP6270981B2 (en) | Methods for the production and synthesis of amino acid linking groups conjugated to compounds used for targeted imaging of tumors | |
US11746086B2 (en) | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | |
ES2465465T3 (en) | Haptenos, haptens conjugates, compositions thereof and method for their preparation and use | |
US11406719B2 (en) | Dichromic fluorescent compounds | |
EP3510399B1 (en) | Psma-targeted nir dyes and their uses | |
WO2016072984A1 (en) | A new class of stable heptamethine cyanine fluorophores and biomedical applications thereof | |
Cheng et al. | Synthesis of a novel HER2 targeted aza-BODIPY–antibody conjugate: synthesis, photophysical characterisation and in vitro evaluation | |
Du et al. | A ratiometric fluorescent probe based on quinoline for monitoring and imaging of Leucine aminopeptidase in liver tumor cells | |
KR101822761B1 (en) | New compounds or pharmaceutically acceptable salt thereof selective for amyloid-β plaque and method for imaging amyloid-β plaque in vivo using the same | |
WO2010054330A2 (en) | Monofunctional carbocyanine dyes for in vivo and in vitro imaging | |
WO2019126565A1 (en) | Lipid derivatives for in vitro or in vivo delivery | |
WO2022203930A9 (en) | Fluorogenic cyanine carbamates | |
US10718028B2 (en) | Fluorescent probes for abasic site detection | |
Fang et al. | A novel near-infrared fluorescent probe with hemicyanine scaffold for sensitive mitochondrial pH detection and mitophagy study | |
KR101842633B1 (en) | Diagnostic or therapeutic composition of cancer which is activated by cathepsin B, and near-infrared imaging and phototherapy of tumor using the same | |
CA3090797C (en) | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | |
Giel et al. | The application of click chemistry in the design of aggregation-induced emission luminogens for activity-based sensing | |
Walker | O 6-Methylguanine DNA Methyltransferase Activatable Photosensitizers for Cancer Therapeutics | |
CN114560850A (en) | Near-infrared fluorescent molecular probe, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22715267 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22715267 Country of ref document: EP Kind code of ref document: A1 |